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Abstract 
Purpose Environmental phthalate exposure has been associated with attention-deficit disorders in 
children. We hypothesized that in children treated in the pediatric intensive care unit (PICU), circulating 
phthalates leaching from indwelling medical devices contribute to their long-term attention-deficit.  
Methods Circulating plasma concentrations of di(2-ethylhexyl)phthalate (DEHP) metabolites were 
quantified in 100 healthy children and 449 children who had been treated in PICU and were 
neurocognitively tested 4 years later. In a development patient cohort (N=228), a multivariable bootstrap 
study identified stable thresholds of exposure to circulating DEHP metabolites above which there was 
an independent association with worse neurocognitive outcome. Subsequently, in a second patient 
cohort (N=221), the observed independent associations were validated. 
Results Plasma concentrations of DEHP metabolites, that were virtually undetectable [0.029(0.027-
0.031) µmol/l] in healthy children, were 4.41(3.76-5.06) µmol/l in critically ill children upon PICU 
admission (P<0.001). Plasma DEHP metabolite concentrations decreased rapidly but remained 18-
times elevated until PICU discharge (P<0.001). After adjusting for baseline risk factors and duration of 
PICU stay, and further for PICU complications and treatments, exceeding the potentially harmful 
threshold for exposure to circulating DEHP metabolites was independently associated with the attention-
deficit (all P≤0.008) and impaired motor coordination (all P≤0.02). The association with the attention-
deficit was confirmed in the validation cohort (all P≤0.01). This phthalate exposure effect explained half 
of the attention-deficit in post-PICU patients.  
Conclusions Iatrogenic exposure to DEHP metabolites during intensive care was independently and 
robustly associated with the important attention-deficit observed in children 4 years after critical illness. 
 
 
Trial registration clinicaltrials.gov Identifier NCT00214916 
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Take-home message: Critically ill children have very high circulating levels of phthalate metabolites, 
explained by leaching indwelling medical devices, and these high levels are independently associated 
with the important attention-deficit observed 4 years later.  
 
140-character Tweet: Exposure to plastic softeners released from indwelling medical devices is 
associated with long-term attention-deficit in children 
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Introduction 
 
Children who have been critically ill at young age suffer from a substantial neurocognitive deficit 
when assessed years after admission to the pediatric intensive care unit (PICU) [1-5]. This 
neurocognitive legacy comprises, besides lower scores for intelligence, visual-motor integration, 
memory and behavior, also an important deficit in executive functions, motor coordination and attention 
[1]. The degree of this impairment is not negligible as for example the intelligence deficit is 15 IQ points 
and the attention-deficit is about 40% larger than that reported for children with attention-deficit 
disorders [1, 6]. Until recently, this neurocognitive legacy was considered the consequence of the illness 
and thus not modifiable. However, recent studies support the notion that it can be, at least partially, 
diminished by altering medical care. For example, changing the surgical technique for correcting 
congenital heart defects and preventing hyperglycemia during intensive care have shown to reduce the 
neurocognitive impairment [1, 7, 8]. Nevertheless, the neurocognitive legacy of critical illness in children 
is likely multifactorial [9].  
Intensive medical care relies heavily on indwelling medical devices, made smaller for use in 
children and made soft and pliable by incorporating chemical plastic softeners such as phthalates. 
Phthalates are not chemically bound to these devices and thus can gradually leach during use [10]. One 
of the most widespread phthalates, di(2-ethylhexyl)phthalate (DEHP), has been banned from children’s 
toys but is still used to soften medical devices. When DEHP leaches from the plastic into the circulation, 
it is hydrolyzed to mono(2-ethylhexyl)phthalate (MEHP). Further metabolization of MEHP occurs mainly 
in the liver and includes 6-hydroxylation, with formation of 2-ethyl-5-carboxy-pentylphthalate (5cx-
MEPP), and 5-hydroxylation to 2-ethyl-5-hydroxy-hexylphthalate (5OH-MEHP) and subsequent 
conversion to 2-ethyl-5-oxo-hexylphthalate (5oxo-MEHP) [11]. These metabolites are eliminated via the 
urine [11]. A few small observational studies have reported high urinary levels of DEHP metabolites in 
premature neonates inferred to originate from indwelling medical devices [12-14].  
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In recent years, concerns have been expressed about potential toxicity for fertility and 
development of phthalate exposure via the food-chain and via long-term hemodialysis, long-term blood 
transfusions and repeated use of extracorporeal oxygenation in children [15-18]. In vitro studies, animal 
studies and observational reports in humans suggest that chronic exposure to DEHP may deleteriously 
affect neurocognitive development [19-23]. Specifically, a toxic effect on dopaminergic neurons was 
suggested to contribute to an increased incidence of attention-deficit disorders in young children 
exposed to environmental phthalates [24, 25]. However, it is unclear whether any phthalate leaching 
from routinely used medical devices during the short time that children are being treated in PICUs plays 
a causal role in the neurocognitive legacy of pediatric critical illness [18].  
We hypothesized that high circulating phthalate levels are present in critically ill children treated 
in the PICU, contributing to the attention-deficit and possibly other aspects of the long-term 
neurocognitive legacy. To test this hypothesis, concentrations of DEHP metabolites were quantified in 
plasma samples obtained during PICU stay from children who were tested for neurocognitive 
development 4 years later [1, 26] and compared with healthy children. In a development cohort, stable 
potentially harmful threshold levels of exposure to circulating DEHP metabolites were first identified with 
a multivariable bootstrap approach. Subsequently, the observed independent associations between 
phthalate exposure during PICU stay and the neurocognitive test results were validated in a second 
cohort.  
 6 
Methods 
 
Study population: development and validation cohort 
In this study, 449 critically ill infants and children (0–16 years upon PICU admission) who had 
been enrolled in a randomized controlled trial on blood glucose control in PICU [26], of whom plasma 
was available and who underwent neurocognitive testing at 4 years follow-up [1], were included 
(Figure_1a). For comparison with plasma concentrations of DEHP metabolites resulting from 
environmental exposure, 100 healthy children with comparable age and gender were sampled 
immediately after IV catheterization for minor elective surgery (Figure_1a, eMethods_1). For the full 
study protocol we refer to the original articles and electronic supplementary protocol. The study was 
approved by the institutional ethical review board (ML2586) and performed in accordance with the 1964 
Declaration of Helsinki and its amendments. Written informed consent for blood sampling/analyses and 
neurocognitive testing was obtained from the parents/legal guardians and/or the child when 18 years or 
older at follow-up. 
Given the inevitably observational study design, we a priori decided to chronologically divide the 
study population in two (Figure_1a). This was done to first identify any independent associations 
between exposure to circulating DEHP metabolites during PICU stay and the neurocognitive test results 
4 years later in a development cohort and to subsequently validate the findings in a second cohort (see 
statistical analyses). 
 
Measurement of plasma concentrations of phthalate metabolites, identification of phthalate-
leaching devices and definition of “phthalate exposure” during PICU stay 
Blood samples were taken upon PICU admission and daily at 6 a.m. until discharge, with 
plasma stored at -80°C. Plasma concentrations of 4 DEHP metabolites (MEHP, 5OH-MEHP, 5cx-
MEPP, and 5oxo-MEHP) were quantified with high-performance liquid-chromatography tandem-mass-
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spectrometry (Agilent 6410 Triple-Quad LCMS; Agilent, Santa Clara, California) [27] (eMethods_2, 
eTable_1).  
 Leaching experiments excluded any contamination with DEHP from the containers used to 
collect and store the plasma. Leaching experiments were also performed to assess which of the 
indwelling devices used in these patients were actively leaching DEHP when placed in DEHP-free 
saline for 18h at room temperature [28]. The number and type of indwelling medical devices used per 
child during 24h preceding sampling was noted.  
 We assumed that plasma DEHP metabolite concentrations would be highest upon PICU 
admission and lowest on the last PICU day. This assumption was based on the fact that many patients 
were admitted after exposure to extracorporeal circuits for surgery [29], and on the number of indwelling 
medical devices that typically diminishes throughout PICU stay, taking into account the half-life of the 
metabolites (between 5-15h) [11]. We first confirmed the inferred time course, by measuring plasma 
concentrations on day 1, 2, and 3 in a subset of 25 children from the development cohort. Subsequently, 
plasma concentrations of the DEHP metabolites were measured upon admission and on the last day for 
all patients. The available evidence suggests that both the concentration of circulating DEHP 
metabolites to which the brain is exposed and the duration of this exposure determine any eventual 
long-term neurocognitive harm [19] within a concept of “threshold” toxicity [15]. Therefore, we decided to 
consider the product of the last day plasma concentration and duration of PICU stay as that exposure to 
circulating phthalates during PICU stay that was minimally present for each patient, further referred to 
as the phthalate “exposure”. This was done for the sum of all DEHP metabolites, for each of the 
individual DEHP metabolites and for the sum of the 3 MEHP metabolites [11]. The latter was considered 
necessary to exclude bias originating from any artifactual ex vivo hydrolysis of DEHP [11].  
 
Neurocognitive testing 
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Experienced pediatric psychologists (blinded to phthalate exposure) used validated, 
internationally recognized tests with adequate normative data to quantify performance for a broad range 
of neurocognitive functions [1]. The neuropsychological test battery comprised age range-specific tests 
measuring attention, motor coordination, inhibitory control and cognitive flexibility (Amsterdam 
Neuropsychological Tasks), general intellectual functioning (Wechsler Intelligence Quotient scales), 
visual-motor integration (Beery-Buktenica Developmental Test), verbal and visual-spatial learning and 
memory (Children’s Memory Scale), and behavior (Child Behavior Checklist) (eMethods_3) [1]. These 
tests have been extensively used to quantify neurocognitive development in various pediatric 
populations [30, 31].  
 
Statistical Analyses 
Data are presented as means and 95% confidence intervals, medians and interquartile ranges 
or numbers and proportions. Differences between plasma concentrations of DEHP metabolites in 
critically ill and healthy children, and among patients with increasing numbers of indwelling medical 
devices, were compared with Wilcoxon rank-sum test. The latter analysis was subsequently corrected 
for markers of liver and kidney function.  
 The primary study aim was to assess, in a multivariable regression analysis adjusting for other 
risk factors, the presence of an independent association between “exposure” to the total circulating 
DEHP metabolites during PICU stay and the attention-deficit 4 years later, in the development and the 
validation patient cohort. Secondary study aims were similar analyses for the other neurocognitive 
outcomes, and for the individual DEHP metabolites and the sum of MEHP metabolites.  
First, in the development cohort, the “exposure”/concentration values were evaluated as 
potential harmful thresholds for neurocognitive development, via a minimum P-value approach in 
multivariable regression analyses [32], adjusted for the following risk factors (eMethods_4, eFigure_1): 
age at PICU admission, gender, race [33], geographic and linguistic origin, history of malignancy or 
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diabetes, prior to PICU admission presence of a syndrome/illness a priori defined as affecting 
neurocognitive development, socioeconomic status of the parents, type and severity of critical illness, 
blood glucose management and duration of PICU stay. The stability of the identified thresholds was 
evaluated via 400 bootstrap resamplings per neurocognitive outcome (eMethods_4, eFigures_2-3). 
Each child received a dichotomized label according to whether or not these potentially harmful 
thresholds were exceeded. Second, the significance and effect sizes of exceeding the identified 
potentially harmful thresholds of phthalate “exposure” in the multivariable regression models, adjusted 
for other risk factors as described above, were determined for the development cohort and, to exclude 
findings by chance, repeated for the validation cohort. Third, as a sensitivity analysis, the multivariable 
models were further adjusted for extracorporeal circulation, aortic clamp times and “Risk-Adjusted 
Classification for Congenital Heart Surgery” (RACHS) score and for complications occurring during 
PICU stay, including new infections, duration of antibiotic and corticosteroid use, organ failure as 
reflected by peak levels of plasma creatinine and bilirubin, duration of hemodynamic/ventilatory support, 
treatment with hypnotics and cumulative doses of benzodiazepines and opioids [34]. In addition, it was 
also assessed whether any of the documented independent associations with the attention-deficit 
observed for “exposure” to the circulating DEHP metabolites in the validation cohort were also present 
for the raw plasma concentrations.   
 
Statistical analyses were performed with Matlab 2014b® (The MathWorks, Natick, MA) and 
JMP® version 11.0.0 (SAS Institute, Inc, Cary, NC). Two-sided P-values of 0.05 or less were considered 
to indicate statistical significance. No corrections for multiple comparisons were done. 
 10 
Results 
 
 Demographic and medical characteristics and neurocognitive test results of patients in the 
development and validation cohorts and of healthy children are presented in Table_1 and eTable_2.  
In healthy children, total DEHP metabolites in plasma were virtually undetectable [0.029 (0.027-
0.031) µmol/l], with just detectable levels of some individual DEHP metabolites in only 15 children. 
Mean plasma concentrations of DEHP metabolites were 4.41 (3.76-5.06) µmol/l upon PICU admission 
in the development cohort and 3.42 (2.98-3.87) µmol/l in the validation cohort, and thus 152-times and 
118-times higher than in healthy children (P<0.0001) (Figure_1b,c), decreasing subsequently with time 
(Figure_1b). The lowest plasma concentrations of the total DEHP metabolites were found on the last 
PICU day, which were still 18- and 17-times higher than in healthy children (P<0.0001, Figure_1b,c).  
During the 24h preceding PICU discharge, children were instrumented with 1-12 indwelling 
medical devices, of which up to 5 were intravascular. All these indwelling devices and/or the essential 
accessories for using them (eTable_3) were shown to leach DEHP ex vivo. Plasma concentrations of 
DEHP metabolites were always elevated irrespective of the number of indwelling medical devices and 
significantly increased by reduced kidney function (eFigure_4a).  
The multivariable bootstrap analysis of the development cohort identified all stable threshold 
levels of exposure to circulating DEHP metabolites as potentially harmful for neurocognitive 
development (eTable_4, Figure_2). These thresholds were between the 25th percentile and the median 
of the distribution (Table_2).  
The multivariable linear regression analyses of the development cohort, adjusted for baseline 
risk factors and duration of PICU stay, revealed that exceeding the potentially harmful threshold for 
“exposure” to circulating DEHP metabolites was independently and highly significantly associated only 
with the attention-deficit and with the impaired motor coordination (Table_2, eTable_5). The 
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independent association with the attention-deficit, and part of the association with impaired motor 
coordination, were reproduced in the validation cohort (Table_3, eTable_5). Similar findings were 
obtained for the “exposure” to the sum of the 3 circulating MEHP metabolites, to MEHP and most 
robustly, to 5oxo-MEHP (Table_2-3, eTable_5). These independent associations remained highly 
significant after further adjustment for extracorporeal circulation and aortic clamp times as well as for 
occurrence of new infections, organ failure, use of vital treatments during PICU stay and treatment with 
hypnotics, benzodiazepines and opioids (Table_2-3, eTable_5). Adjusting for number of indwelling 
devices did not change the results (eTable_6). In the subgroup of patients who required intensive care 
after cardiac surgery, further adjustment for RACHS score [35] did not alter any of the findings 
(eTable_7). Although in about 20% of patients last day DEHP metabolite concentrations were slightly 
higher than upon PICU admission, explained by baseline sampling before full instrumentation, sensitivity 
analyses confirmed that this did not cause bias (eMethods_5, eTable_8-9). The calculated estimates, 
reflecting the size of the effects on attention of exceeding the potentially harmful threshold, were the 
equivalent of about 50% of the differences between post-PICU patients and healthy children 
(eTable_10).  
The sensitivity analyses performed on the raw data of the plasma concentrations revealed that 
the briefly, but substantially, elevated plasma concentrations of DEHP metabolites upon PICU 
admission were not significantly associated with the attention-deficit or any of the other neurocognitive 
test results (data not shown). However, on the last PICU day, the sum of the plasma concentrations of 
the 3 MEHP metabolites was also significantly associated only with the attention-deficit (eTable_11-13). 
This potentially harmful threshold could be reached even with minimal instrumentation of the patients 
(eFigure_4b). 
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Discussion 
 
 Critically ill children revealed very high circulating levels of DEHP metabolites throughout PICU 
stay, whereas these were virtually undetectable in healthy children. All indwelling medical devices 
and/or essential accessories showed to actively leach DEHP. Exceeding the potentially harmful 
threshold of exposure to circulating DEHP metabolites, identified by a multivariable bootstrap study of 
the development cohort, was found to be independently associated with the attention-deficit and to a 
lesser extent with the motor coordination deficit documented 4 years after PICU admission. These 
independent associations were largely confirmed in the validation cohort, even after further adjustment 
for PICU morbidities and treatments. This phthalate exposure effect statistically explained about half of 
the attention-deficit in post-PICU patients. By comparison with the attention-deficit reported for children 
with attention-deficit disorders, the effect size of phthalate exposure during pediatric critical illness was 
large [6].  
 As hypothesized, a large part of the attention-deficit in post-PICU patients could be statistically 
explained by exceeding a threshold of exposure to circulating DEHP metabolites, composed of the 
minimal plasma concentrations and time in PICU that these concentrations were present, and not by the 
extremely high plasma concentrations that were only briefly present upon PICU admission. This further 
supports the notion that phthalates leaching from a single run of extracorporeal support in children may 
not be a concern. However, these data are in line with experimental studies suggesting that both level 
and duration of exposure to phthalates determine their toxicity [15, 19]. The potentially harmful threshold 
could be reached even with minimal indwelling instrumentation of the children and thus, with the 
currently used material, appears unavoidable. Although the daily amount of phthalates that leached from 
these routinely used medical devices (which could not be quantitatively assessed) may well have been 
below the previously identified minimal dose that may evoke toxicity to the gonads [17], alterations in 
kidney and liver function may have augmented circulating levels (regardless of number of indwelling 
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devices) and increased the risk of exceeding a threshold that is potentially harmful to early life brain 
development.  
It was striking that the phthalate exposure was specifically associated with attention and to a 
lesser extent motor coordination, but not the other aspects of the neurocognitive legacy. This 
corroborates epidemiological studies [21, 36, 37] suggesting a rather selective toxic effect of DEHP 
exposure on the biological substrate of the attention function. Attention is determined by neuronal 
networks involving connections between cerebellum, thalamus and frontoparietal cortex [38]. The exact 
brain areas vulnerable to the neurodevelopmental toxicity of phthalates related to the attention-deficit 
remain unclear. Degeneration of midbrain dopaminergic nuclei and an effect on dopamine transporters 
may play a role [39] as aberrations in the dopaminergic system are involved in the pathophysiology of 
attention-deficit disorders [40].  
 As compared with previous epidemiological studies, this study has some strengths. First, the 
timing and duration of the iatrogenic exposure to circulating phthalates related to the indwelling devices 
was accurately defined. Second, more than one measurement was done per child, reducing risk of 
inaccurate classification of exposure as may occur with single-spot urine samples [16]. Third, the current 
study used a development and a validation cohort, the latter to reduce the risk of observations by 
chance. The strikingly similar results in these two cohorts specifically for the association between 
phthalate exposure and the attention-deficit strongly supports that these associations are reproducible 
and biologically meaningful. Fourth, highly standardized tests were used to quantify attentional 
performance and other neurocognitive functions, whereas other studies drew conclusions based only on 
responses to questionnaires provided by teachers, parents or guardians [37]. 
This study also has limitations, most importantly that it was not a randomized controlled 
intervention trial and hence cannot provide proof of causality. However, unlike in animal models, 
deliberate random exposure of humans to potentially toxic phthalates is not possible for obvious ethical 
reasons. Also, with the currently used material, it is impossible to include a post-PICU control-group of 
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patients who were not exposed to phthalate-leaching indwelling devices during intensive care. There is 
some evidence for causality generated via studies in animal models [25]. We adjusted the analyses for 
dominant premorbid predestinators of neurocognition as well as for severity of the critical illness and its 
treatments. Although we cannot exclude residual confounding, the reproducibility of the current results 
in two patient cohorts underscores the robustness of the findings. One can only speculate about 
underlying molecular mechanisms in which epigenetic alterations may play a role [16].  
 In conclusion, a robust and reproducible independent association was found between the 
iatrogenic exposure to circulating phthalates during treatment in intensive care and the attention-deficit 
observed 4 years after pediatric critical illness. These data underscore a recent suggestion by the 
European Commission to use, whenever possible, medical devices with low phthalate release potential.  
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Figure legends 
 
Figure 1. Plasma phthalate concentrations in critically ill and healthy children 
Panel A shows the CONSORT flow diagram of the study participants. We included two cohorts of 
healthy children. A first cohort of 215 children was recruited for neurocognitive testing at the time of 
neurocognitive follow-up of the critically ill children (grey shading) [1]. A second cohort was included for 
quantification of plasma concentrations of the DEHP metabolites. Panel B shows the time course of the 
DEHP metabolite concentrations in 25 critically ill children, with quantification of the respective 
concentrations upon admission to the PICU (Adm), day 1 (d1), day 2 (d2), day 3 (d3) and last day in the 
PICU (LD). Panel C shows the DEHP metabolite concentrations upon admission and the last PICU day 
for the patients in the development (N=228) and the patients in the validation cohort (N=221). Inserts 
show the last day plasma concentrations at a higher magnification. Total DEHP metabolite 
concentrations are calculated as the sum of MEHP and its metabolites 5cx-MEPP, 5OH-MEHP and 
5oxo-MEHP, total MEHP metabolite concentrations are calculated as the sum of 5cx-MEPP, 5OH-
MEHP and 5oxo-MEHP. Concentrations in matched healthy children were mostly below the 
quantification limit of the assay and are represented by thick dark grey lines upon the x-axis of the 
graphs. Data of the critically ill children are presented as means and 95% confidence intervals. Mean 
plasma concentrations of DEHP metabolites in the critically ill children from the development and 
validation cohorts were at least 152-times and 118-times higher upon PICU admission and at least 18- 
and 17-times higher on the last PICU day than those in healthy children. Tighter matching of the 100  
healthy children with 100 critically ill children by propensity score matching for age and gender 
(eMethods_1) yielded similar results, with 111-times and 8-times higher plasma DEHP concentrations in 
the critically ill children upon PICU admission and on the last PICU day. 
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Figure 2. Univariate illustration of the alertness test results for patients who did and those who 
did not exceed the potentially harmful thresholds of exposure to circulating phthalate levels that 
were identified via multivariable bootstrap analysis 
Measures of alertness are presented for patients in the development and the validation cohorts who had 
a total circulating DEHP metabolite exposure above and below the potentially harmful threshold (T), the 
latter identified with multivariable bootstrap analysis of the development cohort. Similar data are shown 
for the exposure to the sum of the 3 circulating MEHP metabolites and to 5oxo-MEHP. Data are 
presented as means and 95% confidence intervals. The size of the effect of exposure to these 
phthalates and the level of significance were determined with multivariable analysis after corrections for 
other risk factors as shown in Tables 2 and 3. 
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Tables 
 
Table 1. Demographics and patient PICU outcomes 
 
Development cohort 
N=228 
Validation cohort 
N=221 
Healthy children 
N=100 
 
   
Baseline characteristics    
Male gender, no. (%) 123 (54.0) 133 (60.2) 58 (58.0) 
Age at sampling (years), mean (95% CI) 3.4 (2.9-4.0) 3.3 (2.7-3.8) 4.2 (3.5-4.9) 
Height at sampling (%), mean (95% CI)a 45.6 (41.6-49.6) 44.4 (40.4-48.4) 47.5 (40.4-54.7) 
Weight at sampling (%), mean (95% CI)a 44.4 (40.4-48.5) 41.6 (37.7-45.5) 52.7 (46.6-58.8) 
Caucasian race, no. (%)b 219 (96.1) 200 (90.5) 93 (93.0) 
Exclusively European, no. (%) 210 (92.1) 192 (86.9)  
Exclusively Dutch language, no. (%) 185 (81.1) 175 (79.2)  
Socioeconomic status, mean (95% CI)c 35 (33-37) 35 (33-37)  
Pre-existing syndrome, no. (%)d 58 (25.4) 66 (29.9)  
History of malignancy, no. (%) 5 (2.2) 8 (3.6)  
History of diabetes, no. (%) 2 (0.9) 0 (0.0)  
Randomization to strict glycemic control, no. (%) 105 (46.1) 112 (50.7)  
Diagnostic category, no. (%)    
     Cardiac surgery for congenital heart defects 178 (78.1) 183 (82.8)  
     Complicated/high risk surgery or trauma 25 (11.0) 16 (7.2)  
     Neurological medical disorders 5 (2.2) 3 (1.4)  
     Infectious medical diseases 9 (4.0) 4 (1.8)  
     Other medical disorders 8 (3.5) 10 (4.5)  
     Solid organ transplants 3 (1.3) 5 (2.3)  
PeLOD score first 24 hrs, mean (95% CI) 9 (8-10) 10 (9-11)  
    
PICU Outcomes    
ICU stay (days), mean (95% CI) 5.1 (4.3-5.8) 4.9 (4.0-5.8)  
Duration mechanical ventilation (days), mean (95% CI) 3.6 (3.0-4.2) 3.6 (2.9-4.4)  
Peak creatinine (mg/dl), mean (95% CI) 0.65 (0.62-0.68) 0.66 (0.59-0.73)  
Peak bilirubine (mg/dl), mean (95% CI) 1.42 (1.16-1.67) 1.43 (1.06-1.80)  
Hemodynamic support (days), mean (95% CI) 3.1 (2.6-3.6) 3.0 (2.4-3.6)  
Corticosteroid treatment (days), mean (95% CI) 0.3 (0.1-0.4) 0.8 (0.3-1.4)  
Infection, no. (%) 68 (29.8) 62 (28.1)  
Antibiotics (days), mean (95% CI) 3.3 (2.8-3.8) 3.6 (2.9-4.3)  
a Height and weight, expressed as percentiles of population norms, were calculated with the anthropometric calculators for normal children, based on the 
World Health Organization Growth Charts for Canada (version 2015/02/24), and for children with syndromes known to affect height and weight (version 
2014/09/25) (http://www.bcchildrens.ca/Services/SpecializedPediatrics/EndocrinologyDiabetesUnit/ForProfessionals/AnthropometricCalculators.htm). 
Patients and healthy children were not matched for height and weight, as a growth delay is part of the long-term legacy of critical illness in children.  
b Participants were classified according to race and geographical origin by the investigators. These classifications were performed to capture ethnical and 
regional differences in the frequency of consanguinity, which may adversely affect cognitive performance.38 
c Socioeconomic status of the patient’s parents was calculated with a modified version of the Hollingshead 7-point scale of educational level and the 9-point 
scale of occupational level. More points are given to higher educational or occupational level. Status score of an individual parent is calculated by adding the 
occupation value x 5, and the education value x 3. The average of the paternal and maternal score is used as the socioeconomic status score of the 
patient’s family. A score of 66 is the highest possible score. 
d A prerandomization syndrome or illness a priori defined as affecting neurocognitive development. 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score. 
 24 
Table 2. Multivariable linear regression analyses determining significant and independent associations between exposure to a potentially harmful threshold of circulating phthalate metabolites 
and neurocognitive functions in the development cohort (n=228) 
   
Model adjusted for baseline 
characteristics and duration of PICU stay 
Model further adjusted for extracorporeal 
circulation, aortic clamp time and in-PICU 
complications and treatments 
Phthalate 
exposurea 
Neurocognitive functions affected, as determined by 
a multivariable bootstrap approachb 
Potentially 
harmful 
threshold 
(µmol/l 
×days)c,d 
R² of 
the 
model Estimate [95% CI] P value 
 
R² of 
the 
model Estimate [95% CI] P value 
Total DEHPe Attention and motor coordination        
0.78  Alertness (msec)h        
(0.34-2.66)  Reaction time dominant hand >0.551 0.57 78.26 [37.75;118.76] 0.0002 0.59 79.37 [34.84;123.90] 0.0006 
(µmol/l×days)  Reaction time nondominant hand >0.551 0.55 64.94 [27.61;102.27] 0.0007 0.59 70.51 [30.66;110.36] 0.0006 
g  Reaction time overall  >0.551 0.60 71.44 [35.39;107.49] 0.0001 0.63 74.37 [35.40;113.35] 0.0002 
 Inconsistency of alertness (msec)i        
  SD reaction time dominant hand  >0.551 0.51 55.81 [21.17;90.46] 0.001 0.51 51.48 [12.98;89.97] 0.009 
  SD reaction time nondominant hand >0.551 0.43 43.16 [9.84;76.47] 0.01 0.47 47.68 [11.83;83.53] 0.009 
  SD reaction time overall >0.551 0.55 53.91 [24.03;83.79] 0.0005 0.57 53.42 [20.62;86.21] 0.001 
 Motor coordination (No. of taps in 10s)j        
  No. of unimanual taps        
   Dominant hand >0.551 0.76 -1.10 [-2.20;-0.01] 0.04 0.77 -1.34 [-2.52;-0.16] 0.02 
   Nondominant hand >0.551 0.76 -1.31 [-2.32;-0.29] 0.01 0.78 -1.24 [-2.31;-0.16] 0.02 
  No. of valid synchronous taps >0.551 0.66 -2.19 [-3.40;-0.97] 0.0005 0.67 -2.35 [-3.68;-1.03] 0.0006 
MEHP Attention and motor coordination        
Metabolitesf Alertness (msec)h        
0.47  Reaction time dominant hand >0.365 0.58 84.05 [41.57;126.52] 0.0001 0.59 88.58 [41.61;135.56] 0.0003 
(0.22-1.80)  Reaction time nondominant hand >0.365 0.55 67.94 [28.72;107.17] 0.0008 0.59 74.16 [32.00;116.33] 0.0006 
(µmol/l×days)  Reaction time overall >0.365 0.60 76.07 [38.25;113.89] 0.0001 0.63 81.54 [40.38;122.70] 0.0001 
g Inconsistency of alertness (msec)i        
  SD reaction time dominant hand  >0.365 0.51 61.87 [25.59;98.14] 0.0009 0.52 61.74 [21.19;102.28] 0.003 
  SD reaction time nondominant hand >0.365 0.44 50.73 [15.88;85.57] 0.004 0.48 52.50 [14.65;90.36] 0.006 
  SD reaction time overall >0.365 0.56 61.78 [30.60;92.96] 0.0001 0.57 61.73 [27.19;96.27] 0.0005 
 Motor coordination (No. of taps in 10s)j        
  No. of valid synchronous taps >0.365 0.65 -2.05 [-3.33;-0.77] 0.001 0.66 -2.16 [-3.57;-0.75] 0.003 
MEHP Attention and motor coordination        
0.23 Alertness (msec)h        
(0.10-0.68)  Reaction time dominant hand >0.157 0.56 58.79 [18.29;99.28] 0.004 0.58 57.95 [14.07;101.82] 0.009 
(µmol/l×days)  Reaction time nondominant hand >0.157 0.55 56.24 [19.25;93.24] 0.003 0.59 60.27 [21.21;99.33] 0.002 
g  Reaction time overall >0.157 0.59 57.19 [21.24;93.15] 0.002 0.61 58.33 [19.98;96.69] 0.003 
 Motor coordination (No. of taps in 10s)j        
  No. of valid synchronous taps >0.157 0.66 -2.53 [-3.72;-1.34] 0.00004 0.68 -2.73 [-4.00;-1.45] 0.00004 
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Table 2. Multivariable linear regression analyses determining significant and independent associations between exposure to a potentially harmful threshold of circulating 
phthalate metabolites and neurocognitive functions in the development cohort (n=228) (continued) 
 
5cx-MEPP Memory        
0.39 Verbal-auditory        
(0.17-1.24)  Working memory, repeating numbers  
repeating numbers   
 backward (up to 19 numbers) §§§ 
       
(µmol/l×days)  backward (up to 19 numbers)k >0.379 0.34 -0.95 [-1.67;-0.22] 0.01 0.43 -0.75 [-1.64;0.13] 0.09 
g         
5oxo-MEHP Attention and motor coordination        
0.03 Alertness (msec)h        
(0.01-0.12)  Reaction time dominant hand >0.031 0.57 82.72 [34.77;130.66] 0.0008 0.59 88.28 [35.89;140.66] 0.001 
(µmol/l×days)  Reaction time nondominant hand >0.031 0.57 92.93 [50.07;135.79] 0.00003 0.61 107.79 [62.64;152.93] 0.000005 
g  Reaction time overall >0.031 0.60 87.12 [44.88;129.37] 0.00007 0.63 96.98 [51.73;142.23] 0.00003 
 Inconsistency of alertness (msec)i        
  SD reaction time dominant hand  >0.031 0.51 64.82 [24.07;105.56] 0.002 0.52 63.76 [18.74;108.78] 0.005 
  SD reaction time nondominant hand >0.031 0.44 56.30 [17.62;94.97] 0.004 0.48 69.11 [27.89;110.32] 0.001 
  SD reaction time overall >0.031 0.55 62.34 [27.19;97.50] 0.0006 0.57 67.80 [29.55;106.05] 0.0006 
 Motor coordination (No. of taps in 10s)j        
  No. of unimanual taps        
   Dominant hand >0.031 0.76 -1.89 [-3.17;-0.61] 0.004 0.77 -2.16 [-3.53;-0.78] 0.002 
  No. of valid synchronous taps >0.024 0.64 -1.76 [-3.12;-0.41] 0.01 0.66 -1.95 [-3.46;-0.45] 0.01 
 
a “Exposure” was defined as the product of the last day concentrations in µmol/l and the number of days exposed in PICU. 
b Only the neurocognitive functions that were significantly associated with the phthalate exposures as identified by bootstrapping are listed.   
c identified via bootstrap resampling.  
d Threshold values are rounded to three decimals.  
e Exposure to the sum of MEHP and its metabolites 5cx-MEPP, 5oxo-MEHP and 5OH-MEHP.  
f Exposure to the sum of 5cx-MEPP, 5oxo-MEHP and 5OH-MEHP. 
g Distribution of metabolite exposures within the patient cohort (µmol/l ×days). Data are median (interquartile range). 
h For reaction times, higher scores reflect worse performance. Mean scores for the healthy children are 558 (95% CI 521-595) (range 230-1557) for the dominant hand reaction time, 562 
(95% CI 524-600) (range 223-1532) for the nondominant hand reaction time and 560 (95% CI 524-600) (range 227-1428) for the overall reaction time.1  
i For inconsistency of alertness, higher scores reflect worse performance. Mean scores for the healthy children are 259 (95% CI 229-290) (range 24-1004) for the dominant hand, 262 (95% 
CI 232-292) (range 19-982) for the nondominant hand and 275 (95% CI 246-304) (range 29-861) for the overall SD, standard deviation.1  
j For motor coordination, higher scores reflect better performance. Mean scores for the healthy children are 36 (95% CI 34-38) (range 10-66) for dominant hand unimanual taps, 32 (95% CI 
30-33) (range 8-79) for nondominant hand unimanual taps and 22 (95% CI 20-24) (range 0-52) for valid synchronous taps.1  
k For numbers within verbal-auditory memory, higher scores reflect better performance. Mean scores for the healthy children are 11 (95% CI 10-11) (range 3-18) for working memory 
(repeating numbers backward).1  
 
  
 26 
Table 3. Multivariable linear regression analyses determining significant and independent associations between exposure to a potentially harmful threshold of circulating phthalate metabolites 
and neurocognitive functions in the validation cohort (n=221)  
   
Model adjusted for baseline characteristics 
and duration of PICU stay 
Model further adjusted for extracorporeal 
circulation, aortic clamp time and in-PICU 
complications and treatments 
Phthalate 
exposurea 
Neurocognitive functions from the 
development cohort, significantly affected in 
validation cohortb 
Best 
threshold 
(µmol/l 
×days)c of 
developme
nt cohort 
R² of 
the 
model Estimate [95% CI] P value 
 
R² of 
the 
model Estimate [95% CI] P value 
Total DEHPd Attention and motor coordination        
0.72 Alertness (msec)g        
(0.34-2.19)  Reaction time dominant hand >0.551 0.54 58.30 [17.88;98.72] 0.004 0.60 61.47 [19.87;103.07] 0.004 
(µmol/l×days)  Reaction time nondominant hand >0.551 0.56 47.92 [10.58;85.27] 0.01 0.61 50.89 [11.94;89.85] 0.01 
f  Reaction time overall >0.551 0.58 54.43 [17.44;91.43] 0.004 0.63 57.59 [19.39;95.80] 0.003 
 Inconsistency of alertness (msec)h        
  SD reaction time dominant hand  >0.551 0.45 55.76 [18.1;93.43] 0.003 0.53 55.10 [16.62;93.58] 0.005 
  SD reaction time nondominant hand >0.551 0.45 30.15 [-6.15;66.44] 0.10 0.49 30.20 [-8.50;68.90] 0.12 
  SD reaction time overall >0.551 0.52 44.36 [11.54;77.17] 0.008 0.56 43.98 [9.58;78.38] 0.01 
 Motor coordination (No. of taps in 10s)i        
  No. of unimanual taps        
   Dominant hand >0.551 0.63 -0.83 [-2.14;0.49] 0.21 0.65 -0.78 [-2.18;0.61] 0.26 
   Nondominant hand >0.551 0.63 -1.57 [-2.84;-0.30] 0.01 0.66 -1.63 [-2.96;-0.29] 0.01 
  No. of valid synchronous taps >0.551 0.57 -1.09 [-2.37;0.19] 0.09 0.61 -1.46 [-2.80;-0.13] 0.03 
MEHP Attention and motor coordination        
metabolitese Alertness (msec)g        
0.53  Reaction time dominant hand >0.365 0.54 45.05 [4.77;85.33] 0.03 0.59 44.64 [2.71;86.57] 0.03 
(0.23-1.42)  Reaction time nondominant hand >0.365 0.56 44.23 [7.25;81.21] 0.01 0.60 46.46 [7.52;85.40] 0.01 
(µmol/l×days)  Reaction time overall >0.365 0.57 45.99 [9.21;82.76] 0.01 0.62 47.06 [8.67;85.45] 0.01 
f Inconsistency of alertness (msec)h        
  SD reaction time dominant hand  >0.365 0.45 45.46 [7.97;82.95] 0.01 0.52 42.42 [3.71;81.13] 0.03 
  SD reaction time nondominant hand >0.365 0.45 27.33 [-8.57;63.23] 0.13 0.49 25.90 [-12.74;64.53] 0.18 
  SD reaction time overall >0.365 0.51 38.16 [5.58;70.74] 0.02 0.56 35.73 [1.22;70.23] 0.04 
 Motor coordination (No. of taps in 10s)i        
  No. of valid synchronous taps >0.365 0.57 -0.63 [-1.90;0.63] 0.32 0.49 -1.00 [-2.34;0.34] 0.14 
MEHP Attention and motor coordination        
0.18 Alertness (msec)g        
(0.09-0.53)  Reaction time dominant hand >0.157 0.54 45.57 [5.83;85.31] 0.02 0.59 40.09 [-1.01;81.20] 0.05 
(µmol/l×days)  Reaction time nondominant hand >0.157 0.55 35.62 [-1.07;72.32] 0.05 
 
0.60 32.92 [-5.46;71.31] 0.09 
f  Reaction time overall >0.157 0.57 41.30 [4.88;77.71] 0.02 0.62 37.30 [-0.48;75.07] 0.05 
 Motor coordination (No. of taps in 10s)i        
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Table 3. Multivariable linear regression analyses determining significant and independent associations between exposure to a potentially harmful threshold of circulating 
phthalate metabolites and neurocognitive functions in the validation cohort (n=221) (continued) 
 
  No. of valid synchronous taps >0.157 0.58 -1.77 [-3.00;-0.53] 0.005 0.62 -1.60 [-2.90;-0.31] 0.01 
5cx-MEPP Memory        
0.39 Verbal-auditory        
(0.17-1.24)  Working memory, repeating numbers  
repeating numbers   
 backward (up to 19 numbers) §§§ 
       
(µmol/l×days)  backward (up to 19 numbers)j >0.379 0.28 0.26 [-0.50;1.03] 0.49 0.45 0.63 [-0.19;1.46] 0.12 
f         
5oxo-MEHP Attention and motor coordination        
0.03 Alertness (msec)g        
(0.02-0.10)  Reaction time dominant hand >0.031 0.58 100.67 [59.92;141.41] 0.000002 0.64 108.20 [66.91;149.49] 0.0000006 
(µmol/l×days)  Reaction time nondominant hand >0.031 0.58 73.85 [35.51;112.20] 0.0002 0.63 83.31 [43.91;122.71] 0.00004 
f  Reaction time overall >0.031 0.60 88.60 [51.10;126.11] 0.000006 0.66 96.82 [58.71;134.93] 0.000001 
 Inconsistency of alertness (msec)h         
  SD reaction time dominant hand  >0.031 0.49 91.91 [53.8;130.03] 0.000004 0.56 87.75 [48.93;126.56] 0.00001 
  SD reaction time nondominant hand >0.031 0.46 48.76 [11.11;86.41] 0.01 0.50 51.40 [11.57;91.24] 0.01 
  SD reaction time overall >0.031 0.55 74.64 [41.32;107.96] 0.00001 0.59 74.42 [39.74;109.10] 0.00003 
 Motor coordination (No. of taps in 10s)i        
  No. of unimanual taps        
   Dominant hand >0.031 0.63 -0.93 [-2.30;0.45] 0.18 0.65 -0.77 [-2.23;0.69] 0.29 
  No. of valid synchronous taps >0.024 0.56 -0.35 [-1.73;1.04] 0.62 0.61 -0.30 [-1.76;1.16] 0.68 
 
a “Exposure” was defined as the product of the last day concentrations in µmol/l and the number of days exposed in PICU. 
b Neurocognitive functions, that were significantly associated with the phthalate exposure in the development cohort, were tested in the validation cohort. Only the remaining functions that 
were also significantly associated with the phthalate exposure in the validation cohort are listed.  
c Threshold values are rounded to three decimals.  
d Exposure to the sum of MEHP and its metabolites 5cx-MEPP, 5oxo-MEHP and 5-OH-MEHP.  
e Exposure to the sum of 5cx-MEPP, 5oxo-MEHP and 5-OH-MEHP. 
f Distribution of metabolite exposures within the patient cohort (µmol/l ×days). Data are median (interquartile range). 
g For reaction times, higher scores reflect worse performance. Mean scores for the healthy children are 558 (95% CI 521-595) (range 230-1557) for the dominant hand reaction time, 562 
(95% CI 524-600) (range 223-1532) for the nondominant hand reaction time and 560 (95% CI 524-600) (range 227-1428) for the overall reaction time.1 
h For inconsistency of alertness, higher scores reflect worse performance. Mean scores for the healthy children are 259 (95% CI 229-290) (range 24-1004) for the dominant hand, 262 (95% 
CI 232-292) (range 19-982) for the nondominant hand and 275 (95% CI 246-304) (range 29-861) for the overall SD, standard deviation.1  
i For motor coordination, higher scores reflect better performance. Mean scores for the healthy children are 36 (95% CI 34-38) (range 10-66) for dominant hand unimanual taps, 32 (95% CI 
30-33) (range 8-79) for nondominant hand unimanual taps and 22 (95% CI 20-24) (range 0-52) for valid synchronous taps.1 
j For numbers within verbal-auditory memory, higher scores reflect better performance. Mean scores for the healthy children are 11 (95% CI 10-11) (range 3-18) for working memory 
(repeating numbers backward).1 
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SUPPLEMENTARY ONLINE METHODS 
 
eMethods 1. Propensity score matching of critically ill and healthy children 
 
For comparison with plasma concentrations of DEHP metabolites resulting from environmental exposure, 100 
healthy children with overall comparable age and gender as the total cohorts of critically ill children were 
sampled immediately after IV catheterization for minor elective surgery. To match age and gender more tightly, 
we subsequently performed a propensity score matching with one-to-one nearest neighbor matching with use of 
a caliper of 0.1, where propensity scores were estimated by logistic regression with age and gender as covariates 
(R-3.1.0 under SPSS version 23.0.0.0). The 100 control children were thus matched with 100 critically ill 
children. The age was 4.2+/-3.3 years in the healthy children versus 3.8+/-3.3 years (p=0.3) in the critically ill 
children and there were 58% male children in the healthy control group versus 61% in the critically ill group 
(p=0.6). We also compared the plasma DEHP metabolite concentrations for these propensity score matched 
critically ill and healthy children. 
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eMethods 2. Sample preparation, analysis and QA/QC for DEHP metabolites in plasma 
 
Sample preparation and analysis 
 
The sample preparation protocol for analysis of the DEHP metabolites was applied on 0.25 ml plasma 
fortified with 25 ng of each of the 13C-labeled DEHP metabolites (see eTable 1A). To ensure deconjugation of 
DEHP metabolites, 25 µl of β-glucuronidase-arylsulphatase (from Helix Pomatia, corresponding to ≈ 1 IU 
enzyme per ml of plasma) (Merck, Darmstadt, Germany) and 1 ml of phosphate buffer solution (pH=6) were 
added to the plasma and the mixture was kept at 37°C for 90 min. The samples were further diluted with 1 ml of 
MilliQ water and extracted using Oasis MAX (60 mg/3 ml, Waters, Milford, MA). Afterwards, the sorbent bed 
was washed with MilliQ water containing 5% NH4OH, followed with MilliQ water and dried under vacuum. 
Elution of DEHP metabolites was performed using 6 ml of MeOH containing 2% formic acid. The eluate was 
evaporated to dryness and reconstituted in 100 µl acetonitrile. The extract was filtered through centrifugal filters 
of 0.45 µm pore size (VWR International) and injected into a LC(ESI)-MS/MS system (liquid chromatograph 
1200 series coupled to a 6410 Triple Quad mass spectrometer, Agilent, CA). Additional instrumental conditions 
employed for the analysis of DEHP metabolites are given in eTable 1B. All solvents used in the analyses 
(MeOH, acetonitrile) were of gradient grade for liquid chromatography and were obtained from Merck 
(Darmstadt, Germany). Formic acid (98-100%) was from Merck and NH4OH (aqueous solution of 28-30%) was 
bought from Sigma-Aldrich. All glassware was soaked for 12 h in an alkali solution (diluted RBS T 105, pH 11–
12) and, after washing, glassware was rinsed with water and dried overnight at 400°C. Prior to use, glassware 
was rinsed with acetonitrile. 
 
Quality assurance/ Quality control (QA/QC) 
 
For implementation and to ensure reliability of the data obtained for the DEHP metabolites targeted in this 
study, several validation parameters (calibration linearity, accuracy, precision, and method limits of detection 
(LOD) and quantiﬁcation (LOQ)) were further tested (eTable 1C) and various QA/QC measures were taken 
during sample preparation.  
Multi-level calibration curves in the linear response interval of the detector were created for the 
quantification, and good correlation (r2 > 0.998) was achieved. Since the error on the measurements for 
calibrations should not increase with the concentration, the homoscedasticity was checked by plotting the 
residual error as function of the concentration. Calibration curves were accepted if errors showed a random 
distribution or if the occurring errors were not signiﬁcant in comparison to the obtained results. 
The identification of analytes was based on the relative retention times (RRTs) to the internal standards used 
for quantification, ion chromatograms and intensity ratios of the monitored transitions/ions. A deviation of the 
ion intensity ratios within 20% of the mean values obtained for calibration standards was considered acceptable. 
The internal QA/QC was performed by regular analyses of procedural blanks (3 blanks per batch of 20 
samples), random injection of standards, spiked samples (2 different concentration levels) and solvent blanks. 
The external quality control scheme was assessed through participation to inter-laboratory comparison exercises 
GERMAN EQUAS 2012, 2013 and 2014, for which the obtained concentrations of DEHP metabolites in urine 
deviated with less than 20% from the consensus values (eTable 1D). 
 
Concentrations below the LOQ (2 ng/ml) were assigned a value of 1.9 ng/ml. Concentrations were measured 
in ng/ml and converted to µmol/l for statistical analysis.  
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eMethods 3. Tests and questionnaires to assess neurocognitive functions 
 
Extensively validated tests and questionnaires were used to evaluate a broad range of neurocognitive 
functions, as previously described [1], including attention, motor coordination, inhibitory control and cognitive 
flexibility, general intellectual functioning, visual-motor integration, verbal and visual-spatial learning and 
memory, as well as behavior. 
Three computerized tasks of the Amsterdam Neuropsychological Tasks (ANT) system were used to quantify 
attention/alertness, motor coordination, and executive functions [2, 3]. Alertness was evaluated by the mean of 
the reaction time (msec) to 32 visual stimuli and the inconsistency of alertness by the standard deviation of the 
32 reaction times. Reaction times for the dominant and nondominant hands and overall reaction time were 
recorded. Motor coordination was evaluated by the “Tapping Task”, which counts the number of taps in 10 
seconds for the dominant hand, the nondominant hand, bimanual alternating taps and bimanual synchronous 
taps. Inhibitory control and cognitive flexibility are calculated by the difference in reaction time and in number 
of errors between tests of increasing demand in the “Response Organization Objects” test [3, 4]. 
Total IQ, verbal IQ, and performance IQ were scored with the Wechsler Preschool and Primary Scale of 
Intelligence-Revised (4-5 years) [5], Wechsler Intelligence Scale for Children-3rd Edition (6-16 years) [6], and 
Wechsler Adult Intelligence Scale-3rd Edition (17 years or older) [7], adapted for the Dutch language. The 
Beery-Buktenica Developmental Test of Visual-Motor Integration, 5th Edition (all ages) [8] was used to evaluate 
visual-motor integration. 
Specific verbal-auditory memory and nonverbal, visual-spatial memory functions were assessed with tasks 
from the Children’s Memory Scale (CMS, 5-16 years) [9]. Memory span and verbal working memory were 
assessed with a CMS test where numbers had to be repeated forward or backward, respectively. Proportion of 
correct responses (range 0-1) in the age-adjusted CMS pictures, word pairs and dots test were recorded. In the 
CMS pictures test, picture locations have to be recalled as a measure for visual-spatial memory span. The CMS 
word pairs and dots tests measure verbal-auditory (correctly completed word pairs in 3 learning trials) and 
nonverbal, visual-spatial learning (correctly recalled dot locations in 3 learning trials), immediate memory 
(correctly recalled word pairs or dot locations), delayed memory (correctly recalled word pairs or dot locations 
after delay of 25-35 minutes), and recognition (correctly recognized word pairs after delay of 25-35 minutes). 
Age-adjusted versions of the Child Behavior Checklist, filled out by the parents or the child’s legal guardian, 
scored internalizing, externalizing, and total behavioral problems [10, 11].   
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eMethods 4. Bootstrap selection of significant and stable potentially harmful thresholds 
for circulating DEHP metabolites  
 
In an initial visual exploratory analysis, we compared neurocognitive test results for the patients in the 
development cohort according to the quartiles of total exposure to circulating DEHP metabolites in univariable 
analysis (illustrated in eFigure 1 for alertness), as well as with a “lowess smoother” (data not shown). The results 
of these analyses suggested that there may be a threshold above which this exposure may be harmful for 
neurocognitive functions and provided the rationale for the identification of a threshold for potential harm in 
multivariable analyses [12]. 
Subsequently, unique exposure/concentration values in the development cohort were evaluated 
independently as a potential threshold for neurocognitive developmental harm. The stability of the identified 
thresholds was evaluated via bootstrap resampling of multivariable regression models. Bootstrapping is a 
computational technique introduced by Efron et al. [13] to estimate any statistic of a population from a small 
sample, and used in assessing the (in)stability of multivariable models [14]. Specifically, we made use of the 
0.632 variant of the bootstrap method [15], which is the preferred technique to assess stability in datasets 
comprising less than approximately 250 patients [16]. The following methodology was used to identify the 
potentially harmful thresholds for plasma concentrations or exposures to each of the different DEHP metabolites 
considered combined or separately.  
From the dataset comprising all exposure/concentration values of a given metabolite for the patients in the 
development cohort, 400 so-called “bootstrap sample” datasets were generated. The original development 
dataset consists of values from 228 patients; and each bootstrap sample is generated by random sampling with 
replacement so that it also contains 228 values. The probability that a bootstrap sample is identical to the original 
dataset is extremely low.  
With the exception of a subset of the extreme values, each unique possible value for a given 
exposure/concentration in every bootstrap replica was evaluated as a possible cut-off for potential harm with 
respect to a neurocognitive test. These values were dichotomized as > (greater-than) or ≤ (less-than or equal-to) 
the cut-off, and entered as a covariate in a multivariable regression analysis as described in the statistical analysis 
section. The exposure/concentration values that dichotomized the bootstrap replica into less than 10 patients per 
group (approximately 10% of the values) were not considered as possible-cut-offs. The model was adjusted for 
the following risk factors: age at PICU admission, gender, race, geographic and linguistic origin, history of 
malignancy or diabetes, prior to PICU admission presence of a syndrome or illness a priori defined as affecting 
neurocognitive development, socioeconomic status of the parents, type and severity of the critical illness, blood 
glucose management and the duration of PICU stay.   
The best cut-off for the bootstrap sample was identified via a minimum P-value approach in a multivariable 
model [17], and the overall model performance (highest R2) was used to decide in case of a tie with respect to P-
values [12]. The combined results from all bootstrap replicas produced a distribution of best cut-offs with their 
corresponding P-values. The bootstrap approach better assesses the variation in the cut-offs obtained across the 
resampled datasets [18]. For further evaluation we retained only the cases where: a) the median P-value was 
<0.05 and b) the variation of the cut-off distribution was small as compared to the variation in the measurements 
of the original dataset. This was empirically defined as an interquartile range in the cut-off distribution lower 
than 25% of the interquartile range of all data in the original dataset. Figure S2 illustrates this initial step of the 
methodology. 
The remaining cut-off distributions of the exposure/concentration of interest for each neurocognitive test were 
grouped into 3 categories: low, medium and high cut-offs. The final possibly potentially harmful thresholds were 
obtained via a second 0.632 bootstrap analysis. All cut-offs in the distributions selected from the previous step 
for each category are evaluated as potentially harmful thresholds for all neurocognitive tests in the same category 
via 400 bootstrap samples. The potentially harmful threshold for the category was identified via a minimum P-
value approach in a multivariable model [17], and the overall model performance (highest R2) was used to 
decide in case of a tie with respect to P-values [12] over all bootstrap samples and all neurocognitive tests in the 
same threshold category. The potentially harmful threshold for a neurocognitive test is kept for further analysis 
in the validation cohort only if the median, 25th percentile and 75th percentile p-values of the covariate for this 
threshold distribution are below 0.05. As in the previous step only the cut-offs that dichotomize the development 
cohort with at least 10 patients per group were used in the analyses. eFigure 3 illustrates this step. 
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eMethods 5. Sensitivity analyses for patients with a higher DEHP metabolite 
concentration on the last day in PICU than upon PICU admission  
 
We assumed that plasma concentrations of DEHP metabolites would be highest upon PICU admission and 
lowest on the last PICU day. This assumption was based on the fact that many patients were admitted after 
exposure to extracorporeal circuits for surgery [19] and on the number of indwelling medical devices that 
typically diminishes throughout PICU stay, taking into account the half-life of the metabolites (between 5-15h) 
[20]. The available evidence suggests that both the concentration of circulating DEHP metabolites to which the 
brain is exposed and the duration of this exposure determine any eventual long-term neurocognitive harm [21, 
22] within a concept of “threshold” toxicity [23]. Therefore, we decided to consider the product of the last day 
plasma concentration and the duration of PICU stay as that exposure to circulating phthalates during PICU stay 
that was minimally present for each patient, further referred to as the phthalate “exposure”. 
To exclude bias originating from patients in whom plasma concentrations of DEHP metabolites would be higher 
on the last PICU day than upon PICU admission, we performed two additional sensitivity analyses. 
First, we repeated the multivariable analyses for assessment of the associations with DEHP metabolite exposure 
after exclusion of the patients who had a higher DEHP metabolite concentration on the last day in PICU than at 
baseline. 
Second, we made a new classification of exceeding the potentially harmful threshold for DEHP exposure, where 
we calculated minimal exposure of patients with a higher DEHP metabolite concentration on the last PICU day 
as upon PICU admission as concentration of DEHP metabolites upon PICU admission multiplied with length of 
PICU stay, whereas the previous definition was used for the other patients. 
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SUPPLEMENTARY ONLINE FIGURES 
 
 
eFigure 1. Association of alertness with quartiles of exposure to total 
circulating DEHP metabolites  
Patients from the development cohort were divided in four equally sized groups according to the quartiles of the corresponding 
exposure to circulating DEHP metabolites (total concentration of DEHP metabolites multiplied with ICU stay). Measures of 
alertness and consistency of alertness are shown for the four groups. Data are presented as box plots, with the central line 
indicating the medians, the box the interquartile ranges and the whiskers the 10th and 90th percentiles. 
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eFigure 2. Selection of significant and stable cut-offs 
Bootstrap samples are generated from the original dataset of all values in the development cohort for one 
exposure/concentration (the distribution of these measurements is plotted in black). The 0.632 bootstrap method uses the data 
from the bootstrap sample and the original dataset to determine the best cut-off for that bootstrap sample. The distribution of 
best cutoffs for a given neurocognitive test is plotted in green. If a) the median P value of the covariate of this cutoff distribution 
is <0.05 and b) the cut-off distribution has an IQR < 25% of the IQR of the original dataset, then this cut-off distribution and 
neurocognitive test are selected for further analysis.  
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eFigure 3. Determination of a potentially harmful threshold per grouped 
responses 
The cut-off distributions for the neurocognitive tests remaining from the first analysis are grouped in categories: low (2 example 
distributions shown in red), medium (2 example distributions shown in green), high (1 example distribution shown in blue). A 
bootstrap analysis is performed to identify one potentially harmful threshold per grouped responses. If a) for the neurocognitive 
test in the group, the median, 25th percentile and 75th percentile P values of the covariate of this threshold distribution are < 0.05 
and b) the threshold dichotomizes the development cohort with at least 10 patients in each group, this threshold and 
neurocognitive test are kept for further analysis in the validation cohort. 
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eFigure 4. Circulating DEHP metabolites and number of indwelling medical 
devices on the last PICU day 
Panel A shows the plasma concentrations of the sum of all DEHP metabolites and the sum of the 3 MEHP metabolites per 
number of indwelling medical devices that were present during the 24h preceding the blood sampling in patients who were in 
PICU for more than 24h. The absence of a significant correlation between the number of indwelling medical devices and the 
plasma DEHP metabolite concentrations was explained by a significant impact of kidney function (multivariable estimate +0.47 
(95 CI 0.01-0.92) µmol/l of total DEHP metabolites per mg/dl increase in peak plasma creatinine, P=0.04; multivariable estimate 
+0.42 (95 CI 0.08-0.76) µmol/l of the 3 MEHP metabolites per mg/dl increase in peak plasma creatinine, P=0.01). Panel B 
shows the number of indwelling medical devices present during the 24h preceding the blood sampling of critically ill children with 
plasma concentrations of the 3 MEHP metabolites exceeding the potentially harmful threshold of 0.245 µmol/l versus those with 
lower concentrations. Data are presented as box plots, with the central line indicating the medians, the box the interquartile 
ranges and the whiskers the 10th and 90th percentiles. 
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SUPPLEMENTARY ONLINE TABLES 
eTable 1. Methodological details and quality assessment of phthalate 
metabolite quantification 
A. Mass transitions for quantification of di(2-ethylhexyl)phthalate metabolites in plasma 
DEHP Metabolite Abbreviation MRM 
Mono-(2-ethyl-5-carboxypentyl) phthalate 5cx-MEPP 307-159.1/ 307-113 
     13C4-Mono-(2-ethyl-5-carboxypentyl) phthalate 13C4-5cx-MEPP 311-159.1/ 311-113 
Mono-(2-ethyl-5-hydroxyhexyl) phthalate 5OH-MEHP 293-120.9/ 293-145 
     13C4-Mono-(2-ethyl-5-hydroxyhexyl) phthalate 13C4-5OH-MEHP 297-123.9 
Mono-(2-ethyl-5-oxohexyl) phthalate 5oxo-MEHP 291-121/ 291-143.1 
     13C4-Mono-(2-ethyl-5-oxohexyl) phthalate 13C4-5oxo-MEHP 295-124 
Mono-(2-ethylhexyl) phthalate MEHP 276.7-134/ 276.7-127.1 
     13C4-Mono-(2-ethylhexyl) phthalate 13C4-MEHP 280.7-137 
Quantified DEHP metabolites and the corresponding internal standards with ions used for the analyte quantification and 
qualification is given. Bold values for multiple reaction monitoring (MRM) represent the transitions used for the quantification by 
LC-(ESI)-MS/MS. Individual standards of phthalate metabolites and corresponding 13C-labeled standards were obtained from 
Cambridge Isotope Laboratories, Inc. (Andover, MA). 
 
B. Instrumental conditions employed for the analysis of the DEHP metabolites in plasma 
Instrument Agilent LC 1200, QqQ MS 
Ionization source ESI, negative 
Column Kinetex C18 (100 × 4.60 mm) 2.6µ, 100A 
Mobile phase 
A: H2O, 0.1% acetic acid 
B: acetonitrile, 0.1% acetic acid 
Gradient Time (min) B (%) 
0 15 
4 15 
4.01 45 
10 45 
10.01 100 
20 100 
20.01 15 
30 15 
Flow 0.2 ml/min, constant 
  
C. Validation of the methodology for determination of DEHP metabolites in plasma 
Analyte LOQ 
(ng/mL) 
Spike level 
(ng) 
Recovery 
(%) 
Method precision 
(%, RSD) 
Linear 
regression 
coefficient, r 
MEHP 2.0 10 92 6 0.996 
5cx-MEPP 2.0 10 85 6 0.996 
5OH-MEHP 2.0 10 88 4 0.995 
5oxo-MEHP 2.0 10 91 5 0.996 
LOQ: limit of quantification; RSD: relative standard deviation. 
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D. External quality control of DEHP metabolite quantification method 
 
Analyte comparison 2012, round 49 Solution Result UA Certified Value Tolerance range 
5cx-MEPP A 12.7 11.85 8.70 – 15.00 
 B 85.7 80.25 67.50 – 93.00 
5OH-MEHP A 10.7 9.77 7.04 – 12.50 
 B 87.2 80.27 63.41 – 97.13 
5oxo-MEHP A 6.6 6.15 4.62 – 7.68 
 B 48.7 48.11 40.31 – 55.91 
 
Analyte comparison 2013, round 51 Solution Result UA Reference Value Tolerance range 
MEHP A 3.5 3.3 1.7 – 4.8 
 B 16.8 14.4 10.5 – 18.3 
5cx-MEPP A 32.1 32.9 24.7 – 41.1 
 B 96.4 98.8 85.8 – 111.9 
5OH-MEHP A 22.5 23.1 17.5 – 28.7 
 B 74.7 75.8 61.5 – 90.1 
5oxo-MEHP A 16.4 17.6 13.7 – 21.3 
 B 56.0 58.9 47.6 – 70.2 
 
Analyte comparison 2014, round 53 Solution Result UA Reference Value Tolerance range 
MEHP A 10.7 9.8 7.0 – 12.7 
 B 24.6 22.8 16.7 – 28.9 
5cx-MEPP A 52.6 59.4 46.8 – 72.1 
 B 204.2 221.0 186.6 – 255.5 
5OH-MEHP A 43.1 47.0 33.6 – 60.4 
 B 168.4 189.3 144.4 – 234.2 
5oxo-MEHP A 28.0 32.5 22.6 – 42.4 
 B 118.1 138.0 105.2 – 170.9 
 
Analyte comparison 2014, round 54 Solution Result UA Reference Value Tolerance range 
MEHP A 4.7 4.1 2.8 – 5.4 
 B 16.7 14.2 10.2 – 18.1 
5cx-MEPP A 41.8 46.4 33.0 – 59.7 
 B 161.6 164.9 141.6 – 188.1 
5OH-MEHP A 30.5 34.0 25.2 – 42.7 
 B 114.0 120.0 103.8 – 136.2 
5oxo-MEHP A 22.3 24.5 19.4 – 29.7 
 B 97.0 103.8 91.4 – 116.2  
Comparison is given between reported data on the analysis of urinary DEHP metabolites (ng/ml) and the consensus range for 
each individual metabolite included in the inter-laboratory comparison exercise, GERMAN EQUAS 2012 round 49, GERMAN 
EQUAS 2013 round 51, GERMAN EQUAS 2014 round 53 and round 54. UA-University of Antwerp 
  
15 
 
eTable 2A. Neurocognitive test results in critically ill and healthy children 
 
  Critically ill children 
 
Neurocognitive tests 
Healthy 
children a 
Development 
cohort 
Validation 
cohort 
Attention, motor coordination and executive functions    
     Alertness (msec)    
          Reaction time dominant hand 558 (521-595) 697 (649-745) 730 (682-778) 
          Reaction time nondominant hand 562 (524-600) 670 (626-713) 709 (663-754) 
          Reaction time overall 560 (524-596) 680 (635-724) 718 (672-764) 
     Inconsistency of alertness (msec)    
          SD reaction time dominant hand 259 (229-290) 395 (357-434) 416 (375-457) 
          SD reaction time nondominant hand 262 (232-292) 347 (313-382) 401 (362-440) 
          SD reaction time overall 275 (246-304) 385 (351-420) 423 (385-461) 
     Motor coordination (number of taps in 10s)    
          Number of unimanual taps    
               Dominant hand 36 (34-38) 32 (30-34) 31 (29-33) 
               Nondominant hand 32 (30-33) 27 (26-29) 26 (24-28) 
          Number of valid alternating taps 19 (17-22) 13 (11-15) 13 (11-15) 
          Number of valid synchronous taps 22 (20-24) 18 (17-20) 17 (16-19) 
     Inhibition and flexibility    
          ∆ Reaction time (inhibition), msec 294 (255-333) 323 (278-369) 378 (325-431) 
          ∆ Number of errors (inhibition) 2 (1-2) 2 (1-2) 3 (2-4) 
          ∆ Reaction time (flexibility), msec 584 (537-632) 617 (567-668) 636 (580-692) 
          ∆ Number of errors (flexibility) 2 (2-3) 2 (1-2) 3 (2-3) 
Intelligence – full scale IQ (range, 45-155) 102 (100-104) 88 (86-90) 85 (83-88) 
Visual-motor integration (range, 0.9-20) 10 (10-10) 9 (8-9) 8 (8-9) 
Memory    
     Verbal-auditory    
          Numbers (range, 1-19)    
               Memory span (repeating numbers forward) 9 (9-10) 8 (7-9) 8 (7-8) 
               Working memory (repeating numbers backward) 11 (10-11) 9 (8-9) 9 (8-9) 
          Word pairs (proportion of correct responses)    
               Learning 0.52 (0.49-0.55) 0.44 (0.41-0.48) 0.41 (0.38-0.45) 
               Immediate memory 0.50 (0.46-0.53) 0.36 (0.32-0.40) 0.33 (0.29-0.37) 
               Delayed memory 0.42 (0.38-0.45) 0.31 (0.27-0.34) 0.27 (0.23-0.30) 
               Recognition 0.96 (0.95-0.98) 0.93 (0.90-0.95) 0.90 (0.87-0.93) 
     Non-verbal, visual-spatial (proportion of correct responses)    
          Pictures: Memory span 0.86 (0.84-0.88) 0.80 (0.78-0.83) 0.75 (0.72-0.78) 
          Dots: Learning 0.86 (0.84-0.89) 0.78 (0.75-0.81) 0.74 (0.71-0.78) 
          Dots: Immediate memory 0.87 (0.84-0.90) 0.77 (0.73-0.82) 0.73 (0.68-0.78) 
          Dots: Delayed memory 0.86 (0.82-0.89) 0.75 (0.70-0.79) 0.73 (0.68-0.78) 
     Learning index (range, 50-150) 100 (97-102) 92 (89-94) 89 (86-92) 
Behavior (by proxy), T score    
     CBCL-internalizing problems (range, 29-100) 49 (47-50) 54 (52-55) 52 (51-54) 
     CBCL-externalizing problems (range, 28-100) 48 (46-49) 50 (49-52) 50 (49-52) 
     CBCL-total problems (range, 24-100) 48 (46-49) 52 (51-54) 52 (51-54) 
IQ, intelligence quotient; CBCL, Child Behavior Checklist. For intelligence, visual-motor integration, motor coordination and memory, 
higher scores reflect better performance. For reaction times, inconsistency of alertness, inhibition and flexibility, higher scores reflect 
worse performance. Internalizing problems (e.g. anxious/depressed behavior) and externalizing problems (e.g. aggressive behavior) are 
calculated as standardized T-scores, which indicate the presence of behavioral problems when higher than 60.S10,S11 Memory was only 
tested from the age of 5 years onwards (N=124 for the healthy control group, N=96 for the development cohort and N=102 for the 
validation cohort. Ranges indicate the respective range of possible scores. Data are presented as means and 95% confidence intervals. 
a 215 healthy children neurocognitively tested in Mesotten et al [1]. 
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eTable 2B. Neurocognitive test results in critically ill and healthy children 
 
Neurocognitive tests Healthy children a Critically ill children 
Attention, motor coordination and executive functions   
     Alertness (msec)   
          Reaction time dominant hand 230 – 1557 221 – 2189 
          Reaction time nondominant hand 223 – 1532 207 – 1883 
          Reaction time overall 227 – 1428 214 – 1843 
     Inconsistency of alertness (msec)   
          SD reaction time dominant hand 24 – 1004 30 – 1258 
          SD reaction time nondominant hand 19 – 982 22 – 1168 
          SD reaction time overall 29 – 861 34 – 1141 
     Motor coordination (number of taps in 10s)   
          Number of unimanual taps   
               Dominant hand 10 – 66 1 – 76 
               Nondominant hand 8 – 79 2 – 89 
          Number of valid alternating taps 0 – 79 0 – 97 
          Number of valid synchronous taps 0 – 52 0 – 58 
     Inhibition and flexibility   
          ∆ Reaction time (inhibition), msec -345 – 1363 -557 – 1640 
          ∆ Number of errors (inhibition) -9 – 26 -11 – 29 
          ∆ Reaction time (flexibility), msec -361 – 1504 -817 – 1680 
          ∆ Number of errors (flexibility) -6 – 29 -7 – 16 
Intelligence – full scale IQ (range, 45-155) 57 – 142 45 – 139 
Visual-motor integration (range, 0.9-20) 4 – 17 0.9 – 19 
Memory   
     Verbal-auditory   
          Numbers (range, 1-19)   
               Memory span (repeating numbers forward) 3 – 19 2 – 18 
               Working memory (repeating numbers backward) 3 – 18 1 – 17 
          Word pairs (proportion of correct responses)   
               Learning 0.17 – 0.93 0.03 – 0.83 
               Immediate memory 0.00 – 1.00 0.00 – 1.00 
               Delayed memory 0.00 – 0.93 0.00 – 0.64 
               Recognition 0.57 – 1.00 0.40 – 1.00 
     Non-verbal, visual-spatial (proportion of correct responses)   
          Pictures: Memory span 0.53 – 1.00 0.27 – 1.00 
          Dots: Learning 0.50 – 1.00 0.17 – 1.00 
          Dots: Immediate memory 0.33 – 1.00 0.13 – 1.00 
          Dots: Delayed memory 0.17 – 1.00 0.13 – 1.00 
     Learning index (range, 50-150) 67 – 135 50 – 125 
Behavior (by proxy), T score   
     CBCL-internalizing problems (range, 29-100) 29 – 78 29 – 90 
     CBCL-externalizing problems (range, 28-100) 28 – 79 28 – 97 
     CBCL-total problems (range, 24-100) 28 – 76 28 – 86 
IQ, intelligence quotient; CBCL, Child Behavior Checklist. For intelligence, visual-motor integration, motor coordination and memory, 
higher scores reflect better performance. For reaction times, inconsistency of alertness, inhibition and flexibility, higher scores reflect 
worse performance. Internalizing problems (e.g. anxious/depressed behavior) and externalizing problems (e.g. aggressive behavior) are 
calculated as standardized T-scores, which indicate the presence of behavioral problems when higher than 60.S10,S11 Memory was only 
tested from the age of 5 years onwards (N=124 for the healthy control group, N=198 for the critically ill group. Ranges indicated with the 
tests indicate the respective range of possible scores. Data are presented as the ranges of the actual scores of the children that were 
tested here. a 215 healthy children neurocognitively tested in Mesotten et al [1]. 
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eTable 3. Evaluation of DEHP leaching from indwelling medical devices and their accessories 
 
 
 
ACCESS 
INDWELLING MEDICAL DEVICES AND ESSENTIAL ACCESSORIES 
Leaching DEHP Not leaching DEHP 
Product Reference Product Reference 
Intravascular Intravenous, central: 
catheters and accessories 
Burette from Dialex Biomedica© 
Monitoring Set from Edwards© 
1.101.834 
T322242B 
2-way infusion system from Dialex Biomedica© 
Central venous catheters from: 
Cook©  
Arrow© 
1.101.569 
 
C-SDLM-401J 
ES-04150 
Intravenous, peripheral: 
catheters and accessories 
Peripheral intravenous catheters from BD© 381323 2-way infusion system from Dialex Biomedica© 1.101.569 
Arterial catheters and 
accessories 
Monitoring Set from Edwards© 
Vamp Junior from Edwards© 
Arterial catheters from BD© 
T322242B 
VMP306 
381123 
Baby Flush from ICU Medical© 
Arterial catheters from BD© 
011-H3543 
381112 
682245 
Blood transfusion systems 
and accessories 
Blood infusion system from Baxter© EMC0349 Burette from Hospira© 14202 
Parenteral nutrition Parenteral nutrition bags from: 
Fresenius Kabi©  
Baxter© (Olimel N7E 1500 ml) 
 
B2859061 
JDB3WG1F 
Parenteral nutrition bags from Baxter© 
 
E13020D 
E13100D 
Extravascular Endotracheal tubes Tracheal tubes from: 
Portex© 
 
Mallinckrodt Pharmaceuticals©  
 
Hudson RCI© 
 
100/105/040  
100/111/060 
111-50 
107-75 
5-10108 
  
Gastric tubes Gastric tubes from:  
Vygon©  
Covidien© 
 
312.06 
8888265215 
  
Chest tubes and 
accessories 
Chest tubes from:  
Biovac© 
Cook© 
 
MW-3240 
C-PPD-850-WCE-IMH 
Trocart Catheter from Covidien© 8888561027 
Bladder catheters Bladder catheters from Coloplast© AA6106 Bladder catheters from RÜSH© 178000 
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eTable 4-1. Identification of a potentially harmful threshold for total circulating DEHP metabolite exposure  
 
A. Descriptive statistics 
Exposure to Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
Total DEHP metabolites 228 228 0.779096347 0.342825765 2.65980847 2.316982705 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Memory span, numbers 0.143670286 0.133669352 0.158417234 1.07 0.445208161 0.000511239 
Valid alternating taps 0.151467872 0.121789452 0.539447492 18.03 0.392184844 0.025200611 
Flexibility, no. of errors 0.191940639 0.051886074 1.670249568 69.85 0.203026651 0.148026269 
Delayed memory, word pairs 0.194520746 0.189360531 0.267549318 3.37 0.4366197 0.020672514 
Memory, learning dots 0.206213742 0.110435775 0.332131235 9.57 0.383884834 0.005619255 
Memory, learning index 0.206213742 0.0742137 0.339191614 11.44 0.50811701 0.014135509 
Immediate memory, word pairs 0.267549318 0.194520746 1.099340726 39.05 0.415275622 0.086384103 
Memory, learning word pairs 0.515685042 0.320136106 0.750663806 18.58 0.422403776 0.216127217 
Valid synchronous taps 0.521530322 0.449562424 0.550840276 4.37 0.665907155 0.000665777 
Reaction time dominant hand 0.550840276 0.539447492 0.662911628 5.33 0.58889347 0.000275916 
Overall reaction time 0.550840276 0.543450892 0.773896204 9.95 0.610242084 0.000444206 
Tapping nondominant hand 0.550840276 0.536405246 0.784296489 10.70 0.771988658 0.017782567 
Memory, recognition word pairs 0.614366643 0.091928441 0.627847002 23.13 0.371859993 0.063394432 
Delayed memory, dots 0.662911628 0.206213742 5.367595338 222.76 0.376333035 0.135551668 
Working memory 0.683336988 0.435053444 0.773896204 14.62 0.368451424 0.036491498 
Inhibition, ∆ reaction time 0.683336988 0.46387171 3.852489087 146.25 0.287961843 0.06897673 
Reaction time nondominant hand 0.753720162 0.550840276 0.883647126 14.36 0.564002771 0.001276149 
Tapping dominant hand 0.767363568 0.550840276 7.536841592 301.51 0.768181597 0.031658515 
Visual-motor integration 0.784296489 0.398008486 1.354535502 41.28 0.369773452 0.094379326 
Externalizing problems 0.886750746 0.261250575 5.012589435 205.07 0.187101664 0.324292474 
Total behavioral problems 1.031935378 0.261250575 7.892008515 329.34 0.219259905 0.238124858 
Memory span, pictures 1.279688322 0.364714796 5.134469873 205.86 0.483989488 0.185579236 
Inhibition, no. of errors 2.662411884 0.424722276 2.866534115 105.39 0.14069656 0.048655446 
Verbal IQ 3.38976969 0.136586557 3.579672685 148.60 0.380477581 0.024910988 
Full-scale IQ 3.475090696 0.217754045 3.579672685 145.10 0.37081073 0.020084966 
Internalizing problems 3.475090696 0.334032527 10.7580311 449.90 0.222447232 0.216614423 
Performance IQ 3.579672685 0.804960108 14.92518408 609.42 0.317392131 0.023300757 
Immediate memory, dots 7.044402204 1.354535502 10.7580311 405.85 0.401223192 0.001697544 
Flexibility, ∆ reaction time 8.627097918 2.679551866 16.4259857 593.29 0.317867768 0.029917931 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together around a similar cut-off are shown 
in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.133669352 Memory span, numbers 0.456035568 0.000228169 0.000166629 0.00155615 
Memory, learning dots 0.367560744 0.009003253 0.005943164 0.024913385 
Memory, learning index 0.475160863 0.107771088 0.07205136 0.195748668 
Delayed memory, word pairs 0.421010706 0.034506423 0.025037878 0.068810117 
Valid alternating taps 0.371736381 0.59727575 0.520610327 0.718849658 
0.550840276 Overall reaction time 0.613460036 0.0000834 0.0000528 0.000596427 
Reaction time dominant hand 0.589378727 0.000125005 0.0000716 0.000500706 
Valid synchronous taps 0.667359331 0.00050767 0.000267123 0.002461922 
Reaction time nondominant hand 0.565142773 0.000529972 0.000366328 0.003027742 
Tapping nondominant hand 0.772780822 0.009737228 0.005759908 0.025941555 
Working memory 0.343977504 0.12523501 0.094619111 0.231083458 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. Both thresholds dichotomize the development cohort 
with at least 10 patients per group and are retained for further analyses. Neurocognitive tests are ordered from the lowest to the highest median exposure 
covariate P value found for comparison of patients according to the identified potentially harmful threshold.  
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eTable 4-2. Identification of a potentially harmful threshold for total circulating MEHP metabolite exposure  
 
A. Descriptive statistics 
Exposure to Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
Total MEHP metabolites 228 228 0.473072615 0.218775794 1.775369139 1.556593345 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Inhibition, no. of errors 0.021387148 0.021387148 1.191199159 75.15 0.198924332 0.0000113 
Memory, recognition word pairs  0.03144131 0.021387148 0.250863337 14.74 0.417899227 0.001761387 
Memory, learning index 0.043117112 0.021387148 0.216860657 12.56 0.496707124 0.025819153 
Memory, learning dots 0.061242492 0.021387148 0.242893228 14.23 0.362731921 0.087113465 
Delayed memory, word pairs 0.061242492 0.043117112 0.236277541 12.41 0.411164461 0.123376802 
Valid alternating taps 0.112620719 0.086901369 0.607738767 33.46 0.383348874 0.094179791 
Memory span, numbers 0.118667007 0.11672104 0.364705952 15.93 0.400740633 0.028220267 
Immediate memory, word pairs 0.213956516 0.045063079 0.445413 25.72 0.4070281 0.187229517 
Memory, learning word pairs 0.250863337 0.11022957 0.460060208 22.47 0.425370087 0.098384389 
Visual-motor integration 0.264266822 0.045063079 0.64477232 38.53 0.371199871 0.063581423 
Memory span, pictures 0.289237642 0.021387148 1.977354132 125.66 0.497322453 0.080253591 
Flexibility, no. of errors 0.318487242 0.080396323 2.408666507 149.57 0.196486829 0.154280849 
Delayed memory, dots 0.331950185 0.078900475 1.977354132 121.96 0.368035721 0.314942106 
Valid synchronous taps 0.352831701 0.35192904 0.389415405 2.41 0.660464737 0.002396296 
Overall reaction time 0.364705952 0.362281636 0.391998458 1.91 0.615477434 0.0000971 
Reaction time dominant hand 0.364705952 0.364705952 0.432444829 4.35 0.589873273 0.00011341 
Reaction time nondominant hand 0.389415405 0.364705952 0.449527327 5.45 0.564489151 0.001005303 
Working memory 0.416968924 0.269336151 0.520044835 16.11 0.398837827 0.0075893 
Inhibition, ∆ reaction time 0.460060208 0.432444829 2.141713834 109.81 0.296746369 0.02675596 
Tapping dominant hand 0.586526686 0.128241477 6.12713228 385.39 0.769023437 0.038423401 
Tapping nondominant hand 0.606416662 0.268713597 3.917846097 234.43 0.768757733 0.063612044 
Performance IQ 0.645051793 0.022360131 6.787361443 434.60 0.327524068 0.004662879 
Externalizing problems 0.856153153 0.264266822 4.145566682 249.35 0.187861415 0.248474572 
Full-scale IQ 3.109146442 0.022360131 3.885859353 248.20 0.377265652 0.00442295 
Verbal IQ 3.109146442 0.095315404 3.117832389 194.18 0.384282106 0.013316581 
Total behavioral problems 3.117832389 0.406434099 5.860541167 350.39 0.221104076 0.162878696 
Immediate memory, dots 3.238985638 0.235777629 8.245434559 514.56 0.390920609 0.01568226 
Internalizing problems 3.238985638 0.712552764 5.124914255 283.46 0.228192537 0.094565592 
Flexibility, ∆ reaction time 4.53192005 0.119249716 12.30178464 782.64 0.320392501 0.025894113 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together around a similar cut-off are shown 
in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.021387148 
 
 
0.364705952 
Memory, recognition word pairs 0.416519471 0.000453118 0.000441799 0.000571175 
Memory, learning index 0.50249533 0.004299438 0.004035218 0.005972278 
Memory span, numbers 0.348377053 0.380427605 0.323205082 0.431830043 
Overall reaction time 0.618699698 0.0000368 0.0000204 0.000221145 
Reaction time dominant hand 0.594789034 0.0000491 0.0000286 0.000278926 
Reaction time nondominant hand 0.567307737 0.000335429 0.000203957 0.001901431 
Valid synchronous taps 0.662466894 0.002374469 0.001192846 0.00931671 
Working memory 0.358960568 0.047590038 0.040114119 0.099208925 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. Only the green threshold dichotomizes the development 
cohort with at least 10 patients per group and is retained for further analyses. Neurocognitive tests are ordered from the lowest to the highest median exposure 
covariate P value found for comparison of patients according to the identified potentially harmful threshold.  
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eTable 4-3. Identification of a potentially harmful threshold for circulating MEHP exposure  
 
A. Descriptive statistics 
Exposure to Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
MEHP 228 210 0.225982611 0.098800029 0.680283107 0.581483078 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Memory span, numbers 0.01652655 0.01652655 0.030897464 2.47 0.456156939 0.000226 
Delayed memory, word pairs 0.046705468 0.041316376 0.05460947 2.29 0.464414384 0.001429523 
Valid alternating taps 0.048501832 0.048501832 0.403822663 61.11 0.388447357 0.01932192 
Memory, learning dots 0.051016742 0.047424014 0.266580441 37.69 0.374734968 0.011173828 
Memory, learning index 0.055328016 0.05460947 0.066106201 1.98 0.524543499 0.004446924 
Full-scale IQ 0.055328016 0.040957103 0.517352878 81.93 0.36407142 0.067974087 
Verbal IQ 0.055328016 0.030538191 0.477293957 76.83 0.373988538 0.093855571 
Memory, learning word pairs 0.08119566 0.055328016 0.118560034 10.87 0.43721618 0.046937764 
Immediate memory, word pairs 0.08119566 0.05460947 0.485018323 74.02 0.417195211 0.134193896 
Reaction time nondominant hand 0.118560034 0.103470576 0.1573615 9.27 0.559747605 0.002257383 
Tapping dominant hand 0.13580513 0.10778185 0.506574693 68.58 0.766258683 0.088347566 
Externalizing problems 0.137242222 0.048322196 0.69519293 111.24 0.208736425 0.014992751 
Overall reaction time 0.150714953 0.10778185 0.1573615 8.53 0.601436331 0.001913259 
Valid synchronous taps 0.155205863 0.109937487 0.1573615 8.16 0.673002843 0.0000923 
Reaction time dominant hand 0.155205863 0.10778185 0.1573615 8.53 0.574663982 0.005822439 
Tapping nondominant hand 0.1573615 0.115326579 0.364302651 42.82 0.771482955 0.03507091 
Total behavioral problems 0.165984048 0.103829849 1.901271826 309.11 0.238312539 0.008833957 
Working memory 0.170295322 0.061076381 0.328016095 45.91 0.34648295 0.197715935 
Delayed memory, dots 0.198677876 0.055328016 1.921391104 320.91 0.395776692 0.038840386 
Visual-motor integration 0.204426241 0.099159302 0.837464971 126.97 0.366179988 0.094847986 
Memory, recognition word pairs 0.348135374 0.328016095 0.348135374 3.46 0.416498886 0.001576333 
Performance IQ 0.388014658 0.055328016 0.816986419 130.99 0.306226162 0.108983294 
Flexibility, no. of errors 0.394481569 0.023712007 1.929295107 327.71 0.199400909 0.110967296 
Memory span, pictures 0.395559388 0.027484372 2.512394913 427.34 0.499064093 0.082270048 
Inhibition, no. of errors 0.633757275 0.080477114 0.953869368 150.20 0.128412414 0.169810064 
Inhibition, ∆ reaction time 0.816986419 0.241431343 7.996335417 1333.64 0.283228787 0.235367451 
Internalizing problems 1.76223324 0.10778185 1.922828196 312.14 0.244751977 0.008112363 
Immediate memory, dots 2.512394913 0.721060573 3.809010563 531.05 0.406544379 0.001508481 
Flexibility, ∆ reaction time 4.123733563 0.684055472 5.165624775 770.71 0.321264817 0.043496988 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together around a similar cut-off are shown 
in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.01652655 
 
 
0.1573615 
Memory span, numbers 0.468627111 0.000115141 0.0000630 0.001830743 
Delayed memory, word pairs 0.399560086 0.122722085 0.093620448 0.19019494 
Memory, learning index 0.45822248 0.387351835 0.304616069 0.500786651 
Valid synchronous taps 0.674635535 0.0000572 0.0000207 0.000336337 
Overall reaction time 0.605268151 0.000902865 0.000610691 0.004057737 
Reaction time nondominant hand 0.562165676 0.001344824 0.000892403 0.004666121 
Reaction time dominant hand 0.577159492 0.002661985 0.001815565 0.008299062 
0.348135374 Memory, recognition word pairs 0.427473318 0.000679273 0.000492455 0.008760581 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. Only the green and blue thresholds dichotomize the 
development cohort with at least 10 patients per group and is retained for further analyses. Neurocognitive tests are ordered from the lowest to the highest 
median exposure covariate P value found for comparison of patients according to the identified potentially harmful threshold.  
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eTable 4-4. Identification of a potentially harmful threshold for circulating 5cx-MEPP exposure  
 
A. Descriptive statistics 
Exposure to Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
5cx-MEPP 228 214 0.386436611 0.165407194 1.230824117 1.065416923 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Inhibition, no. of errors 0.008432524 0.008432524 0.526059741 48.58 0.204914231 0.00000751 
Memory, learning index 0.018486686 0.008432524 0.201083255 18.08 0.497880348 0.021096827 
Memory, recognition word pairs 0.018486686 0.008432524 0.18681283 16.74 0.402612983 0.021986774 
Memory, learning dots 0.040540979 0.008432524 0.231894399 20.97 0.361895257 0.087121698 
Flexibility, no. of errors 0.056433043 0.032108455 0.991794506 90.08 0.203939268 0.057235519 
Delayed memory, word pairs 0.082379269 0.032108455 0.18681283 14.52 0.417082958 0.071529196 
Immediate memory, word pairs 0.09275776 0.050270814 0.244218856 18.20 0.409251866 0.181386072 
Memory span, numbers 0.11805533 0.02237862 0.306814128 26.70 0.395681763 0.037212558 
Valid alternating taps 0.145298868 0.057406026 5.69584536 529.22 0.380053094 0.178293631 
Memory, learning word pairs 0.177082995 0.069406156 0.304219505 22.04 0.424458983 0.13162662 
Memory span, pictures 0.252002725 0.008432524 1.452988681 135.59 0.499004961 0.098760616 
Valid synchronous taps 0.305516816 0.213083385 0.687575001 44.54 0.651481804 0.069236927 
Delayed memory, dots 0.305516816 0.040540979 1.628774365 149.07 0.369450978 0.190295554 
Working memory 0.378814906 0.262056887 0.38270684 11.32 0.405943121 0.003988965 
Overall reaction time 0.387571758 0.244218856 0.670709954 40.03 0.597955832 0.005962203 
Inhibition, ∆ reaction time 0.387571758 0.344436156 2.084130639 163.29 0.29968163 0.009767576 
Reaction time dominant hand 0.395193462 0.244218856 0.670709954 40.03 0.578355551 0.004191985 
Reaction time nondominant hand 0.402815166 0.241948562 0.687575001 41.83 0.551504913 0.024145523 
Visual-motor integration 0.433626309 0.060324976 3.038465281 279.53 0.373362084 0.053500674 
Tapping dominant hand 0.526059741 0.165407194 4.352155158 392.97 0.767152192 0.031265811 
Performance IQ 0.53514092 0.009405507 4.352155158 407.61 0.328978642 0.005337256 
Flexibility, ∆ reaction time 0.636817696 0.05546006 8.268089385 770.84 0.320594629 0.033636118 
Tapping nondominant hand 0.711250933 0.09567671 2.830733305 256.71 0.76848645 0.075051208 
Immediate memory, dots 1.663801771 0.056433043 4.91259365 455.80 0.397862514 0.010912635 
Full-scale IQ 2.530405734 0.018162359 4.36383096 407.88 0.378248984 0.00308717 
Internalizing problems 2.530405734 2.516783965 3.942529108 133.82 0.245045925 0.003891829 
Verbal IQ 2.530405734 0.091136121 3.988907988 365.84 0.386256884 0.013705281 
Externalizing problems 3.455388707 0.199461616 10.07362242 926.79 0.193329051 0.196570563 
Total behavioral problems 3.942529108 2.452891383 10.07362242 715.28 0.228085349 0.044486037 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together around a similar cut-off are shown 
in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.008432524 Memory, learning index 0.500464381 0.004395556 0.004031862 0.006697831 
 Memory, recognition word pairs 0.416093382 0.000457298 0.000441704 0.000643282 
0.378814906 Working memory 0.418206604 0.000917655 0.00082055 0.002173791 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. Only the green threshold dichotomizes the development 
cohort with at least 10 patients per group and is retained for further analyses. Neurocognitive tests are ordered from the lowest to the highest median exposure 
covariate P value found for comparison of patients according to the identified potentially harmful threshold.  
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eTable 4-5. Identification of a potentially harmful threshold for circulating 5OH-MEHP exposure  
 
A. Descriptive statistics 
Exposure to Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
5OH-MEHP 228 161 0.055378135 0.023102534 0.262281715 0.239179181 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Inhibition, no. of errors 0.008432524 0.008432524 0.526059741 216.42 0.204914231 0.00000751 
Memory, learning index 0.018486686 0.008432524 0.201083255 80.55 0.497880348 0.021096827 
Memory, recognition word pairs 0.018486686 0.008432524 0.18681283 74.58 0.402612983 0.021986774 
Memory, learning dots 0.040540979 0.008432524 0.231894399 93.43 0.361895257 0.087121698 
Flexibility, no. of errors 0.056433043 0.032108455 0.991794506 401.24 0.203939268 0.057235519 
Delayed memory, word pairs 0.082379269 0.032108455 0.18681283 64.68 0.417082958 0.071529196 
Immediate memory, word pairs 0.09275776 0.050270814 0.244218856 81.09 0.409251866 0.181386072 
Memory span, numbers 0.11805533 0.02237862 0.306814128 118.92 0.395681763 0.037212558 
Valid alternating taps 0.145298868 0.057406026 5.69584536 2357.41 0.380053094 0.178293631 
Memory, learning word pairs 0.177082995 0.069406156 0.304219505 98.17 0.424458983 0.13162662 
Memory span, pictures 0.252002725 0.008432524 1.452988681 603.96 0.499004961 0.098760616 
Valid synchronous taps 0.305516816 0.213083385 0.687575001 198.38 0.651481804 0.069236927 
Delayed memory, dots 0.305516816 0.040540979 1.628774365 664.03 0.369450978 0.190295554 
Working memory 0.378814906 0.262056887 0.38270684 50.44 0.405943121 0.003988965 
Overall reaction time 0.387571758 0.244218856 0.670709954 178.31 0.597955832 0.005962203 
Inhibition, ∆ reaction time 0.387571758 0.344436156 2.084130639 727.36 0.29968163 0.009767576 
Reaction time dominant hand 0.395193462 0.244218856 0.670709954 178.31 0.578355551 0.004191985 
Reaction time nondominant hand 0.402815166 0.241948562 0.687575001 186.31 0.551504913 0.024145523 
Visual-motor integration 0.433626309 0.060324976 3.038465281 1245.15 0.373362084 0.053500674 
Tapping dominant hand 0.526059741 0.165407194 4.352155158 1750.47 0.767152192 0.031265811 
Performance IQ 0.53514092 0.009405507 4.352155158 1815.69 0.328978642 0.005337256 
Flexibility, ∆ reaction time 0.636817696 0.05546006 8.268089385 3433.67 0.320594629 0.033636118 
Tapping nondominant hand 0.711250933 0.09567671 2.830733305 1143.52 0.76848645 0.075051208 
Immediate memory, dots 1.663801771 0.056433043 4.91259365 2030.34 0.397862514 0.010912635 
Full-scale IQ 2.530405734 0.018162359 4.36383096 1816.91 0.378248984 0.00308717 
Internalizing problems 2.530405734 2.516783965 3.942529108 596.10 0.245045925 0.003891829 
Verbal IQ 2.530405734 0.091136121 3.988907988 1629.65 0.386256884 0.013705281 
Externalizing problems 3.455388707 0.199461616 10.07362242 4128.35 0.193329051 0.196570563 
Total behavioral problems 3.942529108 2.452891383 10.07362242 3186.20 0.228085349 0.044486037 
For none of the neurocognitive tests, criteria for selection are met (median, 25th and 75th percentile lower than or equal to 0.05. Neurocognitive tests are ordered 
from the lowest to the highest median cut-off that was identified.  
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eTable 4-6. Identification of a potentially harmful threshold for circulating 5oxo-MEHP exposure  
 
A. Descriptive statistics 
Exposure to Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
5oxo-MEHP 228 127 0.029247768 0.013683166 0.118701468 0.105018302 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Valid alternating taps 0.01231485 0.008551979 0.038312866 28.34 0.386470139 0.0358 
Memory, recognition word pairs 0.01231485 0.006499504 0.024629699 17.26 0.359232535 0.091314531 
Memory, learning index 0.019840591 0.019840591 0.051996032 30.62 0.48758716 0.028042766 
Delayed memory, word pairs 0.019840591 0.014367325 0.045496528 29.64 0.41074448 0.154760835 
Verbal IQ 0.020524749 0.019840591 0.081414839 58.63 0.376472053 0.054768623 
Valid synchronous taps 0.023603462 0.017788117 0.028734649 10.42 0.652936677 0.02174489 
Delayed memory, dots 0.024629699 0.015051483 0.170013341 147.56 0.371486219 0.120945667 
Memory, learning dots 0.024629699 0.019840591 0.170013341 143.00 0.337850591 0.190970481 
Immediate memory, word pairs 0.025998016 0.012999008 0.045496528 30.94 0.415157103 0.099743387 
Memory, learning word pairs 0.026682174 0.013683166 0.051996032 36.48 0.428197592 0.123253886 
Tapping nondominant hand 0.028734649 0.004789108 0.035918312 29.64 0.775871956 0.00182606 
Memory span, numbers 0.028734649 0.023603462 0.06499504 39.41 0.366148304 0.27531837 
Overall reaction time 0.029760887 0.028734649 0.03249752 3.58 0.622493453 0.0000128 
Reaction time dominant hand 0.029760887 0.027366333 0.033523757 5.86 0.58950272 0.000166767 
Memory span, pictures 0.029760887 0.026682174 0.038997024 11.73 0.506648251 0.013025399 
Reaction time nondominant hand 0.030787124 0.029760887 0.033523757 3.58 0.583298906 0.00000719 
Tapping dominant hand 0.030787124 0.028734649 0.042759895 13.36 0.770433799 0.003932781 
Visual-motor integration 0.041733657 0.025998016 0.06499504 37.13 0.365084558 0.09127876 
Working memory 0.041733657 0.019498512 0.045496528 24.76 0.358098753 0.118349624 
Full-scale IQ 0.049943557 0.020524749 0.281360107 248.37 0.362530866 0.100886835 
Performance IQ 0.049943557 0.042417815 0.431019738 370.03 0.304956134 0.114359709 
Flexibility, no. of errors 0.058495536 0.029760887 0.307871241 264.82 0.205594865 0.053638862 
Inhibition, ∆ reaction time 0.070981425 0.036260391 0.243218281 197.07 0.294004649 0.034270297 
Flexibility, ∆ reaction time 0.156501214 0.044128211 0.636951391 564.50 0.312811148 0.068752976 
Inhibition, no. of errors 0.160093046 0.055074745 0.189853932 128.34 0.139740833 0.04261267 
Externalizing problems 0.170013341 0.060205932 0.172407895 106.84 0.205615656 0.023100389 
Total behavioral problems 0.172407895 0.037970786 0.189853932 144.63 0.229445291 0.033112994 
Internalizing problems 0.181644032 0.035576232 0.445387063 390.23 0.231914244 0.047053046 
Immediate memory, dots 0.517223686 0.038997024 0.889747888 810.10 0.384466955 0.038611691 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together around a similar cut-off are shown 
in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.023603462 Valid synchronous taps 0.657438104 0.011034807 0.007472748 0.029778369 
0.030787124 Reaction time nondominant hand 0.584787654 0.00000443 0.00000352 0.0000194 
Overall reaction time 0.620162398 0.0000167 0.0000128 0.0000977 
Reaction time dominant hand 0.585388226 0.000414661 0.000286864 0.001806588 
Tapping dominant hand 0.770650078 0.00239275 0.001495413 0.007403731 
Memory span, pictures 0.502271868 0.019683833 0.011171404 0.051572301 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. Both thresholds dichotomize the development cohort 
with at least 10 patients per group and are retained for further analyses. Neurocognitive tests are ordered from the lowest to the highest median exposure 
covariate P value found for comparison of patients according to the identified potentially harmful threshold.  
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eTable 5-1. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and reaction time dominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -9.84 [-44.56;24.88] 0.57 -3.88 [-40.54;32.79] 0.83 
Age at sampling (per year added) -435.61 [-505.28;-365.94] <0.001 -430.78 [-521.67;-339.89] <0.001 
Caucasian vs. other race 28.94 [-97.07;154.96] 0.65 83.54 [-38.65;205.72] 0.17 
Exclusively European vs. other origin -13.16 [-117.90;91.58] 0.80 -127.62 [-253.73;-1.51] 0.04 
Exclusively Dutch language vs. non-exclusively Dutch language 54.88 [-0.09;109.85] 0.05 51.21 [-14.97;117.38] 0.12 
Socioeconomic status (per category of 1 to 66) -101.22 [-183.18;-19.25] 0.01 -60.87 [-149.46;27.73] 0.17 
Pre-existing syndrome vs. no pre-existing syndrome 24.35 [-20.16;68.87] 0.28 50.94 [2.81;99.07] 0.03 
History vs. no history of malignancy -41.03 [-167.36;85.30] 0.52 7.64 [-105.23;120.50] 0.89 
History vs. no history of diabetes -38.42 [-214.86;138.01] 0.66   
Randomization to strict glycemic control vs. conventional therapy 5.27 [-28.77;39.32] 0.76 -4.25 [-40.87;32.37] 0.81 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 59.00 [-54.74;172.73] 0.30 199.94 [84.47;315.42] <0.001 
          randomized for glycemic control postoperatively -74.71 [-157.86;8.43] 0.07 78.11 [-15.99;172.21] 0.10 
     Complicated/high risk surgery or trauma -56.29 [-180.33;67.74] 0.37 -74.16 [-218.37;70.05] 0.31 
     Neurological medical disorders 209.21 [-20.64;439.06] 0.07 2.28 [-258.28;262.85] 0.98 
     Infectious medical diseases -173.01 [-330.31;-15.71] 0.03 -78.90 [-312.46;154.67] 0.50 
     Other medical disorders -63.71 [-227.83;100.41] 0.44 -44.00 [-224.46;136.46] 0.63 
     Solid organ transplants 99.51 [-153.78;352.80] 0.43 -83.29 [-322.10;155.53] 0.49 
PeLOD score first 24 hrs (per point added) -56.42 [-147.55;34.70] 0.22 33.20 [-62.02;128.41] 0.49 
PICU stay (per day added) 17.67 [-88.95;124.28] 0.74 161.03 [-16.63;338.69] 0.07 
Exceeding potentially harmful threshold for phthalate exposure 78.26 [37.75;118.76] 0.0002 58.30 [17.88;98.72] 0.004 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-1. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and reaction time dominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -13.19 [-50.25;23.88] 0.48 -14.61 [-51.37;22.15] 0.43 
Age at sampling (per year added) -434.23 [-521.75;-346.71] <0.001 -384.52 [-485.88;-283.17] <0.001 
Caucasian vs. other race 7.20 [-125.35;139.76] 0.91 78.55 [-43.18;200.28] 0.20 
Exclusively European vs. other origin -3.01 [-112.88;106.87] 0.95 -125.19 [-250.42;0.04] 0.05 
Exclusively Dutch language vs. non-exclusively Dutch language 49.93 [-9.50;109.37] 0.09 62.93 [-2.90;128.75] 0.06 
Socioeconomic status (per category of 1 to 66) -112.52 [-199.78;-25.26] 0.01 -77.58 [-166.60;11.44] 0.08 
Pre-existing syndrome vs. no pre-existing syndrome 28.66 [-20.11;77.42] 0.24 57.94 [9.92;105.96] 0.01 
History vs. no history of malignancy -47.43 [-181.89;87.02] 0.48 -8.54 [-119.94;102.87] 0.88 
History vs. no history of diabetes -51.38 [-233.82;131.05] 0.57   
Randomization to strict glycemic control vs. conventional therapy 4.04 [-32.48;40.56] 0.82 6.16 [-31.71;44.02] 0.74 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 247.90 [20.61;475.19] 0.03 131.23 [-40.49;302.95] 0.13 
          randomized for glycemic control postoperatively 115.29 [-95.03;325.60] 0.28 45.47 [-97.56;188.49] 0.53 
     Complicated/high risk surgery or trauma 61.29 [-162.22;284.80] 0.58 -42.07 [-204.23;120.09] 0.60 
     Neurological medical disorders 52.17 [-311.14;415.49] 0.77 -93.68 [-386.10;198.75] 0.52 
     Infectious medical diseases -378.65 [-657.44;-99.85] 0.008 18.16 [-237.26;273.59] 0.88 
     Other medical disorders -189.13 [-411.63;33.37] 0.09 -8.07 [-261.05;244.91] 0.94 
     Solid organ transplants 91.13 [-291.72;473.97] 0.63 -51.04 [-327.27;225.18] 0.71 
PeLOD score first 24 hrs (per point added) -48.02 [-156.17;60.13] 0.38 5.91 [-94.06;105.88] 0.90 
PICU stay (per day added) -292.13 [-782.08;197.82] 0.24 -274.46 [-1160.07;611.16] 0.54 
Extracorporeal circulation versus no extracorporeal circulation a -40.23 [-122.26;41.79] 0.33 -31.67 [-98.97;35.63] 0.35 
Aortic clamp time (per min added)  19.21 [-89.02;127.45] 0.72 146.35 [-4.01;296.71] 0.05 
Duration of mechanical ventilation (per day added) 316.60 [-79.68;712.88] 0.11 1804.99 [-12.66;1622.65] 0.05 
Peak creatinine (per mg/dl added) -17.09 [-252.04;217.86] 0.88 -121.82 [-360.72;117.09] 0.31 
Peak bilirubine (per mg/dl added) -75.73 [-250.56;99.10] 0.39 348.95 [7.32;690.57] 0.04 
Infection vs. no infection 6.32 [-57.12;69.75] 0.84 38.86 [-16.77;94.48] 0.16 
Antibiotics (per day added) 11.77 [-239.13;262.66] 0.92 -595.12 [-1237.02;46.78] 0.06 
Duration of hemodynamic support (per day added) 31.25 [-186.85;249.35] 0.77 191.65 [-461.00;844.31] 0.56 
Duration of corticosteroid treatment (per day added) 243.95 [-139.05;626.94] 0.21 145.62 [-303.70;594.34] 0.52 
Cumulative dose of opioids (per mg morphine-equivalent added) 11.57 [-263.33;286.47] 0.93 -203.07 [-465.07;58.93] 0.12 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 9.30 [-269.57;288.17] 0.94 -89.94 [-280.73;100.84] 0.35 
Received hypnotics versus no hypnotics -155.36 [-349.14;38.41] 0.11 14.62 [-136.98;166.22] 0.84 
Exceeding potentially harmful threshold for phthalate exposure 79.37 [34.84; 123.90] 0.0006 61.47 [19.87;103.07] 0.004 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-2. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and reaction time nondominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -19.44 [-51.56;12.68] 0.23 9.26 [-24.61;43.13] 0.59 
Age at sampling (per year added) -392.03 [-456.39;-327.66] <0.001 -408.37 [-492.34;-324.40] <0.001 
Caucasian vs. other race -17.03 [-134.36;100.30] 0.77 27.17 [-85.71;140.05] 0.63 
Exclusively European vs. other origin -19.36 [-116.81;78.09] 0.69 -104.86 [-221.36;11.65] 0.07 
Exclusively Dutch language vs. non-exclusively Dutch language 52.19 [1.14;103.23] 0.04 64.73 [3.59;125.86] 0.03 
Socioeconomic status (per category of 1 to 66) -52.70 [-128.48;23.09] 0.16 -100.37 [-182.22;-18.52] 0.01 
Pre-existing syndrome vs. no pre-existing syndrome 10.05 [-30.91;51.00] 0.62 46.33 [1.86;90.80] 0.04 
History vs. no history of malignancy -28.02 [-145.65;89.61] 0.63 24.86 [-79.41;129.13] 0.63 
History vs. no history of diabetes -6.05 [-170.29;158.18] 0.94   
Randomization to strict glycemic control vs. conventional therapy 5.19 [-26.22;36.60] 0.74 0.90 [-32.93;34.73] 0.95 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 66.70 [-72.16;139.55] 0.53 184.34 [77.65;291.03] <0.001 
          randomized for glycemic control postoperatively -34.00 [-111.02;43.03] 0.38 65.22 [-21.72;152.16] 0.14 
     Complicated/high risk surgery or trauma -16.50 [-132.01;99.00] 0.77 -178.35 [-311.58;-45.12] 0.009 
     Neurological medical disorders 85.91 [-127.79;299.61] 0.42 94.57 [-146.16;335.30] 0.43 
     Infectious medical diseases -103.18 [-249.63;43.26] 0.16 -68.99 [-284.78;146.79] 0.52 
     Other medical disorders -88.95 [-241.70;63.79] 0.25 -43.84 [-210.57;122.88] 0.60 
     Solid organ transplants 123.03 [-112.77;358.84] 0.30 -52.94 [-273.58;167.69] 0.63 
PeLOD score first 24 hrs (per point added) -15.20 [-99.69;69.30] 0.72 7.23 [-80.74;95.19] 0.87 
PICU stay (per day added) -14.97 [-112.64;82.69] 0.76 191.94 [27.80;356.07] 0.02 
Exceeding potentially harmful threshold for phthalate exposure 64.94 [27.61;102.27] 0.0007 47.92 [10.58;85.27] 0.01 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-2. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and reaction time nondominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -19.80 [-53.08;13.48] 0.24 3.08 [-31.34;37.50] 0.85 
Age at sampling (per year added) -401.54 [-479.99;-323.09] <0.001 -376.13 [-471.03;-281.22] <0.001 
Caucasian vs. other race -41.56 [-161.26;78.14] 0.49 30.11 [-83.88;144.09] 0.60 
Exclusively European vs. other origin -10.14 [-109.27;88.98] 0.84 -104.85 [-222.11;12.42] 0.07 
Exclusively Dutch language vs. non-exclusively Dutch language 52.31 [-1.19;105.80] 0.05 74.89 [13.25;136.52] 0.01 
Socioeconomic status (per category of 1 to 66) -61.72 [-139.92;16.48] 0.12 -118.72 [-202.08;-35.36] 0.005 
Pre-existing syndrome vs. no pre-existing syndrome 12.51 [-30.87;55.90] 0.57 48.85 [3.89;93.82] 0.03 
History vs. no history of malignancy -28.12 [-149.48;93.24] 0.64 9.27 [-95.05;113.58] 0.86 
History vs. no history of diabetes -25.20 [-189.87;139.47] 0.76   
Randomization to strict glycemic control vs. conventional therapy 6.73 [-25.86;39.33] 0.68 13.09 [-22.37;48.55] 0.46 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 222.03 [18.17;425.89] 0.03 132.77 [-28.03;293.57] 0.10 
          randomized for glycemic control postoperatively 143.83 [-44.91;332.58] 0.13 35.83 [-98.10;169.76] 0.59 
     Complicated/high risk surgery or trauma 51.31 [-149.80;252.42] 0.61 -181.13 [-332.97;-29.28] 0.01 
     Neurological medical disorders -25.15 [-352.74;302.44] 0.87 82.40 [-191.43;356.23] 0.55 
     Infectious medical diseases -277.14 [-528.62;-25.66] 0.03 -25.82 [-265.00;213.36] 0.83 
     Other medical disorders -257.33 [-457.91;-56.74] 0.01 44.53 [-192.35;281.42] 0.71 
     Solid organ transplants 142.45 [-203.28;488.17] 0.41 -88.59 [-347.25;170.07] 0.49 
PeLOD score first 24 hrs (per point added) -7.04 [-104.16;90.07] 0.88 -4.80 [-98.41;88.81] 0.91 
PICU stay (per day added) -167.36 [-601.49;266.78] 0.44 -505.23 [-1334.51;324.06] 0.23 
Extracorporeal circulation versus no extracorporeal circulation a -49.11 [-120.84;22.62] 0.17 -55.88 [-118.90;7.14] 0.08 
Aortic clamp time (per min added)  -21.89 [-118.94;75.16] 0.65 115.46 [-25.33;256.26] 0.10 
Duration of mechanical ventilation (per day added) 192.84 [-158.64;544.32] 0.28 514.37 [-251.27;1280.02] 0.18 
Peak creatinine (per mg/dl added) 26.95 [-184.67;238.57] 0.80 -72.47 [-296.18;151.24] 0.52 
Peak bilirubine (per mg/dl added) -184.60 [-342.06;-27.14] 0.02 255.12 [-64.78;575.02] 0.11 
Infection vs. no infection 3.70 [-53.36;60.76] 0.89 29.57 [-22.52;81.66] 0.26 
Antibiotics (per day added) -58.12 [-284.48;168.25] 0.61 -153.94 [-755.01;447.13] 0.61 
Duration of hemodynamic support (per day added) 57.55 [-139.11;254.21] 0.56 337.02 [-274.12;948.16] 0.27 
Duration of corticosteroid treatment (per day added) 189.21 [-155.17;533.59] 0.27 210.17 [-210.57;630.90] 0.32 
Cumulative dose of opioids (per mg morphine-equivalent added) 128.19 [-120.15;376.53] 0.30 -169.02 [-414.36;76.32] 0.17 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 117.21 [-134.36;368.78] 0.35 -77.29 [-255.94;101.36] 0.39 
Received hypnotics versus no hypnotics -128.61 [-303.59;46.37] 0.14 69.49 [-72.47;211.45] 0.33 
Exceeding potentially harmful threshold for phthalate exposure 70.51 [30.66;110.36] 0.0006 50.89 [11.94;89.85] 0.01 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-3. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and reaction time overall 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -16.08 [-46.99;14.82] 0.30 3.89 [-29.66;37.45] 0.81 
Age at sampling (per year added) -409.36 [-471.36;-347.35] <0.001 -419.27 [-502.46;-336.09] <0.001 
Caucasian vs. other race 6.06 [-106.09;118.22] 0.91 55.25 [-56.58;167.07] 0.33 
Exclusively European vs. other origin -15.92 [-109.14;77.30] 0.73 -115.74 [-231.15;-0.32] 0.04 
Exclusively Dutch language vs. non-exclusively Dutch language 51.47 [2.54;100.39] 0.03 57.25 [-3.31;117.82] 0.06 
Socioeconomic status (per category of 1 to 66) -72.94 [-145.89;0.01] 0.05 -82.78 [-163.86;-1.70] 0.04 
Pre-existing syndrome vs. no pre-existing syndrome 14.70 [-24.92;54.32] 0.46 45.98 [1.93;90.03] 0.04 
History vs. no history of malignancy -34.69 [-147.12;77.75] 0.54 16.76 [-86.54;120.05] 0.74 
History vs. no history of diabetes -19.62 [-176.65;137.40] 0.80   
Randomization to strict glycemic control vs. conventional therapy 4.59 [-25.72;34.89] 0.76 -2.38 [-35.90;31.13] 0.88 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 45.33 [-55.89;146.56] 0.37 189.34 [83.65;295.03] <0.001 
          randomized for glycemic control postoperatively -58.25 [-132.25;15.75] 0.12 68.18 [-17.95;154.31] 0.12 
     Complicated/high risk surgery or trauma -36.33 [-146.72;74.07] 0.51 -125.59 [-257.57;6.40] 0.06 
     Neurological medical disorders 151.90 [-52.68;356.47] 0.14 52.36 [-186.12;290.84] 0.66 
     Infectious medical diseases -137.53 [-277.53;2.47] 0.05 -75.29 [-289.05;138.48] 0.48 
     Other medical disorders -78.85 [-224.91;67.22] 0.28 -42.09 [-207.25;123.07] 0.61 
     Solid organ transplants 113.72 [-111.71;339.15] 0.32 -66.91 [-285.48;151.66] 0.54 
PeLOD score first 24 hrs (per point added) -33.91 [-115.01;47.20] 0.41 18.12 [-69.02;105.26] 0.68 
PICU stay (per day added) 4.14 [-90.74;99.03] 0.93 177.83 [15.23;340.43] 0.03 
Exceeding potentially harmful threshold for phthalate exposure 71.44 [35.39;107.49] 0.0001 54.43 [17.44;91.43] 0.004 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-3. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and reaction time overall (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -17.94 [-50.38;14.50] 0.27 -4.31 [-38.07;29.45] 0.80 
Age at sampling (per year added) -412.91 [-489.51;-336.31] <0.001 -378.36 [-471.45;-285.28] <0.001 
Caucasian vs. other race -17.14 [-133.16;98.87] 0.77 54.18 [-57.62;165.97] 0.34 
Exclusively European vs. other origin -6.01 [-102.18;90.16] 0.90 -114.97 [-229.98;0.04] 0.05 
Exclusively Dutch language vs. non-exclusively Dutch language 49.08 [-2.94;101.10] 0.06  68.29 [7.84;128.75] 0.02 
Socioeconomic status (per category of 1 to 66) -83.53 [-159.91;-7.16] 0.03 -100.21 [-181.97;-18.46] 0.01 
Pre-existing syndrome vs. no pre-existing syndrome 18.18 [-24.50;60.87] 0.40 50.27 [6.17;94.38] 0.02 
History vs. no history of malignancy -37.78 [-155.46;79.90] 0.52 1.10 [-101.21;103.42] 0.98 
History vs. no history of diabetes -36.93 [-196.61;122.74] 0.64   
Randomization to strict glycemic control vs. conventional therapy 5.14 [-26.83;37.10] 0.75 8.68 [-26.10;43.46] 0.62 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 239.60 [40.66;438.53] 0.01 130.46 [-27.25;288.17] 0.10 
          randomized for glycemic control postoperatively 131.45 [-52.62;315.53] 0.16 38.17 [-93.18;169.53] 0.56 
     Complicated/high risk surgery or trauma 55.35 [-140.28;250.97] 0.57 -111.72 [-260.64;37.21] 0.14 
     Neurological medical disorders 12.76 [-305.23;330.75] 0.93 -2.85 [-271.42;265.71] 0.98 
     Infectious medical diseases -331.22 [-575.23;-87.20] 0.008 -6.49 [-241.07;228.10] 0.95 
     Other medical disorders -227.89 [-422.63;-33.15] 0.02 18.87 [-213.47;251.20] 0.87 
     Solid organ transplants 119.95 [-215.13;455.03] 0.48 -66.45 [-320.13;187.24] 0.60 
PeLOD score first 24 hrs (per point added) -26.31 [-120.96;68.35] 0.58 -2.12 [-93.93;89.69] 0.96 
PICU stay (per day added) -231.16 [-659.98;197.66] 0.28 -384.91 [-1198.26;428.44] 0.35 
Extracorporeal circulation versus no extracorporeal circulation a -44.26 [-120.05;23.53] 0.18 -44.29 [-106.10;17.52] 0.15 
Aortic clamp time (per min added)  -0.05 [-94.78;94.68] 0.99 130.46 [-7.63;268.55] 0.06 
Duration of mechanical ventilation (per day added) 257.58 [-89.36;604.32] 0.14 673.66 [-77.28;1424.59] 0.07 
Peak creatinine (per mg/dl added) 6.92 [-198.72;212.56] 0.94 -96.51 [-315.93;122.90] 0.38 
Peak bilirubine (per mg/dl added) -126.67 [-279.69;26.35] 0.10 289.75 [-24.00;603.50] 0.07 
Infection vs. no infection 5.81 [-49.71;61.33] 0.83 35.35 [-15.73;86.44] 0.17 
Antibiotics (per day added) -20.26 [-239.86;199.33] 0.85 -380.14 [-969.66;209.39] 0.20 
Duration of hemodynamic support (per day added) 45.13 [-145.76;236.02] 0.64 260.13 [-339.27;859.53] 0.39 
Duration of corticosteroid treatment (per day added) 213.32 [-121.89;548.53] 0.21 169.05 [-243.61;581.70] 0.41 
Cumulative dose of opioids (per mg morphine-equivalent added) 68.47 [-172.14;309.08] 0.57 -187.64 [-428.27;52.98] 0.12 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 61.67 [-182.41;305.75] 0.61 -82.49 [-257.70;92.73] 0.35 
Received hypnotics versus no hypnotics -143.41 [-313.01;26.18] 0.09 42.20 [-97.03;181.43] 0.55 
Exceeding potentially harmful threshold for phthalate exposure 74.37 [35.40;113.35] 0.0002 57.59 [19.39;95.80] 0.003 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-4. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and inconsistency of reaction time dominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 17.39 [-12.31;47.08] 0.24 -0.79 [-34.95;33.38] 0.96 
Age at sampling (per year added) -325.58 [-385.17;-266.00] <0.001 -337.00 [-421.70;-252.30] <0.001 
Caucasian vs. other race 40.37 [-67.41;148.15] 0.46 69.89 [-43.97;183.75] 0.22 
Exclusively European vs. other origin -36.82 [-126.40;52.76] 0.41 -95.38 [-212.89;22.14] 0.11 
Exclusively Dutch language vs. non-exclusively Dutch language 24.77 [-22.25;71.78] 0.30 28.49 [-33.18;90.15] 0.36 
Socioeconomic status (per category of 1 to 66) -80.80 [-150.90;-10.70] 0.02 -109.15 [-191.71;-26.60] 0.01 
Pre-existing syndrome vs. no pre-existing syndrome 22.86 [-15.21;60.94] 0.23 63.59 [18.74;108.44] 0.005 
History vs. no history of malignancy -25.34 [-133.38;82.71] 0.64 45.89 [-59.29;151.06] 0.39 
History vs. no history of diabetes -15.98 [-166.88;143.91] 0.83   
Randomization to strict glycemic control vs. conventional therapy -8.73 [-37.85;20.39] 0.55 7.10 [-27.02;41.23] 0.67 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 72.48 [-24.80;169.75] 0.14 140.59 [32.97;248.20] 0.01 
          randomized for glycemic control postoperatively -27.65 [-98.76;43.46] 0.44 58.82 [-28.87;146.51] 0.18 
     Complicated/high risk surgery or trauma -22.28 [-128.36;83.80] 0.67 -76.10 [-210.48;58.28] 0.26 
     Neurological medical disorders 130.64 [-65.94;327.22] 0.19 -0.69 [-243.51;242.13] 0.99 
     Infectious medical diseases -126.84 [-261.37;7.69] 0.06 -46.02 [-263.67;171.64] 0.67 
     Other medical disorders -12.55 [-152.92;127.81] 0.86 -80.61 [-248.77;87.56] 0.34 
     Solid organ transplants -13.80 [-230.42;202.83] 0.90 4.01 [-218.53;226.56] 0.96 
PeLOD score first 24 hrs (per point added) -22.65 [-100.59;55.28] 0.56 29.11 [-59.62;117.84] 0.51 
PICU stay (per day added) 9.14 [-82.04;100.32] 0.84 77.28 [-88.28;242.84] 0.36 
Exceeding potentially harmful threshold for phthalate exposure 55.81 [21.17;90.46] 0.001 55.76 [18.10;93.43] 0.003 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-4. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and inconsistency of reaction time dominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 12.14 [-19.90;44.18] 0.45 -12.73 [-46.73;21.28] 0.46 
Age at sampling (per year added) -330.86 [-406.52;-255.21] <0.001 -292.50 [-386.27;-198.74] <0.001 
Caucasian vs. other race 33.97 [-80.62;148.55] 0.55 80.69 [-31.92;193.31] 0.15 
Exclusively European vs. other origin -37.86 [-132.84;57.12] 0.43 -112.50 [-228.35;3.35] 0.05 
Exclusively Dutch language vs. non-exclusively Dutch language 23.56 [-27.82;74.94] 0.36 35.11 [-25.78;96.00] 0.25 
Socioeconomic status (per category of 1 to 66) -81.16 [-156.60;-5.73] 0.03 -122.33 [-204.68;-39.98] 0.003 
Pre-existing syndrome vs. no pre-existing syndrome 29.95 [-12.20;72.11] 0.16 69.05 [24.62;113.47] 0.002 
History vs. no history of malignancy -26.34 [-142.57;89.88] 0.65 37.13 [-65.93;140.19] 0.47 
History vs. no history of diabetes -25.59 [-183.29;132.11] 0.74   
Randomization to strict glycemic control vs. conventional therapy -6.91 [-38.48;24.66] 0.66 15.03 [-20.00;50.06] 0.39 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 198.96 [2.49;395.44] 0.04 48.58 [-110.28;207.44] 0.54 
          randomized for glycemic control postoperatively 99.33 [-82.47;281.13] 0.28 0.78 [-131.54;133.09] 0.99 
     Complicated/high risk surgery or trauma 42.46 [-150.74;235.67] 0.66 -97.37 [-247.38;52.65] 0.20 
     Neurological medical disorders -6.14 [-320.20;307.92] 0.96 -27.27 [-297.80;243.26] 0.84 
     Infectious medical diseases -223.48 [-464.48;17.52] 0.06 37.62 [-198.67;273.92] 0.75 
     Other medical disorders -78.98 [-271.32;113.35] 0.41 -32.65 [-266.68;201.39] 0.78 
     Solid organ transplants -32.16 [-363.10;298.79] 0.84 70.31 [-185.24;325.85] 0.58 
PeLOD score first 24 hrs (per point added) -32.55 [-126.04;60.93] 0.49 -20.27 [-112.75;72.21] 0.66 
PICU stay (per day added) -168.06 [-591.58;255.46] 0.43 682.78 [-136.52;1502.07] 0.10 
Extracorporeal circulation versus no extracorporeal circulation a -19.67 [-90.58;51.23] 0.58 -2.77 [-65.03;59.49] 0.93 
Aortic clamp time (per min added)  -4.44 [-98.00;89.11] 0.92 174.48 [35.38;313.58] 0.01 
Duration of mechanical ventilation (per day added) 144.69 [-197.86;487.24] 0.40 427.98 [-328.44;1184.40] 0.26 
Peak creatinine (per mg/dl added) 26.57 [-176.53;229.67] 0.79 -1.66 [-222.68;219.36] 0.98 
Peak bilirubine (per mg/dl added) -4.13 [-155.26;147.00] 0.95 279.52 [-36.53;595.56] 0.08 
Infection vs. no infection 23.01 [-31.83;77.84] 0.40 53.17 [1.71;104.63] 0.04 
Antibiotics (per day added) 11.73 [-205.14;228.61] 0.91 -947.58 [-1541.41;-353.75] 0.001 
Duration of hemodynamic support (per day added) 11.62 [-176.91;200.15] 0.90 -257.20 [-860.97;346.58] 0.40 
Duration of corticosteroid treatment (per day added) 141.94 [-189.13;473.01] 0.39 23.37 [-392.29;439.04] 0.91 
Cumulative dose of opioids (per mg morphine-equivalent added) 40.02 [-197.62;277.65] 0.74 -278.65 [-521.03;-36.27] 0.02 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 30.47 [-210.59;271.54] 0.80 -39.56 [-216.05;136.94] 0.65 
Received hypnotics versus no hypnotics -80.90 [-248.41;86.60] 0.34  61.84 [-78.41;202.09] 0.38 
Exceeding potentially harmful threshold for phthalate exposure 51.48 [12.98;89.97] 0.009 55.10 [16.62;93.58] 0.005 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
 
  
32 
 
eTable 5-5. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and inconsistency of reaction time nondominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -1.15 [-29.81;27.51] 0.93 4.25 [-28.66;37.17] 0.79 
Age at sampling (per year added) -270.91 [-328.35;-213.48] <0.001 -310.99 [-392.59;-229.39] <0.001 
Caucasian vs. other race 13.00 [-91.70;117.70] 0.80 21.21 [-88.48;130.91] 0.70 
Exclusively European vs. other origin -48.31 [-135.27;38.65] 0.27 -86.58 [-199.80;26.63] 0.13 
Exclusively Dutch language vs. non-exclusively Dutch language 44.86 [-0.69;90.41] 0.05 49.86 [-9.55;109.26] 0.09 
Socioeconomic status (per category of 1 to 66) -33.47 [-101.10;34.16] 0.33 -87.72 [-167.26;-8.19] 0.03 
Pre-existing syndrome vs. no pre-existing syndrome 15.58 [-20.97;52.12] 0.40 43.96 [0.75;87.17] 0.04 
History vs. no history of malignancy -57.33 [-162.29;47.64] 0.28 14.67 [-86.66;116.00] 0.77 
History vs. no history of diabetes 2.05 [-144.51;148.60] 0.97   
Randomization to strict glycemic control vs. conventional therapy -7.27 [-35.30;20.76] 0.61 7.44 [-25.44;40.32] 0.65 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 28.50 [-65.95;122.96] 0.55 159.21 [55.54;262.89] 0.002 
          randomized for glycemic control postoperatively 16.94 [-51.80;85.67] 0.62 46.63 [-37.86;131.11] 0.28 
     Complicated/high risk surgery or trauma 47.77 [-55.31;150.84] 0.36 -207.07 [-336.54;-77.60] 0.002 
     Neurological medical disorders 29.35 [-161.34;220.05] 0.76 152.36 [-81.57;386.29] 0.20 
     Infectious medical diseases -123.44 [-254.12;7.24] 0.06 -118.29 [-327.98;91.40] 0.27 
     Other medical disorders -61.02 [-197.32;75.28] 0.37 -50.80 [-212.81;111.22] 0.53 
     Solid organ transplants 61.89 [-148.53;272.32] 0.56 17.95 [-196.45;232.35] 0.86 
PeLOD score first 24 hrs (per point added) -5.34 [-80.73;70.06] 0.88 32.25 [-53.23;117.73] 0.45 
PICU stay (per day added) 7.91 [-79.24;95.07] 0.85 88.04 [-71.46;247.54] 0.27 
Exceeding potentially harmful threshold for phthalate exposure 43.16 [9.84;76.47] 0.01 30.15 [-6.15;66.44] 0.10 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
  
33 
 
eTable 5-5. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and inconsistency of reaction time nondominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 2.63 [-27.31;32.57] 0.86 0.21 [-33.98;34.41] 0.99 
Age at sampling (per year added) -295.79 [-366.37;-225.21] <0.001 -299.07 [-393.37;-204.78] <0.001 
Caucasian vs. other race -4.84 [-112.53;102.86] 0.92 22.64 [-90.61;135.89] 0.69 
Exclusively European vs. other origin -45.76 [-134.94;43.43] 0.31 -84.94 [-201.44;31.56] 0.15 
Exclusively Dutch language vs. non-exclusively Dutch language 49.63 [1.50;97.76] 0.04 58.14 [-3.10;119.38] 0.06 
Socioeconomic status (per category of 1 to 66) -43.48 [-113.83;26.88] 0.22 -110.02 [-192.84;-27.20] 0.009 
Pre-existing syndrome vs. no pre-existing syndrome 18.90 [-20.13;57.93] 0.34 45.19 [0.51;89.86] 0.04 
History vs. no history of malignancy -75.93 [-185.11;33.26] 0.17 3.06 [-100.58;106.70] 0.95 
History vs. no history of diabetes -6.07 [-154.22;142.08] 0.93   
Randomization to strict glycemic control vs. conventional therapy -9.30 [-38.63;20.02] 0.53 16.71 [-18.52;51.94] 0.35 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 127.66 [-55.75;311.08] 0.17 184.21 [24.45;343.97] 0.02 
          randomized for glycemic control postoperatively 113.20 [-56.61;283.01] 0.19 78.60 [-54.46;211.66] 0.24 
     Complicated/high risk surgery or trauma 110.52 [-70.41;291.46] 0.22 -221.02 [-371.89;-70.16] 0.004 
     Neurological medical disorders -7.04 [-301.76;287.69] 0.96 152.41 [-119.64;424.46] 0.27 
     Infectious medical diseases -186.53 [-412.78;39.73] 0.10 -105.75 [-343.38;131.88] 0.38 
     Other medical disorders -147.21 [-327.67;33.26] 0.10 -2.03 [-237.39;233.32] 0.98 
     Solid organ transplants -10.61 [-321.65;300.44] 0.94 -86.41 [-343.40;170.57] 0.50 
PeLOD score first 24 hrs (per point added) -5.96 [-93.33;81.42] 0.89 17.01 [-75.99;110.01] 0.71 
PICU stay (per day added) -177.19 [-567.78;213.40] 0.37 -437.67 [-1261.58;386.25] 0.29 
Extracorporeal circulation versus no extracorporeal circulation a -24.12 [-88.66;40.41] 0.46 -63.43 [-126.04;-0.81] 0.04 
Aortic clamp time (per min added)  -3.31 [-90.63;84.01] 0.94 127.45 [-12.43;267.34] 0.07 
Duration of mechanical ventilation (per day added) 210.43 [-105.79;526.66] 0.19 422.23 [-338.45;1182.92] 0.27 
Peak creatinine (per mg/dl added) 97.85 [-92.54;288.25] 0.31 18.98 [-203.29;241.24] 0.86 
Peak bilirubine (per mg/dl added) -176.52 [-318.19;-34.85] 0.01 122.78 [-195.04;440.61] 0.44 
Infection vs. no infection -17.17 [-68.50;34.17] 0.51 29.54 [-22.21;81.29] 0.26 
Antibiotics (per day added) -57.36 [-261.01;146.30] 0.57 -174.71 [-771.89;422.47] 0.56 
Duration of hemodynamic support (per day added) 73.11 [-103.83;250.04] 0.41 110.37 [-496.81;717.55] 0.72 
Duration of corticosteroid treatment (per day added) 295.25 [-14.59;605.09] 0.06 350.06 [-67.95;768.07] 0.10 
Cumulative dose of opioids (per mg morphine-equivalent added) 129.64 [-93.79;353.07] 0.25 -64.81 [-308.56;178.93] 0.60 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 106.94 [-119.40;333.27] 0.35 -41.26 [-218.75;136.23] 0.64 
Received hypnotics versus no hypnotics -64.26 [-221.69;93.17] 0.42 52.07 [-88.97;193.11] 0.46 
Exceeding potentially harmful threshold for phthalate exposure 47.68 [11.83;83.53] 0.009 30.20 [-8.50;68.90] 0.12 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-6. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and inconsistency of reaction time overall 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 7.64 [-17.97.33.25] 0.55 -0.45 [-30.25;29.34] 0.97 
Age at sampling (per year added) -305.31 [-356.70.-253.92] <0.001 -330.18 [-403.78;-256.58] <0.001 
Caucasian vs. other race 29.14 [-63.81.122.09] 0.53 44.97 [-53.97;143.91] 0.37 
Exclusively European vs. other origin -42.62 [-119.88.34.64] 0.27 -91.44 [-193.56;10.69] 0.07 
Exclusively Dutch language vs. non-exclusively Dutch language 37.11 [-3.44.77.66] 0.07 42.63 [-10.96;96.23] 0.11 
Socioeconomic status (per category of 1 to 66) -50.68 [-111.14;9.78] 0.09 -98.65 [-170.51;-26.79] 0.007 
Pre-existing syndrome vs. no pre-existing syndrome 18.49 [-14.35;51.33] 0.26 53.02 [13.69;92.35] 0.008 
History vs. no history of malignancy -43.47 [-136.65;49.71] 0.35 31.14 [-60.27;122.54] 0.50 
History vs. no history of diabetes -14.51 [-144.65;115.63] 0.82   
Randomization to strict glycemic control vs. conventional therapy -7.07 [-32.18;18.04] 0.57 4.87 [-24.84;34.58] 0.74 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 50.97 [-32.92;134.87] 0.23 144.80 [51.08;238.51] 0.002 
          randomized for glycemic control postoperatively -12.67 [-73.99;48.66] 0.68 54.28 [-22.23;130.79] 0.16 
     Complicated/high risk surgery or trauma 11.30 [-80.19;102.79] 0.80 -128.45 [-245.24;-11.67] 0.03 
     Neurological medical disorders 93.02 [-76.52;262.57] 0.28 75.45 [-135.67;286.57] 0.48 
     Infectious medical diseases -117.66 [-233.69;-1.63] 0.04 -87.25 [-276.41;101.90] 0.36 
     Other medical disorders -31.17 [-152.23;89.89] 0.61 -66.38 [-212.57;79.80] 0.37 
     Solid organ transplants 6.20 [-180.63;193.03] 0.94 7.56 [-185.86;200.98] 0.93 
PeLOD score first 24 hrs (per point added) -9.85 [-77.06;57.37] 0.77 31.36 [-45.81;108.54] 0.42 
PICU stay (per day added) 9.05 [-69.59;87.69] 0.82 83.35 [-60.52;227.23] 0.25 
Exceeding potentially harmful threshold for phthalate exposure 53.91 [24.03;83.79] 0.0005 44.36 [11.54;77.17] 0.008 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-6. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and inconsistency of reaction time overall (continued) 
 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 6.49 [-20.81;33.79] 0.63 -8.36 [-38.80;22.09] 0.58 
Age at sampling (per year added) -325.69 [-390.14;-261.23] <0.001 -301.39 [-385.02;-217.76] <0.001 
Caucasian vs. other race 15.81 [-81.81;113.44] 0.74 50.32 [-50.09;150.72] 0.32 
Exclusively European vs. other origin -42.46 [-123.38;38.47] 0.30 -98.79 [-202.08;4.49] 0.06 
Exclusively Dutch language vs. non-exclusively Dutch language 38.57 [-5.20;82.34] 0.08 50.41 [-3.88;104.71] 0.06 
Socioeconomic status (per category of 1 to 66) -54.87 [-119.14;9.40] 0.09 -117.57 [-191.11;-44.02] 0.001 
Pre-existing syndrome vs. no pre-existing syndrome 23.91 [-12.01;59.82] 0.19 56.33 [16.27;96.39] 0.006 
History vs. no history of malignancy -54.58 [-153.60;44.44] 0.27 20.96 [-70.95;112.86] 0.65 
History vs. no history of diabetes -24.01 [-158.37;110.35] 0.72   
Randomization to strict glycemic control vs. conventional therapy -7.12 [-34.02;19.77] 0.60 13.54 [-17.77;44.85] 0.39 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 168.24 [0.84;335.63] 0.04 117.30 [-24.35;258.95] 0.10 
          randomized for glycemic control postoperatively 104.13 [-50.76;259.02] 0.18 46.81 [-71.20;164.82] 0.43 
     Complicated/high risk surgery or trauma 81.58 [-83.03;246.19] 0.32 -143.60 [-277.36;-9.85] 0.03 
     Neurological medical disorders -18.70 [-286.28;248.87] 0.89 53.40 [-187.84;294.65] 0.66 
     Infectious medical diseases -207.57 [-412.90;-2.24] 0.04 -44.65 [-255.43;166.13] 0.67 
     Other medical disorders -107.94 [-271.81;55.93] 0.19 -28.14 [-236.80;180.52] 0.79 
     Solid organ transplants -19.74 [-301.70;262.22] 0.89 -1.12 [-229.05;226.82] 0.99 
PeLOD score first 24 hrs (per point added) -21.84 [-101.49;57.81] 0.58 -1.89 [-84.48;80.69] 0.96 
PICU stay (per day added) -188.51 [-549.34;172.33] 0.30 131.71 [-598.81;862.22] 0.72 
Extracorporeal circulation versus no extracorporeal circulation a -17.90 [-78.31;42.51] 0.55 -33.12 [-88.65;22.42] 0.24 
Aortic clamp time (per min added)  -7.55 [-87.27;72.16] 0.85 150.69 [26.67;274.70] 0.01 
Duration of mechanical ventilation (per day added) 191.81 [-100.04;483.67] 0.19 405.99 [-268.91;1080.88] 0.23 
Peak creatinine (per mg/dl added) 91.48 [-81.56;264.51] 0.29 -0.78 [-197.86;196.29] 0.99 
Peak bilirubine (per mg/dl added) -85.87 [-214.62;42.89] 0.18 223.92 [-58.18;506.03] 0.11 
Infection vs. no infection 3.52 [-43.20;50.24] 0.88 43.34 [-2.59;89.27] 0.06 
Antibiotics (per day added) -13.71 [-198.49;171.07] 0.88 -542.53 [-1072.04;-13.02] 0.04 
Duration of hemodynamic support (per day added) 32.22 [-128.41;192.85] 0.69 -81.43 [-620.07;457.20] 0.76 
Duration of corticosteroid treatment (per day added) 209.02 [-73.05;491.09] 0.14 171.12 [-199.68;541.92] 0.36 
Cumulative dose of opioids (per mg morphine-equivalent added) 76.28 [-126.18;278.74] 0.45 -166.31 [-382.43;49.80] 0.13 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 62.36 [-143.02;267.75] 0.54 -54.05 [-211.42;103.31] 0.49 
Received hypnotics versus no hypnotics -81.73 [-224.44;60.98] 0.25 46.62 [-78.42;171.66] 0.46 
Exceeding potentially harmful threshold for phthalate exposure 53.42 [20.62;86.21] 0.001 43.98 [9.58;78.38] 0.01 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-7. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and tapping dominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 0.26 [-0.68;1.20] 0.58 0.02 [-1.17;1.22] 0.96 
Age at sampling (per year added) 19.50 [17.63;21.37] <0.001 19.90 [16.93;22.86] <0.001 
Caucasian vs. other race 2.14 [-1.27;5.56] 0.21 -1.63 [-5.60;2.35] 0.42 
Exclusively European vs. other origin -2.09 [-4.93;0.76] 0.14 2.88 [-1.29;7.04] 0.17 
Exclusively Dutch language vs. non-exclusively Dutch language -0.73 [-2.22;0.75] 0.33 -0.81 [-3.11;1.49] 0.48 
Socioeconomic status (per category of 1 to 66) 1.41 [-0.82;3.64] 0.21 -1.91 [-4.77;0.95] 0.18 
Pre-existing syndrome vs. no pre-existing syndrome 0.74 [-0.46;1.93] 0.22 -1.08 [-2.67;0.50] 0.17 
History vs. no history of malignancy 0.04 [-3.37;3.44] 0.98 0.38 [-3.27;4.03] 0.83 
History vs. no history of diabetes 1.94 [-2.84;6.73] 0.42   
Randomization to strict glycemic control vs. conventional therapy 0.17 [-0.75;1.10] 0.71 0.37 [-0.82;1.56] 0.53 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 1.28 [-1.81;4.37] 0.41 -2.07 [-5.81;1.67] 0.27 
          randomized for glycemic control postoperatively 3.10 [0.85;5.36] 0.007 -0.78 [-3.85;2.30] 0.61 
     Complicated/high risk surgery or trauma -0.53 [-3.82;2.76] 0.75 1.93 [-6.48;2.62] 0.40 
     Neurological medical disorders -3.03 [-9.26;3.19] 0.33 -0.34 [-8.82;8.13] 0.93 
     Infectious medical diseases -2.38 [-6.64;1.89] 0.27 -0.22 [-7.81;7.37] 0.95 
     Other medical disorders 1.66 [-2.79;6.11] 0.46 2.52 [-3.34;8.39] 0.40 
     Solid organ transplants -0.10 [-6.98;6.77] 0.98 2.81 [-4.93;10.55] 0.47 
PeLOD score first 24 hrs (per point added) 0.45 [-2.02;2.92] 0.71 0.34 [-2.73;3.41] 0.83 
PICU stay (per day added) -0.43 [-3.33;2.47] 0.76 -1.45 [-7.16;4.25] 0.61 
Exceeding potentially harmful threshold for phthalate exposure -1.10 [-2.20;-0.01] 0.04 -0.83 [-2.14;0.49] 0.21 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-7. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and tapping dominant hand (continued) 
 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 0.37 [-0.61;1.36] 0.45 0.03 [-1.20;1.27] 0.95 
Age at sampling (per year added) 18.11 [15.78;20.44] <0.001 18.37 [14.97;21.77] <0.001 
Caucasian vs. other race 2.19 [-1.34;5.73] 0.22 -1.90 [-6.00;2.20] 0.36 
Exclusively European vs. other origin -2.24 [-5.17;0.69] 0.13 3.47 [-0.81;7.74] 0.11 
Exclusively Dutch language vs. non-exclusively Dutch language -0.80 [-2.38;0.78] 0.31 -0.84 [-3.23;1.55] 0.48 
Socioeconomic status (per category of 1 to 66) 1.52 [-0.80;3.84] 0.19 -1.72 [-4.69;1.25] 0.25 
Pre-existing syndrome vs. no pre-existing syndrome 0.89 [-0.40;2.18] 0.17 -1.04 [-2.68;0.60] 0.21 
History vs. no history of malignancy -0.50 [-4.05;3.06] 0.78 0.71 [-3.04;4.46] 0.70 
History vs. no history of diabetes 2.50 [-2.36;7.36] 0.31   
Randomization to strict glycemic control vs. conventional therapy 0.01 [-0.96;0.99] 0.98 0.19 [-1.06;1.43] 0.76 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively -3.09 [-9.12;2.93] 0.31 -0.69 [-6.45;5.07] 0.81 
          randomized for glycemic control postoperatively -0.69 [-6.26;4.88] 0.80 0.17 [-4.60;4.95] 0.94 
     Complicated/high risk surgery or trauma -0.06 [-5.95;5.84] 0.98 -0.23 [-5.65;5.20] 0.93 
     Neurological medical disorders -2.64 [-12.33;7.04] 0.59 0.31 [-9.54;10.16] 0.95 
     Infectious medical diseases -0.39 [-7.82;7.04] 0.91 -0.02 [-8.36;8.32] 0.99 
     Other medical disorders 4.12 [-1.81;10.05] 0.17 0.98 [-7.51;9.47] 0.81 
     Solid organ transplants 2.75 [-7.44;12.94] 0.59 -0.52 [-9.73;8.69] 0.91 
PeLOD score first 24 hrs (per point added) -0.42 [-3.29;2.45] 0.77 0.70 [-2.68;4.07] 0.68 
PICU stay (per day added) -5.02 [-18.05;8.02] 0.44 -19.07 [-45.72;7.58] 0.15 
Extracorporeal circulation versus no extracorporeal circulation a 2.51 [0.37;4.65] 0.02 0.70 [-1.55;2.94] 0.54 
Aortic clamp time (per min added)  0.61 [-2.29;3.52] 0.68 -2.45 [-7.56;2.65] 0.34 
Duration of mechanical ventilation (per day added) 7.04 [-3.52;17.60] 0.19 2.73 [-23.61;29.08] 0.83 
Peak creatinine (per mg/dl added) 4.39 [-1.87;10.64] 0.16 4.73 [-3.24;12.71] 0.24 
Peak bilirubine (per mg/dl added) 1.26 [-3.39;5.92] 0.59 0.22 [-11.86;12.29] 0.97 
Infection vs. no infection 0.15 [-1.54;1.84] 0.86 -0.91 [-2.73;0.92] 0.32 
Antibiotics (per day added) -1.72 [-8.41;4.97] 0.61 7.44 [-13.53;28.40] 0.48 
Duration of hemodynamic support (per day added) -4.36 [-10.15;1.43] 0.13 0.05 [-19.20;19.31] 0.99 
Duration of corticosteroid treatment (per day added) -0.89 [-11.10;9.32] 0.86 11.26 [-2.88;25.40] 0.11 
Cumulative dose of opioids (per mg morphine-equivalent added) -2.39 [-9.72;4.94] 0.52 3.89 [-4.71;12.49] 0.37 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 2.35 [-5.07;9.78] 0.53 3.72 [-2.66;10.11] 0.25 
Received hypnotics versus no hypnotics 1.01 [-4.16;6.18] 0.69 -1.34 [-6.45;3.77] 0.60 
Exceeding potentially harmful threshold for phthalate exposure -1.34 [-2.52;-0.16] 0.02 -0.78 [-2.18;0.61] 0.26 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-8. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and tapping nondominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 0.74 [-0.14;1.61] 0.09 0.33 [-0.83;1.49] 0.57 
Age at sampling (per year added) 18.12 [16.38;19.87] <0.001 18.84 [15.97;21.70] <0.001 
Caucasian vs. other race 1.30 [-1.88;4.48] 0.42 -3.69 [-7.53;0.15] 0.05 
Exclusively European vs. other origin -2.32 [-4.96;0.32] 0.08 3.27 [-0.76;7.29] 0.11 
Exclusively Dutch language vs. non-exclusively Dutch language -0.35 [-1.73;1.03] 0.61 -0.84 [-3.06;1.38] 0.45 
Socioeconomic status (per category of 1 to 66) 1.73 [-0.34;3.79] 0.10 0.17 [-2.60;2.95] 0.90 
Pre-existing syndrome vs. no pre-existing syndrome 0.59 [-0.53;1.70] 0.29 0.26 [-1.27;1.80] 0.73 
History vs. no history of malignancy 1.37 [-1.79;4.54] 0.39 -0.48 [-4.01;3.04] 0.78 
History vs. no history of diabetes -0.10 [-4.55;4.35] 0.96   
Randomization to strict glycemic control vs. conventional therapy 0.59 [-0.26;1.45] 0.17 0.46 [-0.70;1.61] 0.43 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 1.67 [-1.20;4.54] 0.25 1.44 [-2.19;5.07] 0.43 
          randomized for glycemic control postoperatively 2.84 [0.75;4.94] 0.008 0.22 [-2.75;3.20] 0.88 
     Complicated/high risk surgery or trauma 0.59 [-2.47;3.65] 0.70 3.69 [-0.70;8.09] 0.09 
     Neurological medical disorders -3.91 [-9.70;1.88] 0.18 -5.36 [-13.55;2.82] 0.19 
     Infectious medical diseases -1.10 [-5.07;2.86] 0.58 4.31 [-3.03;11.65] 0.24 
     Other medical disorders -1.98 [-6.12;2.16] 0.35 -0.57 [-6.24;5.09] 0.84 
     Solid organ transplants 1.89 [-4.50;8.28] 0.56 -3.73 [-11.21;3.75] 0.32 
PeLOD score first 24 hrs (per point added) 0.43 [-1.86;2.73] 0.71 1.08 [-1.91;4.06] 0.47 
PICU stay (per day added) -0.45 [-3.14;2.24] 0.74 -2.00 [-7.53;3.52] 0.47 
Exceeding potentially harmful threshold for phthalate exposure -1.31 [-2.32;-0.29] 0.01 -1.57 [-2.84;-0.30] 0.01 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-8. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and tapping nondominant hand (continued) 
 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 0.93 [0.04;1.83] 0.04 0.15 [-1.03;1.34] 0.79 
Age at sampling (per year added) 17.92 [15.81;20.04] <0.001 17.27 [14.00;20.54] <0.001 
Caucasian vs. other race 1.90 [-1.32;5.11] 0.24 -4.61 [-8.54;-0.68] 0.02 
Exclusively European vs. other origin -2.69 [-5.36;-0.02] 0.04 4.11 [0.01;8.20] 0.04 
Exclusively Dutch language vs. non-exclusively Dutch language -0.52 [-1.96;0.91] 0.47 -0.62 [-2.90;1.66] 0.59 
Socioeconomic status (per category of 1 to 66) 1.92 [-0.19;4.02] 0.07 0.19 [-2.67;3.04] 0.89 
Pre-existing syndrome vs. no pre-existing syndrome 0.40 [-0.77;1.58] 0.49 0.46 [-1.11;2.03] 0.56 
History vs. no history of malignancy 0.84 [-2.40;4.07] 0.61 -0.48 [-4.06;3.11] 0.79 
History vs. no history of diabetes 0.30 [-4.12;4.72] 0.89   
Randomization to strict glycemic control vs. conventional therapy 0.42 [-0.46;1.31] 0.34 0.25 [-0.96;1.45] 0.68 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively -1.05 [-6.53;4.44] 0.70 1.67 [-3.87;7.21] 0.55 
          randomized for glycemic control postoperatively 0.86 [-4.21;5.93] 0.73 0.83 [-3.78;5.43] 0.72 
     Complicated/high risk surgery or trauma 1.64 [-3.73;7.00] 0.54 6.38 [1.15;11.61] 0.01 
     Neurological medical disorders -5.40 [-14.21;3.41] 0.22 -5.88 [-15.32;3.56] 0.22 
     Infectious medical diseases -0.36 [-7.12;6.40] 0.91 4.97 [-3.01;12.95] 0.22 
     Other medical disorders 2.37 [-3.02;7.77] 0.38 -2.90 [-11.05;5.24] 0.48 
     Solid organ transplants 1.94 [-7.33;11.21] 0.68 -5.07 [-13.89;3.76] 0.25 
PeLOD score first 24 hrs (per point added) -0.15 [-2.76;2.46] 0.90 1.70 [-1.54;4.94] 0.30 
PICU stay (per day added) 0.12 [-11.72;11.96] 0.98 -17.24 [-46.77;12.29] 0.25 
Extracorporeal circulation versus no extracorporeal circulation a 1.93 [-0.00;3.87] 0.05 1.49 [-0.68;3.67] 0.17 
Aortic clamp time (per min added)  1.13 [-1.49;3.76] 0.39 0.39 [-4.50;5.28] 0.87 
Duration of mechanical ventilation (per day added) 7.51 [-2.09;17.10] 0.12 3.75 [-22.67;30.17] 0.77 
Peak creatinine (per mg/dl added) 0.97 [-4.72;6.65] 0.73 3.22 [-4.46;10.89] 0.40 
Peak bilirubine (per mg/dl added) -0.87 [-5.11;3.36] 0.68 1.79 [-9.81;13.39] 0.76 
Infection vs. no infection 0.40 [-1.14;1.94] 0.60 -1.81 [-3.57;-0.05] 0.04 
Antibiotics (per day added) -5.89 [-11.97;0.19] 0.05 12.48 [-8.65;33.61] 0.24 
Duration of hemodynamic support (per day added) -4.74 [-10.01;0.53] 0.07 -5.56 [-24.15;13.04] 0.55 
Duration of corticosteroid treatment (per day added) 4.18 [-5.12;13.47] 0.37 10.19 [-3.69;24.07] 0.14 
Cumulative dose of opioids (per mg morphine-equivalent added) -3.91 [-10.58;2.76] 0.24 2.08 [-6.18;10.34] 0.62 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) -5.78 [-12.54;0.98] 0.09 1.41 [-4.72;7.54] 0.65 
Received hypnotics versus no hypnotics 0.67 [-4.03;5.37] 0.77 -3.12 [-8.01;1.77] 0.20 
Exceeding potentially harmful threshold for phthalate exposure -1.24 [-2.31;-0.16] 0.02 -1.63 [-2.96;-0.29] 0.01 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-9. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and no. of valid synchronous taps 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 0.46 [-0.58;1.51] 0.38 -0.08 [-1.25;1.08] 0.88 
Age at sampling (per year added) 16.05 [13.97;18.12] <0.001 16.78 [13.91;19.65] <0.001 
Caucasian vs. other race -0.11 [-4.00;3.77] 0.95 -1.4 [-5.25;2.40] 0.46 
Exclusively European vs. other origin -1.57 [-4.72;1.58] 0.32 1.74 [-2.27;5.76] 0.39 
Exclusively Dutch language vs. non-exclusively Dutch language 0.58 [-1.09;2.25] 0.49 -0.07 [-2.29;2.14] 0.94 
Socioeconomic status (per category of 1 to 66) 1.34 [-1.12;3.80] 0.28 0.67 [-2.11;3.46] 0.63 
Pre-existing syndrome vs. no pre-existing syndrome -0.13 [-1.48;1.21] 0.84 -2.14 [-3.69;-0.60] 0.006 
History vs. no history of malignancy -0.88 [-4.64;2.88] 0.64 1.88 [-1.63;5.39] 0.29 
History vs. no history of diabetes 3.39 [-1.89;8.66] 0.20   
Randomization to strict glycemic control vs. conventional therapy 0.23 [-0.79;1.26] 0.65 0.51 [-0.66;1.69] 0.38 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 5.05 [1.63;8.47] 0.004 1.77 [-1.88;5.42] 0.33 
          randomized for glycemic control postoperatively 1.88 [-0.62;4.37] 0.14 2.27 [-0.71;5.25] 0.13 
     Complicated/high risk surgery or trauma 2.23 [-1.40;5.85] 0.22 3.48 [-0.90;7.86] 0.11 
     Neurological medical disorders -3.27 [-10.13;3.60] 0.34 -5.55 [-13.71;2.61] 0.18 
     Infectious medical diseases -0.33 [-5.03;4.37] 0.89 -0.05 [-7.36;7.27] 0.98 
     Other medical disorders -0.34 [-5.25;4.57] 0.89 6.16 [0.52;11.81] 0.03 
     Solid organ transplants -5.22 [-12.79;2.36] 0.17 -8.08 [-15.54;-0.63] 0.03 
PeLOD score first 24 hrs (per point added) 1.75 [-0.99;4.49] 0.20 1.71 [-1.28;4.71] 0.25 
PICU stay (per day added) -1.07 [-4.28;2.15] 0.51 -1.80 [-7.32;3.72] 0.52 
Exceeding potentially harmful threshold for phthalate exposure -2.19 [-3.40;-0.97] 0.0005 -1.09 [-2.37;0.19] 0.09 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-9. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
exposure and no. of valid synchronous taps (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 0.54 [-0.56;1.65] 0.33 -0.18 [-1.35;1.00] 0.76 
Age at sampling (per year added) 16.07 [13.48;18.67] <0.001 15.24 [12.00;18.47] <0.001 
Caucasian vs. other race 0.42 [-3.66;4.50] 0.83 -1.85 [-5.72;2.01] 0.34 
Exclusively European vs. other origin -1.17 [-4.44;2.10] 0.48 2.80 [-1.23;6.84] 0.17 
Exclusively Dutch language vs. non-exclusively Dutch language -0.14 [-1.93;1.65] 0.87 -0.55 [-2.80;1.69] 0.62 
Socioeconomic status (per category of 1 to 66) 1.60 [-0.98;4.18] 0.22 0.86 [-1.97;3.70] 0.54 
Pre-existing syndrome vs. no pre-existing syndrome -0.49 [-1.94;0.96] 0.50 -2.07 [-3.64;-0.50] 0.01 
History vs. no history of malignancy -0.77 [-4.72;3.18] 0.69 2.58 [-0.95;6.11] 0.15 
History vs. no history of diabetes 3.35 [-2.05;8.74] 0.22   
Randomization to strict glycemic control vs. conventional therapy 0.46 [-0.63;1.54] 0.40 -0.03 [-1.23;1.17] 0.96 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 3.45 [-3.32;10.23] 0.31 1.58 [-3.92;7.09] 0.57 
          randomized for glycemic control postoperatively 0.65 [-5.59;6.89] 0.83 2.21 [-2.34;6.75] 0.33 
     Complicated/high risk surgery or trauma 1.42 [-5.13;7.97] 0.66 4.96 [-0.19;10.11] 0.05 
     Neurological medical disorders -3.14 [-13.91;7.63] 0.56 -6.41 [-15.71;2.89] 0.17 
     Infectious medical diseases -1.40 [-9.66;6.86] 0.73 1.41 [-6.45;9.26] 0.72 
     Other medical disorders 1.81 [-4.78;8.39] 0.58 3.34 [-4.67;11.35] 0.41 
     Solid organ transplants -2.79 [-14.13;8.54] 0.62 -7.09 [-15.77;1.60] 0.10 
PeLOD score first 24 hrs (per point added) 1.34 [-1.90;4.59] 0.41 1.08 [-2.15;4.30] 0.51 
PICU stay (per day added) 2.42 [-12.18;17.01] 0.74 -15.84 [-45.05;13.37] 0.28 
Extracorporeal circulation versus no extracorporeal circulation a 1.14 [-1.30;3.58] 0.35 2.64 [0.46;4.83] 0.01 
Aortic clamp time (per min added)  0.05 [-3.17;3.28] 0.97 -4.23 [-9.04;0.59] 0.08 
Duration of mechanical ventilation (per day added) 3.15 [-8.63;14.94] 0.59 23.23 [-3.04;49.50] 0.08 
Peak creatinine (per mg/dl added) -0.72 [-7.75;6.32] 0.84 8.82 [1.25;16.40] 0.02 
Peak bilirubine (per mg/dl added) -0.70 [-5.95;4.55] 0.79 -5.81 [-17.28;5.67] 0.31 
Infection vs. no infection 1.10 [-0.80;3.00] 0.25 -0.77 [-2.54;1.00] 0.39 
Antibiotics (per day added) -4.25 [-11.70;3.20] 0.26 -1.59 [-22.92;19.74] 0.88 
Duration of hemodynamic support (per day added) -5.82 [-12.25;0.61] 0.07 -5.89 [-24.19;12.42] 0.52 
Duration of corticosteroid treatment (per day added) -2.51 [-13.84;8.82] 0.66 -0.27 [-14.01;13.48] 0.96 
Cumulative dose of opioids (per mg morphine-equivalent added) -5.74 [-13.87;2.39] 0.16 6.22 [-1.90;14.33] 0.13 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) -1.65 [-9.92;6.62] 0.69 -0.41 [-6.49;5.67] 0.89 
Received hypnotics versus no hypnotics 0.54 [-5.21;6.29] 0.85 -1.79 [-6.61;3.02] 0.46 
Exceeding potentially harmful threshold for phthalate exposure -2.35 [-3.68;-1.03] 0.0006 -1.46 [-2.80;-0.13] 0.03 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-10. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and reaction time dominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -8.66 [-43.35;26.02] 0.62 -3.95 [-41.02;33.12] 0.83 
Age at sampling (per year added) -411.10 [-484.31;-337.89] <0.001 -437.05 [-529.09;-345.01] <0.001 
Caucasian vs. other race 24.73 [-100.99;150.45] 0.69 72.63 [-50.06;195.33] 0.24 
Exclusively European vs. other origin -21.04 [-125.73;83.65] 0.69 -107.82 [-233.84;18.20] 0.09 
Exclusively Dutch language vs. non-exclusively Dutch language 63.73 [9.07;118.38] 0.02 50.43 [-16.31;117.16] 0.13 
Socioeconomic status (per category of 1 to 66) -96.53 [-178.55;-14.50] 0.02 -62.03 [-151.47;27.41] 0.17 
Pre-existing syndrome vs. no pre-existing syndrome 19.77 [-24.80;64.34] 0.38 51.83 [3.27;100.38] 0.03 
History vs. no history of malignancy -64.41 [-191.32;62.49] 0.32 13.07 [-100.97;127.10] 0.82 
History vs. no history of diabetes -36.65 [-212.77;139.48] 0.68   
Randomization to strict glycemic control vs. conventional therapy 3.02 [-31.06;37.09] 0.86 -4.63 [-41.56;32.31] 0.80 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 50.57 [-63.42;164.57] 0.38 205.13 [88.81;321.45] <0.001 
          randomized for glycemic control postoperatively -72.66 [-155.57;10.26] 0.08 72.36 [-22.67;167.39] 0.13 
     Complicated/high risk surgery or trauma -48.71 [-172.58;75.15] 0.43 -82.16 [-227.45;63.14] 0.26 
     Neurological medical disorders 215.73 [-13.81;445.28] 0.06 -8.31 [-270.82;254.20] 0.95 
     Infectious medical diseases -168.80 [-325.94;-11.65] 0.03 -74.74 [-310.24;160.76] 0.53 
     Other medical disorders -71.06 [-234.89;92.77] 0.39 -28.07 [-209.80;153.66] 0.76 
     Solid organ transplants 94.92 [-157.92;347.76] 0.45 -84.21 [-325.10;156.68] 0.49 
PeLOD score first 24 hrs (per point added) -56.51 [-147.41;34.40] 0.22 43.51 [-52.08;139.11] 0.37 
PICU stay (per day added) 20.71 [-84.97;126.39] 0.69 172.68 [-6.42;351.77] 0.05 
Exceeding potentially harmful threshold for phthalate exposure 84.05 [41.57;126.52] 0.0001 45.05 [4.77;85.33] 0.03 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-10. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and reaction time dominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -13.03 [-49.95;23.89] 0.48 -14.30 [-51.53;22.94] 0.44 
Age at sampling (per year added) -392.79 [-486.82;-298.75] <0.001 -395.42 [-498.87;-291.97] <0.001 
Caucasian vs. other race 8.73 [-123.33;140.79] 0.89 69.04 [-53.73;191.80] 0.26 
Exclusively European vs. other origin -10.68 [-120.24;98.88] 0.84 -105.12 [-230.52;20.28] 0.09 
Exclusively Dutch language vs. non-exclusively Dutch language 55.77 [-3.25;114.80] 0.06 60.87 [-5.69;127.42] 0.07 
Socioeconomic status (per category of 1 to 66) -106.81 [-193.92;-19.70] 0.01 -78.01 [-168.06;12.03] 0.08 
Pre-existing syndrome vs. no pre-existing syndrome 24.25 [-24.60;73.09] 0.32 59.50 [10.87;108.13] 0.01 
History vs. no history of malignancy -70.99 [-205.42;63.43] 0.29 -2.52 [-115.44;110.40] 0.96 
History vs. no history of diabetes -52.61 [-234.34;129.11] 0.56   
Randomization to strict glycemic control vs. conventional therapy 3.08 [-33.33;39.50] 0.86 5.98 [-32.33;40.30] 0.75 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 252.80 [26.46;479.14] 0.02 127.65 [-46.01301.31] 0.14 
          randomized for glycemic control postoperatively 133.01 [-76.49;342.51] 0.21 31.01 [-113.28;175.29] 0.67 
     Complicated/high risk surgery or trauma 56.40 [-166.17;278.98] 0.61 -56.87 [-220.76;107.03] 0.49 
     Neurological medical disorders 58.79 [-303.02;420.60] 0.74 -96.40 [-392.17;199.38] 0.52 
     Infectious medical diseases -370.72 [-648.35;-93.09] 0.009 27.82 [-230.39;286.03] 0.83 
     Other medical disorders -199.56 [-421.31;22.18] 0.07 21.26 [-233.93;276.46] 0.87 
     Solid organ transplants 69.28 [-311.47;450.03] 0.71 -54.48 [-333.88;224.93] 0.70 
PeLOD score first 24 hrs (per point added) -47.92 [-155.59;59.76] 0.38 16.54 [-84.64;117.72] 0.74 
PICU stay (per day added) -223.65 [-714.92;267.63] 0.37 -251.14 [-1147.03;644.75] 0.58 
Extracorporeal circulation versus no extracorporeal circulation a -61.24 [-143.38;20.90] 0.14 -30.19 [-98.48;38.10] 0.38 
Aortic clamp time (per min added)  39.68 [-68.55;147.91] 0.47 142.01 [-10.28;294.30] 0.06 
Duration of mechanical ventilation (per day added) 238.09 [-161.44;637.61] 0.24 798.18 [-29.03;1625.40] 0.05 
Peak creatinine (per mg/dl added) -52.00 [-288.01;184.01] 0.66 -113.50 [-355.84;128.83] 0.35 
Peak bilirubine (per mg/dl added) -56.04 [-228.93;116.85] 0.52 332.38 [-13.89;678.65] 0.05 
Infection vs. no infection 14.55 [-47.59;76.68] 0.64 37.58 [-18.76;93.92] 0.18 
Antibiotics (per day added) -0,80 [-250.93;249.32] 0.99 -607.54 [-1256.71;41.63] 0.06 
Duration of hemodynamic support (per day added) 43.28 [-173.92;260.48] 0.69 223.77 [-435.66;883.20] 0.50 
Duration of corticosteroid treatment (per day added) 221.27 [-160.77;603.32] 0.25 121.44 [-333.28;576.17] 0.59 
Cumulative dose of opioids (per mg morphine-equivalent added) 13.20 [-260.60;287.01] 0.92 -183.41 [-448.25;81.44] 0.17 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 1.79 [-276.23;279.80] 0.98 -103.10 [-297.01;90.81] 0.29 
Received hypnotics versus no hypnotics -149.33 [-342.07;43.41] 0.12 26.92 [-126.23;180.08] 0.72 
Exceeding potentially harmful threshold for phthalate exposure 88.58 [41.61;135.56] 0.0003 44.64 [2.71;86.57] 0.03 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-11. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and reaction time nondominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -18.47 [-50.62;13.68] 0.25 8.44 [-25.59;42.48] 0.62 
Age at sampling (per year added) -372.99 [-440.76;-305.22] <0.001 -408.81 [-493.32;-324.31] <0.001 
Caucasian vs. other race -20.67 [-137.96;96.63] 0.72 19.64 [-93.01;132.29] 0.73 
Exclusively European vs. other origin -25.71 [-123.29;71.86] 0.60 -89.50 [-205.20;26.21] 0.12 
Exclusively Dutch language vs. non-exclusively Dutch language 59.59 [8.73;110.45] 0.02 64.59 [3.32;125.86] 0.02 
Socioeconomic status (per category of 1 to 66) -49.26 [-125.22;26.71] 0.20 -102.31 [-184.43;-20.19] 0.01 
Pre-existing syndrome vs. no pre-existing syndrome 6.51 [-34.59;47.62] 0.75 46.37 [1.79;90.95] 0.04 
History vs. no history of malignancy -46.84 [-165.21;71.53] 0.43 25.29 [-79.41;129.99] 0.63 
History vs. no history of diabetes -4.65 [-168.93;159.62] 0.95   
Randomization to strict glycemic control vs. conventional therapy 3.47 [-28.03;34.97] 0.82 0.44 [-33.47;34.36] 0.97 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 27.38 [-78.92;133.69] 0.61 186.85 [80.05;293.65] <0.001 
          randomized for glycemic control postoperatively -31.95 [-108.90;45.00] 0.41 59.59 [-27.66;146.85] 0.17 
     Complicated/high risk surgery or trauma -10.34 [-125.90;105.23] 0.86 -184.77 [-318.18;-51.37] 0.006 
     Neurological medical disorders 90.77 [-123.07;304.62] 0.40 87.98 [-153.05;329.00] 0.47 
     Infectious medical diseases -100.09 [-246.67;46.49] 0.17 -67.25 [-283.48;148.98] 0.54 
     Other medical disorders -94.89 [-247.67;57.89] 0.22 -30.44 [-197.30;136.42] 0.71 
     Solid organ transplants 119.11 [-116.73;354.96] 0.32 -51.96 [-273.13;169.21] 0.63 
PeLOD score first 24 hrs (per point added) -14.61 [-99.08;69.85] 0.73 15.20 [-72.57;102.97] 0.73 
PICU stay (per day added) -11.24 [-108.27;85.79] 0.82 195.11 [30.67;359.54] 0.02 
Exceeding potentially harmful threshold for phthalate exposure 67.94 [28.72;107.17] 0.0008 44.23 [7.25;81.21] 0.01 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-11. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and reaction time nondominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -19.77 [-53.06;13.52] 0.24 2.58 [-32.00;37.16] 0.88 
Age at sampling (per year added) -369.19 [-453.84;-284.54] <0.001 -376.69 [-472.76;-280.62] <0.001 
Caucasian vs. other race -40.64 [-160.40;79.12] 0.50 24.08 [-89.92;138.09] 0.67 
Exclusively European vs. other origin -16.67 [-115.92;82.57] 0.74 -90.04 [-206.49;26.41] 0.12 
Exclusively Dutch language vs. non-exclusively Dutch language 57.70 [4.35;111.05] 0.03 74.04 [12.24;135.85] 0.01 
Socioeconomic status (per category of 1 to 66) -57.43 [-135.81;20.95] 0.14 -119.39 [-203.02;-35.77] 0.005 
Pre-existing syndrome vs. no pre-existing syndrome 9.69 [-33.94;53.32] 0.66 48.82 [3.66;93.98] 0.03 
History vs. no history of malignancy -48.27 [-170.12;73.58] 0.43 9.64 [-95.22;114.51] 0.85 
History vs. no history of diabetes -25.92 [-190.65;138.81] 0.75   
Randomization to strict glycemic control vs. conventional therapy 5.98 [-26.67;38.63] 0.71 12.60 [-22.98;48.19] 0.48 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 225.05 [21.15;428.95] 0.03 130.29 [-30.97;291.56] 0.11 
          randomized for glycemic control postoperatively 157.72 [-31.08;346.53] 0.10 24.07 [-109.92;158.05] 0.72 
     Complicated/high risk surgery or trauma 47.86 [-153.28;249.00] 0.63 -194.24 [-346.44;-42.03] 0.01 
     Neurological medical disorders -18.80 [-346.44;308.85] 0.91 81.59 [-193.08;356.26] 0.55 
     Infectious medical diseases -268.79 [-520.28;-17.30] 0.03 -21.68 [-261.47;218.11] 0.85 
     Other medical disorders -264.91 [-465.66;-64.16] 0.01 69.24 [-167.75;306.23] 0.56 
     Solid organ transplants 121.86 [-223.46;467.19] 0.48 -89.27 [-348.74;170.19] 0.49 
PeLOD score first 24 hrs (per point added) -6.10 [-103.21;91.01] 0.90 5.15 [-88.81;99.11] 0.91 
PICU stay (per day added) -117.29 [-554.08;319.50] 0.59 -428.39 [-1314.35;349.57] 0.25 
Extracorporeal circulation versus no extracorporeal circulation a -65.51 [-137.62;6.61] 0.07 -56.87 [-120.28;6.55] 0.07 
Aortic clamp time (per min added)  -4.55 [-101.90;92.80] 0.93 109.92 [-31.51;251.34] 0.12 
Duration of mechanical ventilation (per day added) 133.00 [-222.57;488.58] 0.46 504.08 [-264.10;1272.27] 0.19 
Peak creatinine (per mg/dl added) -0.47 [-214.02;213.08] 0.99 -74.22 [-299.26;150.82] 0.51 
Peak bilirubine (per mg/dl added) -165.64 [-322.07;-9.21] 0.03 236.17 [-85.39;557.73] 0.14 
Infection vs. no infection 11.90 [-44.22;68.03] 0.67 27.76 [-24.56;80.08] 0.29 
Antibiotics (per day added) -68.26 [-294.85;158.34] 0.55 -163.12 [-765.96;439.72] 0.59 
Duration of hemodynamic support (per day added) 67.73 [-128.98;264.44] 0.49 359.10 [-253.27;971.47] 0.24 
Duration of corticosteroid treatment (per day added) 173.76 [-171.15;518.67] 0.32 186.52 [-235.75;608.79] 0.38 
Cumulative dose of opioids (per mg morphine-equivalent added) 130.34 [-118.06;378.74] 0.30 -163.23 [-409.17;82.72] 0.19 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 113.42 [-138.41;365.25] 0.37 -77.35 [-257.42;102.72] 0.39 
Received hypnotics versus no hypnotics -122.21 [-297.00;52.59] 0.16 79.93 [-62.29;222.16] 0.26 
Exceeding potentially harmful threshold for phthalate exposure 74.16 [32.00;116.33] 0.0006 46.46 [7.52;85.40] 0.01 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-12. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and reaction time overall 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -15.03 [-45.91;15.86] 0.33 3.41 [-30.44;37.26] 0.84 
Age at sampling (per year added) -387.41 [-452.61;-322.22] <0.001 -422.56 [-506.60;-338.52] <0.001 
Caucasian vs. other race 2.17 [-109.80;114.13] 0.96 45.85 [-66.18;157.88] 0.42 
Exclusively European vs. other origin -23.03 [-116.27;70.20] 0.62 -97.75 [-212.82;17.32] 0.09 
Exclusively Dutch language vs. non-exclusively Dutch language 59.54 [10.87;108.22] 0.01 56.80 [-4.14;117.73] 0.06 
Socioeconomic status (per category of 1 to 66) -68.79 [-141.83;4.26] 0.06 -84.40 [-166.07;-2.74] 0.04 
Pre-existing syndrome vs. no pre-existing syndrome 10.57 [-29.13;50.26] 0.60 46.43 [2.10;90.77] 0.04 
History vs. no history of malignancy -55.81 [-168.83;57.20] 0.33 19.63 [-84.50;123.75] 0.71 
History vs. no history of diabetes -17.99 [-174.84;138.86] 0.82   
Randomization to strict glycemic control vs. conventional therapy 2.58 [-27.77;32.92] 0.86 -2.82 [-36.54;30.91] 0.86 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 37.87 [-63.65;139.39] 0.46 193.22 [87.01;299.44] <0.001 
          randomized for glycemic control postoperatively -56.29 [-130.13;17.56] 0.12 62.32 [-24.45;149.09] 0.15 
     Complicated/high risk surgery or trauma -29.46 [-139.76;80.85] 0.59 -132.97 [-265.64;-0.30] 0.04 
     Neurological medical disorders 157.73 [-46.70;362.16] 0.13 43.62 [-196.08;283.32] 0.72 
     Infectious medical diseases -133.84 [-273.78;6.11] 0.06 -72.32 [-287.36;142.72] 0.50 
     Other medical disorders -85.54 [-231.44;60.36] 0.24 -27.05 [-192.99;138.89] 0.74 
     Solid organ transplants 109.52 [-115.65;334.68] 0.33 -66.83 [-286.78;153.13] 0.54 
PeLOD score first 24 hrs (per point added) -33.72 [-114.68;47.23] 0.41 27.47 [-59.81;114.76] 0.53 
PICU stay (per day added) 7.43 [-86.68;101.55] 0.87 185.22 [21.69;348.75] 0.02 
Exceeding potentially harmful threshold for phthalate exposure 76.07 [38.25;113.89] 0.0001 45.99 [9.21;82.76] 0.01 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-12. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and reaction time overall (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -17.85 [-50.20;14.50] 0.27 -4.44 [-38.53;29.66] 0.79 
Age at sampling (per year added) -375.33 [-457.71;-292.94] <0.001 -383.91 [-478.63;-289.20] <0.001 
Caucasian vs. other race -15.83 [-131.52;99.87] 0.78 46.29 [-66.11;158.69] 0.41 
Exclusively European vs. other origin -13.04 [-109.03;82.94] 0.78 -97.16 [-211.97;17.65] 0.09 
Exclusively Dutch language vs. non-exclusively Dutch language 54.60 [2.89;106.31] 0.03 66.84 [5.90;127.77] 0.03 
Socioeconomic status (per category of 1 to 66) -78.41 [-154.72;-2.09] 0.04 -100.79 [-183.23;-18.34] 0.01 
Pre-existing syndrome vs. no pre-existing syndrome 14.28 [-28.51;57.08] 0.51 51.01 [6.48;95.53] 0.02 
History vs. no history of malignancy -59.50 [-177.27;58.28] 0.32 4.20 [-99.19;107.59] 0.93 
History vs. no history of diabetes -38.06 [-197.28;121.16] 0.63   
Randomization to strict glycemic control vs. conventional therapy 4.35 [-27.55;36.25] 0.78 8.33 [-26.75;43.42] 0.63 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 244.30 [46.00;442.60] 0.01 127.37 [-31.63;286.37] 0.11 
          randomized for glycemic control postoperatively 147.91 [-35.64;331.46] 0.11 24.74 [-107.36;156.84] 0.71 
     Complicated/high risk surgery or trauma 50.66 [-144.34;245.66] 0.60 -126.05 [-276.11;24.01] 0.09 
     Neurological medical disorders 19.15 [-297.84;336.14] 0.90 -4.61 [-275.41;266.20] 0.97 
     Infectious medical diseases -323.71 [-566.94;-80.47] 0.009 0.44 [-235.98;236.85] 0.99 
     Other medical disorders -237.44 [-431.72;-43.16] 0.01 46.58 [-187.07;280.24] 0.69 
     Solid organ transplants 99.12 [-234.46;432.71] 0.55 -68.47 [-324.28;187.34] 0.59 
PeLOD score first 24 hrs (per point added) -25.90 [-120.23;68.44] 0.58 8.47 [-84.17;101.11] 0.85 
PICU stay (per day added) -168.95 [-599.36;261.47] 0.43 -361.12 [-1181.38;459.14] 0.38 
Extracorporeal circulation versus no extracorporeal circulation a -67.67 [-139.64;4.29] 0.06 -44.13 [-106.65;18.40] 0.16 
Aortic clamp time (per min added)  18.82 [-76.00;113.65] 0.69 125.32 [-14.11;264.75] 0.07 
Duration of mechanical ventilation (per day added) 186.00 [-164.03;536.03] 0.29 664.71 [-92.67;1422.09] 0.08 
Peak creatinine (per mg/dl added) -24.70 [-231.47;182.07] 0.81 -93.48 [-315.35;128.40] 0.40 
Peak bilirubine (per mg/dl added) -107.82 [-259.29;43.65] 0.16 271.35 [-45.69;588.39] 0.09 
Infection vs. no infection 13.84 [-40.59;68.28] 0.61 33.75 [-17.84;85.33] 0.19 
Antibiotics (per day added) -31.69 [-250.83;187.45] 0.77 -391.16 [-985.53;203.20] 0.19 
Duration of hemodynamic support (per day added) 56.36 [-133.93;246.65] 0.55 287.74 [-316.02;891.49] 0.34 
Duration of corticosteroid treatment (per day added) 192.81 [-141.90;527.53] 0.25 144.39 [-271.94;560.73] 0.49 
Cumulative dose of opioids (per mg morphine-equivalent added) 70.19 [169.70;310.08] 0.56 -175.00 [-417.49;67.49] 0.15 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 55.34 [-188.24;298.91] 0.65 -88.85 [-266.38;88.69] 0.32 
Received hypnotics versus no hypnotics -137.40 [-306.27;31.46] 0.11 53.87 [-86.35;194.10] 0.44 
Exceeding potentially harmful threshold for phthalate exposure 81.54 [40.38;122.70] 0.0001 47.06 [8.67;85.45] 0.01 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-13. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and inconsistency of reaction time dominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 18.28 [-11.34;47.90] 0.22 -1.11 [-35.62;33.40] 0.94 
Age at sampling (per year added) -306.85 [-369.38;-244.32] <0.001 -341.45 [-427.12;-255.77] <0.001 
Caucasian vs. other race 37.52 [-69.87;144.91] 0.49 59.93 [-54.28;174.14] 0.30 
Exclusively European vs. other origin -42.69 [-132.11;46.74] 0.34 -76.74 [-194.04;40.56] 0.19 
Exclusively Dutch language vs. non-exclusively Dutch language 31.06 [-15.63;77.75] 0.19 27.91 [-34.21;90.03] 0.37 
Socioeconomic status (per category of 1 to 66) -77.07 [-147.13;-7.00] 0.03 -110.59 [-193.85;-27.34] 0.009 
Pre-existing syndrome vs. no pre-existing syndrome 19.43 [-18.65;57.50] 0.31 64.21 [19.01;109.41] 0.005 
History vs. no history of malignancy -42.67 [-151.07;65.73] 0.43 49.75 [-56.40;155.90] 0.35 
History vs. no history of diabetes -14.73 [-165.17;135.72] 0.84   
Randomization to strict glycemic control vs. conventional therapy -10.48 [-39.59;18.62] 0.47 6.69 [-27.69;41.07] 0.70 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 65.80 [-31.57;163.17] 0.18 144.97 [36.69;253.25] 0.009 
          randomized for glycemic control postoperatively -26.43 [-97.25;44.40] 0.46 53.02 [-35.44;141.48] 0.23 
     Complicated/high risk surgery or trauma -16.73 [-122.53;89.07] 0.75 -83.70 [-218.95;51.55] 0.22 
     Neurological medical disorders 135.65 [-60.42;331.72] 0.17 -10.13 [-254.49;234.23] 0.93 
     Infectious medical diseases -123.39 [-257.62;10.84] 0.07 -42.60 [-261.81;176.62] 0.70 
     Other medical disorders -17.86 [-157.80;122.07] 0.80 -65.27 [-234.44;103.89] 0.44 
     Solid organ transplants -17.04 [-233.01;198.93] 0.87 3.71 [-220.53;227.94] 0.97 
PeLOD score first 24 hrs (per point added) -23.48 [-101.13;54.17] 0.55 38.81 [-50.17;127.79] 0.39 
PICU stay (per day added) 9.80 [-80.47;100.07] 0.83 86.31 [-80.40;253.02] 0.30 
Exceeding potentially harmful threshold for phthalate exposure 61.87 [25.59;98.14] 0.0009 45.46 [7.97;82.95] 0.01 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-13. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and inconsistency of reaction time dominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 12.40 [-19.46;44.26] 0.44 -12.64 [-47.01.21.73] 0.46 
Age at sampling (per year added) -300.33 [-381.48;-219.19] <0.001 -300.13 [-395.63.-204.64] <0.001 
Caucasian vs. other race 35.29 [-78.67;149.25] 0.54 72.63 [-40.69.185.96] 0.20 
Exclusively European vs. other origin -43.29 [-137.83;51.25] 0.36 -94.97 [-210.73.20.78] 0.10 
Exclusively Dutch language vs. non-exclusively Dutch language 27.21 [-23.72;78.14] 0.29 33.48 [-27.96.94.92] 0.28 
Socioeconomic status (per category of 1 to 66) -76.81 [-151.98;-1.64] 0.04 -122.80 [-205.92.-39.68] 0.004 
Pre-existing syndrome vs. no pre-existing syndrome 26.42 [-15.73;68.58] 0.21 70.12 [25.22.115.01] 0.002 
History vs. no history of malignancy -42.68 [-158.68;73.32] 0.46 41.35 [-62.89.145.59] 0.43 
History vs. no history of diabetes -26.48 [-183.30;130.34] 0.73   
Randomization to strict glycemic control vs. conventional therapy -7.84 [-39.27;23.58] 0.62 14.79 [-20.58.50.16] 0.41 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 201.79 [6.47;397.10] 0.04 45.49 [-114.81.205.79] 0.57 
          randomized for glycemic control postoperatively 111.28 [-69.51;292.07] 0.22 -12.13 [-145.32.121.06] 0.85 
     Complicated/high risk surgery or trauma 39.62 [-152.44;231.69] 0.68 -110.85 [-262.14;40.45] 0.15 
     Neurological medical disorders -2.42 [-314.64;309.80] 0.98 -29.34 [-302.38;243.69] 0.83 
     Infectious medical diseases -218.60 [-458.18;20.98] 0.07 45.30 [-193.06;283.66] 0.70 
     Other medical disorders -86.41 [-277.76;104.95] 0.37 -6.24 [-241.82;229.33] 0.95 
     Solid organ transplants -45.26 [-373.83;283.30] 0.78 67.78 [-190.14;325.69] 0.60 
PeLOD score first 24 hrs (per point added) -33.40 [-126.32;59.51] 0.47 -10.45 [-103.85;82.95] 0.82 
PICU stay (per day added) -117.92 [-541.86;306.02] 0.58 704.57 [-122.43;1531.57] 0.09 
Extracorporeal circulation versus no extracorporeal circulation a -34.10 [-104.98;36.79] 0.34 -2.01 [-65.04;61.03] 0.95 
Aortic clamp time (per min added)  9.70 [-83.69;103.10] 0.83 170.09 [29.51;310.67] 0.01 
Duration of mechanical ventilation (per day added) 87.63 [-257.13;432.40] 0.61 420.69 [-342.91;1184.30] 0.27 
Peak creatinine (per mg/dl added) 0.72 [-202.94;204.39] 0.99 3.61 [-220.09;227.30] 0.97 
Peak bilirubine (per mg/dl added) 7.46 [-141.73;156.65] 0.92 263.35 [-56.30;582.99] 0.10 
Infection vs. no infection 27.41 [-26.21;81.02] 0.31 51.84 [-0.17;103.85] 0.05 
Antibiotics (per day added) 2.55 [-213.29;218.39] 0.98 -958.44 [-1557.68;-359.19] 0.001 
Duration of hemodynamic support (per day added) 19.56 [-167.87;206.99] 0.83 -229.55 [-838.27;379.17] 0.45 
Duration of corticosteroid treatment (per day added) 125.07 [-204.61;454.76] 0.45 0.78 [-418.97;420.53] 0.99 
Cumulative dose of opioids (per mg morphine-equivalent added) 40.52 [-195.75.276.80] 0.73 -263.68 [-508.16;-19.20] 0.03 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 23.54 [-216.37.263.45] 0.84 -48.61 [-227.61;130.38] 0.59 
Received hypnotics versus no hypnotics -78.03 [-244.36.88.29] 0.35 72.94 [-68.44;214.31] 0.31 
Exceeding potentially harmful threshold for phthalate exposure 61.74 [21.19.102.28] 0.003 42.42 [3.71;81.13] 0.03 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
  
50 
 
eTable 5-14. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and inconsistency of reaction time nondominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -0.30 [-28.86;28.26] 0.98 3.79 [-29.25;36.83] 0.82 
Age at sampling (per year added) -254.60 [-314.81;-194.39] <0.001 -311.59 [-393.62;-229.56] <0.001 
Caucasian vs. other race 10.99 [-93.22;115.19] 0.83 16.38 [-92.97;125.73] 0.76 
Exclusively European vs. other origin -53.18 [-139.87;33.50] 0.22 -76.86 [-189.18;35.46] 0.17 
Exclusively Dutch language vs. non-exclusively Dutch language 49.74 [4.56;94.92] 0.03 49.74 [-9.74;109.21] 0.10 
Socioeconomic status (per category of 1 to 66) -30.16 [-97.65;37.33] 0.37 -88.88 [-168.59;-9.16] 0.02 
Pre-existing syndrome vs. no pre-existing syndrome 12.67 [-23.85;49.19] 0.49 44.03 [0.76;87.31] 0.04 
History vs. no history of malignancy -71.71 [-176.87;33.45] 0.18 15.22 [-86.42;116.85] 0.76 
History vs. no history of diabetes 2.98 [-142.96;148.92] 0.96   
Randomization to strict glycemic control vs. conventional therapy -8.86 [-36.85;19.12] 0.53 7.16 [-25.76;40.08] 0.66 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 22.30 [-72.14;116.74] 0.64 160.91 [57.24;264.59] 0.002 
          randomized for glycemic control postoperatively 17.54 [-50.82;85.91] 0.61 43.15 [-41.55;127.85] 0.31 
     Complicated/high risk surgery or trauma 52.26 [-50.41;154.93] 0.31 -211.12 [-340.62;-81.62] 0.001 
     Neurological medical disorders 33.77 [-156.21;223.75] 0.72 148.07 [-85.90;382.04] 0.21 
     Infectious medical diseases -120.07 [-250.30;10.15] 0.07 -117.08 [-326.97;92.82] 0.27 
     Other medical disorders -65.19 [-200.92;70.54] 0.34 -42.39 [-204.36;119.58] 0.60 
     Solid organ transplants 59.39 [-150.14;268.92] 0.57 18.45 [-196.25;233.15] 0.86 
PeLOD score first 24 hrs (per point added) -7.08 [-82.12;67.96] 0.85 37.29 [-47.91;122.49] 0.38 
PICU stay (per day added) 6.05 [-80.15;92.26] 0.89 90.47 [-69.15;250.09] 0.26 
Exceeding potentially harmful threshold for phthalate exposure 50.73 [15.88;85.57] 0.004 27.33 [-8.57;63.23] 0.13 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-14. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and inconsistency of reaction time nondominant hand 
(continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 2.75 [-27.15;32.64] 0.85 0.05 [-34.26;34.36] 0.99 
Age at sampling (per year added) -271.88 [-347.89;-195.87] <0.001 -300.90 [-396.22;-205.58] <0.001 
Caucasian vs. other race -4.05 [-111.59;103.48] 0.94 18.74 [-94.38;131.86] 0.74 
Exclusively European vs. other origin -50.40 [-139.52;38.71] 0.26 -75.84 [-191.38;0.39.71] 0.19 
Exclusively Dutch language vs. non-exclusively Dutch language 53.20 [5.30;101.10] 0.02 57.49 [-3.84;118.81] 0.06 
Socioeconomic status (per category of 1 to 66) -40.25 [-110.62;30.13] 0.26 -110.37 [-193.34;-27.39] 0.009 
Pre-existing syndrome vs. no pre-existing syndrome 16.60 [-22.57;55.78] 0.40 45.40 [0.59;90.21] 0.04 
History vs. no history of malignancy -90.14 [-199.55;19.28] 0.10 -4.10 [-108.15;99.95] 0.93 
History vs. no history of diabetes -6.59 [-154.50;141.33] 0.93   
Randomization to strict glycemic control vs. conventional therapy -10 [-39.32;19.32] 0.50 16.48 [-18.82;51.79] 0.35 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 129.49 [-53.59;312.58] 0.16 182.65 [22.64;342.67] 0.02 
          randomized for glycemic control postoperatively 122.80 [-46.73;292.34] 0.15 71.58 [-61.37;204.52] 0.28 
     Complicated/high risk surgery or trauma 108.40 [-72.20;289.01] 0.23 -228.65 [-379.67;-77.63] 0.003 
     Neurological medical disorders -3.01 [-297.21;291.18] 0.98 151.68 [-120.86;424.21] 0.27 
     Infectious medical diseases -181.01 [-406.82;44.81] 0.11 -102.61 [-340.53;135.31] 0.39 
     Other medical disorders -152.71 [-332.97;27.55] 0.09 12.55 [-222.59;247.70] 0.91 
     Solid organ transplants -23.97 [-334.04;286.10] 0.87 -87.20 [-344.64;170.25] 0.50 
PeLOD score first 24 hrs (per point added) -5.77 [-92.97;81.43] 0.89 22.71 [-70.51;115.94] 0.63 
PICU stay (per day added) -140.41 [-532.61;251.79] 0.48 -424.74 [-1250.23;400.76] 0.31 
Extracorporeal circulation versus no extracorporeal circulation a -35.62 [-100.37;29.13] 0.27 -63.62 [-126.55;-0.70] 0.04 
Aortic clamp time (per min added)  8.84 [-78.58;96.25] 0.84 124.50 [-15.82;264.83] 0.08 
Duration of mechanical ventilation (per day added) 166.73 [-152.55;486.00] 0.30 416.95 [-345.27;1179.16] 0.28 
Peak creatinine (per mg/dl added) 77.48 [-114.27;269.23] 0.42 19.46 [-203.83;242.75] 0.86 
Peak bilirubine (per mg/dl added) -164.29 [-304.76;-23.83] 0.02 112.46 [-206.60;431.52] 0.48 
Infection vs. no infection -12.15 [-62.54;38.24] 0.63 28.60 [-23.31;80.51] 0.28 
Antibiotics (per day added) -64.70 [-268.17;138.76] 0.53 -108.35 [-778.51;417.80] 0.55 
Duration of hemodynamic support (per day added) 80.11 [-96.52;256.74] 0.37 124.27 [-483.34;731.88] 0.68 
Duration of corticosteroid treatment (per day added) 283.68 [-26.02;593.38] 0.07 336.67 [-82.33;755.66] 0.11 
Cumulative dose of opioids (per mg morphine-equivalent added) 130.77 [-92.27;353.81] 0.24 -59.53 [-303.57;184.51] 0.63 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 103.24 [-122.89;329.36] 0.36 -43.20 [-221.88;135.47] 0.63 
Received hypnotics versus no hypnotics -60.51 [-217.46;96.44] 0.44 58.22 [-82.90;199.34] 0.41 
Exceeding potentially harmful threshold for phthalate exposure 52.50 [14.65;90.36] 0.006 25.90 [-12.74;64.53] 0.18 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-15. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and inconsistency of reaction time overall 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 8.56 [-16.90;34.03] 0.50 -0.95 [-30.95;29.06] 0.95 
Age at sampling (per year added) -285.89 [-339.64;-232.14] <0.001 -332.39 [-406.64;-258.14] <0.001 
Caucasian vs. other race 26.54 [-65.77;118.85] 0.57 37.46 [-61.52;136.45] 0.45 
Exclusively European vs. other origin -48.55 [-125.41;28.32] 0.21 -76.89 [-178.57;24.79] 0.13 
Exclusively Dutch language vs. non-exclusively Dutch language 43.17 [3.04;83.31] 0.03 42.32 [-11.52;96.17] 0.12 
Socioeconomic status (per category of 1 to 66) -46.67 [-106.90;13.55] 0.12 -100.03 [-172.31;-27.75] 0.006 
Pre-existing syndrome vs. no pre-existing syndrome 14.99 [-17.74;47.72] 0.36 53.38 [13.85;92.91] 0.008 
History vs. no history of malignancy -60.90 [-154.08;32.28] 0.19 33.06 [-58.95;125.07] 0.47 
History vs. no history of diabetes -13.31 [-142.63;116.01] 0.83   
Randomization to strict glycemic control vs. conventional therapy -8.92 [-33.94;16.10] 0.48 4.52 [-25.34;34.37] 0.76 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 43.81 [-39.89;127.51] 0.30 147.85 [53.82;241.89] 0.002 
          randomized for glycemic control postoperatively -11.74 [-72.62;49.14] 0.70 49.49 [-27.51;126.50] 0.20 
     Complicated/high risk surgery or trauma 16.82 [-74.13;107.77] 0.71 -134.47 [-251.69;-17.24] 0.02 
     Neurological medical disorders 98.24 [-70.31;266.78] 0.25 68.47 [-143.42;280.35] 0.52 
     Infectious medical diseases -113.86 [-229.24;1.52] 0.05 -84.97 [-274.98;105.03] 0.37 
     Other medical disorders -36.36 [-156.66;83.93] 0.55 -54.14 [-200.82;92.54] 0.46 
     Solid organ transplants 3.10 [-182.55;188.74] 0.97 7.77 [-186.59;202.14] 0.94 
PeLOD score first 24 hrs (per point added) -11.44 [-78.19;55.30] 0.73 38.97 [-38.21;116.15] 0.32 
PICU stay (per day added) 8.10 [-69.50;85.70] 0.83 88.72 [-55.77;233.21] 0.22 
Exceeding potentially harmful threshold for phthalate exposure 61.78 [30.60;92.97] 0.0001 38.16 [5.58;70.74] 0.02 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-15. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and inconsistency of reaction time overall (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 6.67 [-20.47;33.82] 0.62 -8.48 [-39.15;22.20] 0.58 
Age at sampling (per year added) -295.99 [-365.13;-226.86] <0.001 -305.81 [-390.73;-220.89] <0.001 
Caucasian vs. other race 17.00 [-80.09;114.09] 0.73 44.26 [-56.47;144.99] 0.38 
Exclusively European vs. other origin -47.85 [-128.39;32.70] 0.24 -85.18 [-188.07;17.72] 0.10 
Exclusively Dutch language vs. non-exclusively Dutch language 42.44 [-0.96;85.83] 0.05 49.29 [-5.32;103.91] 0.07 
Socioeconomic status (per category of 1 to 66) -50.71 [-114.75;13.34] 0.12 -117.94 [-191.95;-43.94] 0.002 
Pre-existing syndrome vs. no pre-existing syndrome 20.61 [-15.31;56.52] 0.25 57.00 [16.63;97.37] 0.005 
History vs. no history of malignancy -70.96 [-169.79;27.87] 0.16 23.38 [-69.29;116.05] 0.61 
History vs. no history of diabetes -24.88 [-158.49;108.73] 0.71    
Randomization to strict glycemic control vs. conventional therapy -7.92 [-34.69;18.85] 0.56 13.31 [-12.21;44.83] 0.40 
Diagnostic category (as compared with all other categories)      
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 171.36 [4.96;337.77] 0.04 114.95 [-27.54;257.45] 0.11 
          randomized for glycemic control postoperatively 116.28 [-37.74;270.31] 0.13 36.60 [-81.85;155.04] 0.54 
     Complicated/high risk surgery or trauma 78.46 [-85.18;242.10] 0.34 -154.51 [-289.00;-20.03] 0.02 
     Neurological medical disorders -14.53 [-280.54;251.48] 0.91 51.97 [-190.76;294.71] 0.67 
     Infectious medical diseases -202.37 [-406.48;1.75] 0.05 -39.21 [-251.18;172.76] 0.71 
     Other medical disorders -115.29 [-278.32;47.74] 0.16 -7.01 [-216.41;202.39] 0.94 
     Solid organ transplants -33.92 [-313.85;246.01] 0.81 -2.79 [-232.15;226.56] 0.98 
PeLOD score first 24 hrs (per point added) -22.22 [-101.39;56.94] 0.58 6.23 [-76.89;89.35] 0.88 
PICU stay (per day added) -139.59 [-500.78;221.60] 0.44 149.68 [-585.48;884.83] 0.69 
Extracorporeal circulation versus no extracorporeal circulation a -32.43 [-92.82;27.96] 0.29 -32.93 [-88.99;23.13] 0.24 
Aortic clamp time (per min added)  6.65 [-72.92;86.22] 0.86 146.80 [21.84;271.75] 0.02 
Duration of mechanical ventilation (per day added) 135.94 [-157.79;429.68] 0.36 398.91 [-280.30;1078.12] 0.24 
Peak creatinine (per mg/dl added) 66.40 [-107.12;239.92] 0.45 1.65 [-197.20;200.51] 0.98 
Peak bilirubine (per mg/dl added) -73.20 [-200.30;53.91] 0.25 210.17 [-74.34;494.67] 0.14 
Infection vs. no infection 8.60 [-37.08;54.28] 0.71 42.10 [-4.17;88.37] 0.07 
Antibiotics (per day added) -22.68 [-206.57;161.22] 0.80 -550.85 [-1083.58;-18.13] 0.04 
Duration of hemodynamic support (per day added) 40.39 [-119.30;200.08] 0.61 -60.03 [-601.39;481.33] 0.82 
Duration of corticosteroid treatment (per day added) 192.69 [-88.19;473.58] 0.17 152.66 [-220.81;525.90] 0.42 
Cumulative dose of opioids (per mg morphine-equivalent added) 77.10 [-124.20;278.41] 0.45 -156.43 [-373.76;60.89] 0.15 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 55.29 [-148.11;260.69] 0.58 -59.13 [-218.25;99.98] 0.46 
Received hypnotics versus no hypnotics -78.19 [-219.89;63.52] 0.27 55.51 [-70.15;181.18] 0.38 
Exceeding potentially harmful threshold for phthalate exposure 61.73 [27.19;96.27] 0.0005 35.73 [1.22;70.23] 0.04 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-16. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and no. of valid synchronous taps 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 0.42 [-0.64;1.47] 0.43 -0.10 [-1.28;1.07] 0.86 
Age at sampling (per year added) 15.48 [13.27;17.68] <0.001 17.02 [14.13;19.92] <0.001 
Caucasian vs. other race 0.04 [-3.87;3.95] 0.98 -1.18 [-5.01;2.66] 0.54 
Exclusively European vs. other origin -1.40 [-4.58;1.77] 0.38 1.35 [-2.65;5.36] 0.50 
Exclusively Dutch language vs. non-exclusively Dutch language 0.35 [-1.33;2.03] 0.68 -0.05 [-2.28;2.17] 0.96 
Socioeconomic status (per category of 1 to 66) 1.21 [-1.28;3.69] 0.33 0.67 [-2.13;3.48] 0.63 
Pre-existing syndrome vs. no pre-existing syndrome 0.01 [-1.34;1.37] 0.98 -2.17 [-3.73;-0.62] 0.006 
History vs. no history of malignancy -0.44 [-4.24;3.36] 0.81 1.67 [-1.87;5.20] 0.35 
History vs. no history of diabetes 3.29 [-2.02;8.60] 0.22   
Randomization to strict glycemic control vs. conventional therapy 0.30 [-0.73;1.34] 0.56 0.52 [-0.66;1.69] 0.38 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 5.19 [1.73;8.65] 0.003 1.61 [-2.05;5.28] 0.39 
          randomized for glycemic control postoperatively 1.78 [-0.73;4.29] 0.16 2.37 [-0.63;5.36] 0.12 
     Complicated/high risk surgery or trauma 2.23 [-1.42;5.88] 0.22 3.63 [-0.77;8.03] 0.10 
     Neurological medical disorders -3.51 [-10.43;3.41] 0.31 -5.30 [-13.49;2.89] 0.20 
     Infectious medical diseases -0.44 [-5.18;4.30] 0.85 -0.18 [-7.53;7.17] 0.96 
     Other medical disorders -0.13 [-5.07;4.81] 0.95 5.88 [0.21;11.55] 0.03 
     Solid organ transplants -5.12 [-12.75;2.51] 0.18 -8.01 [-15.51;-0.52] 0.04 
PeLOD score first 24 hrs (per point added) 1.57 [-1.18;4.32] 0.26 1.52 [-1.48;4.52] 0.31 
PICU stay (per day added) -1.43 [-4.63;1.78] 0.38 -2.20 [-7.75;3.34] 0.43 
Exceeding potentially harmful threshold for phthalate exposure -2.05 [-3.33;-0.77] 0.001 -0.63 [-1.90;0.63] 0.32 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-16. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP metabolite exposure and no. of valid synchronous taps (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 0.53 [-0.58;1.64] 0.34 -0.19 [-1.37;1.00] 0.75 
Age at sampling (per year added) 15.14 [12.30;17.98] <0.001 15.54 [12.26;18.83] <0.001 
Caucasian vs. other race 0.39 [-3.72;4.51] 0.85 -1.61 [-5.49;2.28] 0.41 
Exclusively European vs. other origin -0.99 [-4.29;2.31] 0.55 2.32 [-1.71;6.34] 0.25 
Exclusively Dutch language vs. non-exclusively Dutch language -0.30 [-2.10;0.74] 0.74 -0.50 [-2.77;1.76] 0.66 
Socioeconomic status (per category of 1 to 66) 1.40 [-1.20;4.01] 0.28 0.87 [-1.98;3.73] 0.54 
Pre-existing syndrome vs. no pre-existing syndrome -0.39 [-1.86;1.09] 0.60 -2.11 [-3.69;-.53] 0.009 
History vs. no history of malignancy -0.34 [-4.38;3.66] 0.86 2.41 [-1.16;5.97] 0.18 
History vs. no history of diabetes 3.33 [-2.11;8.78] 0.22   
Randomization to strict glycemic control vs. conventional therapy 0.47 [-0.63;1.57] 0.39 -0.02 [-1.23;1.19] 0.97 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 3.23 [-3.60;10.07] 0.35 1.66 [-3.89;7.20] 0.55 
          randomized for glycemic control postoperatively 0.13 [-6.17;6.43] 0.96 2.56 [-2.01;7.12] 0.27 
     Complicated/high risk surgery or trauma 1.86 [-4.75;8.46] 0.57 5.29 [0.10;10.48] 0.04 
     Neurological medical disorders -3.49 [-14.36;7.37] 0.52 -6.37 [-15.74;3.00] 0.18 
     Infectious medical diseases -1.70 [-10.03;6.63] 0.68 1.22 [-6.68;9.13] 0.76 
     Other medical disorders 2.06 [-4.58;8.71] 0.54 2.66 [-5.39;10.71] 0.51 
     Solid organ transplants -2.09 [-13.51;9.33] 0.71 -7.01 [-15.76;1.73] 0.11 
PeLOD score first 24 hrs (per point added) 1.17 [-2.09;4.44] 0.47 0.85 [-2.40;4.11] 0.60 
PICU stay (per day added) 0.88 [-13.95;15.71] 0.80 -16.25 [-45.68;13.17] 0.27 
Extracorporeal circulation versus no extracorporeal circulation a 1.68 [-0.81;4.17] 0.18 2.58 [0.37;4.79] 0.02 
Aortic clamp time (per min added)  -0.47 [-3.74;2.80] 0.77 -4.12 [-8.98;0.73] 0.09 
Duration of mechanical ventilation (per day added) 4.81 [-7.24;16.85] 0.43 23.43 [-3.04;49.89] 0.08 
Peak creatinine (per mg/dl added) -0.02 [-7.17;7.13] 0.99 8.52 [0.87;16.18] 0.02 
Peak bilirubine (per mg/dl added) -1.36 [-6.62;3.90] 0.61 -5.42 [-17.06;6.18] 0.35 
Infection vs. no infection 0.72 [-1.16;2.59] 0.45 -0.75 [-2.54;1.03] 0.40 
Antibiotics (per day added) -3.95 [-11.48;3.57] 0.30 -1.72 [-23.22;19.77] 0.87 
Duration of hemodynamic support (per day added) -6.01 [-12.49;0.48] 0.06 -6.50 [-24.94;11.93] 0.48 
Duration of corticosteroid treatment (per day added) -2.00 [-13.45;9.46] 0.73 0.34 [-13.51;14.20] 0.96 
Cumulative dose of opioids (per mg morphine-equivalent added) -5.85 [-14.06;2.35] 0.16 5.73 [-2.44;13.90] 0.16 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) -1.74 [-10.09;6.61] 0.68 -0.03 [-6.18;6.12] 0.99 
Received hypnotics versus no hypnotics 0.24 [5.55;6.03] 0.93 -2.07 [-6.92;2.77] 0.39 
Exceeding potentially harmful threshold for phthalate exposure -2.16 [-3.57;-0.75] 0.003 -1.00 [-2.34;0.34] 0.14 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-17. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP exposure and reaction time dominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -10.68 [-45.94;24.58] 0.55 -5.93 [-43.19;31.34] 0.75 
Age at sampling (per year added) -443.35 [-514.02;-372.67] <0.001 -452.09 [-541.11;-363.06] <0.001 
Caucasian vs. other race 25.23 [-102.72;153.18] 0.69 77.86 [-45.12;200.83] 0.21 
Exclusively European vs. other origin -13.08 [-119.46;93.30] 0.80 -119.16 [-245.87;7.55] 0.06 
Exclusively Dutch language vs. non-exclusively Dutch language 59.40 [3.69;115.11] 0.03 47.73 [-18.90;114.37] 0.15 
Socioeconomic status (per category of 1 to 66) -106.36 [-189.50;-23.22] 0.01 -58.56 [-147.81;30.69] 0.19 
Pre-existing syndrome vs. no pre-existing syndrome 31.17 [-14.10;76.44] 0.17 54.54 [6.15;102.93] 0.02 
History vs. no history of malignancy -36.06 [-164.33;92.21] 0.57 20.68 [-92.08;133.44] 0.71 
History vs. no history of diabetes -38.78 [-217.97;140.40] 0.66   
Randomization to strict glycemic control vs. conventional therapy 5.48 [-29.13;40.10] 0.75 -2.89 [-39.80;34.02] 0.87 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 86.13 [-28.94;201.19] 0.14 200.58 [83.96;317.20] <0.001 
          randomized for glycemic control postoperatively -58.44 [-142.65;25.77] 0.17 82.50 [-12.42;177.42] 0.08 
     Complicated/high risk surgery or trauma -50.59 [-176.60;75.41] 0.42 -76.31 [-221.63;69.01] 0.30 
     Neurological medical disorders 219.24 [-14.51;453.00] 0.06 -0.67 [-263.37;262.04] >0.99 
     Infectious medical diseases -163.48 [-323.95;-3.02] 0.04 -73.47 [-308.78;161.83] 0.53 
     Other medical disorders -94.05 [-261.65;73.56] 0.26 -28.69 [-210.30;152.92] 0.75 
     Solid organ transplants 61.19 [-196.99;319.37] 0.64 -103.95 [-344.61;136.71] 0.39 
PeLOD score first 24 hrs (per point added) -36.36 [-127.69;54.98] 0.43 36.47 [-59.44;132.37] 0.45 
PICU stay (per day added) 36.28 [-71.47;144.04] 0.50 170.10 [-9.16;349.36] 0.06 
Exceeding potentially harmful threshold for phthalate exposure 58.79 [18.29;99.28] 0.004 45.57 [5.83;85.31] 0.02 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-17. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP exposure and reaction time dominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -14.94 [-52.54;22.66] 0.43 -17.02 [-54.73;20.70] 0.37 
Age at sampling (per year added) -442.56 [-531.42;-353.69] <0.001 -419.77 [-517.72;-321.82] <0.001 
Caucasian vs. other race 5.54 [-129.02;140.10] 0.93 72.48 [-50.88;195.85] 0.24 
Exclusively European vs. other origin -1.29 [-112.83;110.25] 0.98 -110.20 [-236.37;15.97] 0.08 
Exclusively Dutch language vs. non-exclusively Dutch language 53.55 [-6.71;113.80] 0.08 57.21 [-9.37;123.79] 0.09 
Socioeconomic status (per category of 1 to 66) -117.30 [-205.81;-28.80] 0.009 -77.84 [-168.07;12.38] 0.09 
Pre-existing syndrome vs. no pre-existing syndrome 37.59 [-11.65;86.78] 0.13 62.83 [14.37;111.30] 0.01 
History vs. no history of malignancy -45.03 [-181.56;91.49] 0.51 7.25 [-107.71;119.22] 0.89 
History vs. no history of diabetes -53.51 [-238.72;131.70] 0.56   
Randomization to strict glycemic control vs. conventional therapy 4.85 [-32.26;41.97] 0.79 6.87 [-31.50;45.25] 0.72 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 274.17 [43.29;505.05] 0.02 130.71 [-43.37;304.79] 0.14 
          randomized for glycemic control postoperatively 128.63 [-84.85;342.11] 0.23 47.34 [-98.31;193.00] 0.52 
     Complicated/high risk surgery or trauma 57.83 [-169.05;284.71] 0.61 -46.96 [-211.25;117.33] 0.57 
     Neurological medical disorders 88.35 [-280.56;457.27] 0.63 -89.44 [-386.08;207.19] 0.55 
     Infectious medical diseases -346.62 [-629.91;-63.34] 0.01 31.78 [-226.79;290.35] 0.80 
     Other medical disorders -205.57 [-431.93;20.78] 0.07 4.46 [-251.69;260.62] 0.97 
     Solid organ transplants 3.21 [-389.08;392.50] 0.99 -77.89 [-358.02;202.24] 0.58 
PeLOD score first 24 hrs (per point added) -27.00 [-136.26;82.27] 0.62 4.45 [-97.03;105.94] 0.93 
PICU stay (per day added) -345.63 [-842.19;150.94] 0.17 -313.24 [-1212.00;585.52] 0.49 
Extracorporeal circulation versus no extracorporeal circulation a -39.96 [-123.26;43.35] 0.34 -26.38 [-94.43;41.68] 0.44 
Aortic clamp time (per min added)  2.47 [-108.34;113.28] 0.96 135.96 [-17.18;289.11] 0.08 
Duration of mechanical ventilation (per day added) 347.31 [-54.25;748.87] 0.08 845.07 [16.06;1674.09] 0.04 
Peak creatinine (per mg/dl added) -16.56 [-255.54;222.42] 0.89 -52.46 [-293.18;188.26] 0.66 
Peak bilirubine (per mg/dl added) -51.49 [-227.83;124.85] 0.56 325.93 [-21.72;673.58] 0.06 
Infection vs. no infection 18.56 [-44.97;82.08] 0.56 34.35 [-22.43;91.13] 0.23 
Antibiotics (per day added) 27.41 [-227.28;282.12] 0.83 -580.12 [-1231.43;71.19] 0.08 
Duration of hemodynamic support (per day added) 34.40 [-186.99;255.79] 0.75 208.56 [-451.89;871.00] 0.53 
Duration of corticosteroid treatment (per day added) 281.30 [-107.47;670.07] 0.15 155.88 [-299.82;611.58] 0.50 
Cumulative dose of opioids (per mg morphine-equivalent added) -11.96 [-292.30;268.39] 0.93 -169.14 [-432.89;94.61] 0.20 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 46.39 [-239.01;328.79] 0.74 -121.20 [-312.48;70.07] 0.21 
Received hypnotics versus no hypnotics -133.49 [-329.62;62.64] 0.18 20.13 [-133.44;173.69] 0.79 
Exceeding potentially harmful threshold for phthalate exposure 57.95 [14.07;101.82] 0.009 40.09 [-1.01;81.20] 0.05 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-18. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP exposure and reaction time nondominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -20.16 [-52.48;12.17] 0.22 7.85 [-26.56;42.26] 0.65 
Age at sampling (per year added) -395.60 [-460.32;-330.88] <0.001 -426.46 [-508.66;-344.26] <0.001 
Caucasian vs. other race -19.15 [-137.24;98.95] 0.74 21.93 [-91.62;135.48] 0.70 
Exclusively European vs. other origin -19.74 [-117.85;78.37] 0.69 -97.22 [-214.22;19.78] 0.10 
Exclusively Dutch language vs. non-exclusively Dutch language 55.29 [4.01;106.57] 0.03 61.85 [0.33;123.38] 0.04 
Socioeconomic status (per category of 1 to 66) -55.93 [-132.14;20.28] 0.14 -98.37 [-180.78;-15.96] 0.01 
Pre-existing syndrome vs. no pre-existing syndrome 16.31 [-24.91;57.54] 0.43 49.35 [4.67;94.03] 0.03 
History vs. no history of malignancy -23.94 [-142.34;94.45] 0.69 36.29 [-67.83;140.41] 0.49 
History vs. no history of diabetes -6.74 [-172.09;158.60] 0.93   
Randomization to strict glycemic control vs. conventional therapy 4.90 [-26.76;36.56] 0.76 1.99 [-32.09;36.07] 0.90 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 57.09 [-49.00;163.19] 0.28 185.49 [77.81;293.17] <0.001 
          randomized for glycemic control postoperatively -20.00 [-97.29;57.29] 0.61 68.65 [-19.00;156.29] 0.12 
     Complicated/high risk surgery or trauma -11.17 [-127.48;105.14] 0.85 -180.39 [-314.57;-46.21] 0.008 
     Neurological medical disorders 96.43 [-119.04;311.91] 0.38 91.30 [-151.27;333.88] 0.45 
     Infectious medical diseases -92.14 [-240.21;55.94] 0.22 -64.17 [-281.44;153.10] 0.56 
     Other medical disorders -117.35 [-272.00;37.31] 0.13 -31.31 [-199.00;136.38] 0.71 
     Solid organ transplants 87.13 [-151.10;325.36] 0.47 -69.57 [-291.79;152.65] 0.53 
PeLOD score first 24 hrs (per point added) -0.33 [-84.35;83.68] 0.99 10.33 [-78.23;98.88] 0.81 
PICU stay (per day added) -5.94 [-103.78;91.91] 0.90 201.11 [35.58;366.63] 0.01 
Exceeding potentially harmful threshold for phthalate exposure 56.24 [19.25;93.24] 0.003 35.62 [-1.07;72.32] 0.05 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-18. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP exposure and reaction time nondominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -21.27 [-54.77;12.24] 0.21 1.31 [-34.09;36.35] 0.94 
Age at sampling (per year added) -405.23 [-484.30;-326.15] <0.001 -405.42 [-496.89;-313.94] <0.001 
Caucasian vs. other race -42.35 [-162.97;78.27] 0.49 25.00 [-90.20;140.20] 0.66 
Exclusively European vs. other origin -8.75 [-108.64;91.13] 0.86 -92.34 [-210.16;25.47] 0.12 
Exclusively Dutch language vs. non-exclusively Dutch language 54.78 [0.95;106.62] 0.04 70.15 [7.98;132.33] 0.02 
Socioeconomic status (per category of 1 to 66) -65.36 [-144.10;13.38] 0.10 -118.93 [-203.18;-34.67] 0.005 
Pre-existing syndrome vs. no pre-existing syndrome 20.43 [-22.96;63.83] 0.35 52.92 [7.67;98.18] 0.02 
History vs. no history of malignancy -25.33 [-147.65;96.99] 0.68 22.42 [-82.13;126.97] 0.67 
History vs. no history of diabetes -27.54 [-193.49;138.40] 0.74   
Randomization to strict glycemic control vs. conventional therapy 6.79 [-26.10;37.67] 0.68 13.68 [-22.15;49.52] 0.45 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 247.37 [41.76;452.97] 0.01 132.30 [-30.25;294.86] 0.11 
          randomized for glycemic control postoperatively 156.38 [-33.79;346.56] 0.10 37.27 [-98.75;173.28] 0.58 
     Complicated/high risk surgery or trauma 49.31 [-153.33;251.94] 0.63 -185.21 [-338.63;-31.80] 0.01 
     Neurological medical disorders 9.64 [-320.61;339.89] 0.95 85.81 [-191.19;362.81] 0.54 
     Infectious medical diseases -245.78 [-499.40;7.83] 0.05 -14.45 [-255.92;227.01] 0.90 
     Other medical disorders -274.75 [-477.35;-72.16] 0.008 55.01 [-184.19;294.21] 0.65 
     Solid organ transplants 57.84 [-291.16;406.84] 0.74 -110.73 [-372.32;150.86] 0.40 
PeLOD score first 24 hrs (per point added) 11.63 [-85.88;109.15] 0.81 -5.96 [-100.73;88.81] 0.90 
PICU stay (per day added) -213.65 [-650.47;223.18] 0.33 -537.03 [-1376.31;302.25] 0.20 
Extracorporeal circulation versus no extracorporeal circulation a -48.18 [120.49;24.13] 0.19 -51.45 [-115.01;12.10] 0.11 
Aortic clamp time (per min added)  -39.26 [-138.02;59.50] 0.43 106.97 [-36.04;249.98] 0.14 
Duration of mechanical ventilation (per day added) 216.32 [-137.25;569.89] 0.22 547.39 [-226.76;1321.54] 0.16 
Peak creatinine (per mg/dl added) 23.20 [-190.49;236.89] 0.83 -15.18 [-239.97;209.61] 0.89 
Peak bilirubine (per mg/dl added) -166.41 [-324.13;-8.69] 0.03 236.28 [-88.37;560.92] 0.15 
Infection vs. no infection 12.27 [-44.49;68.98] 0.67 25.89 [-27.14;78.91] 0.34 
Antibiotics (per day added) -43.76 [-271.91;184.40] 0.70 -141.75 [-749.95;466.46] 0.64 
Duration of hemodynamic support (per day added) 59.19 [-138.97;257.34] 0.55 352.09 [-265.58;969.75] 0.26 
Duration of corticosteroid treatment (per day added) 224.34 [-122.65;571.32] 0.20 218.55 [-206.99;644.09] 0.31 
Cumulative dose of opioids (per mg morphine-equivalent added) 101.94 [-149.47;353.35] 0.42 -140.69 [-386.98;105.60] 0.26 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 150.43 [-102.41;403.27] 0.24 -103.40 [-282.02;75.22] 0.25 
Received hypnotics versus no hypnotics -109.94 [-285.75;65.86] 0.21 74.09 [-69.31;217.49] 0.30 
Exceeding potentially harmful threshold for phthalate exposure 60.27 [21.21;99.33] 0.002 32.92 [-5.46;71.31] 0.09 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings 
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eTable 5-19. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP exposure and reaction time overall 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -16.82 [-48.14;14.49] 0.29 2.16 [-31.98;36.31] 0.90 
Age at sampling (per year added) -415.06 [-477.82;-352.31] <0.001 -439.56 [-521.13;-357.99] <0.001 
Caucasian vs. other race 3.10 [-110.52;116.73] 0.95 49.55 [-63.13;162.24] 0.38 
Exclusively European vs. other origin -16.02 [-110.48;78.45] 0.73 -107.37 [-223.47;8.73] 0.06 
Exclusively Dutch language vs. non-exclusively Dutch language 55.30 [5.83;104.77] 0.02 54.00 [-7.06;115.05] 0.08 
Socioeconomic status (per category of 1 to 66) -77.22 [-151.05;-3.39] 0.04 -80.56 [-162.33;1.22] 0.05 
Pre-existing syndrome vs. no pre-existing syndrome 21.16 [-19.04;61.36] 0.30 49.38 [5.04;93.72] 0.02 
History vs. no history of malignancy -30.16 [-144.07;83.75] 0.60 29.42 [-73.90;132.74] 0.57 
History vs. no history of diabetes -20.11 [-179.23;139.01] 0.80   
Randomization to strict glycemic control vs. conventional therapy 4.54 [-26.20;35.28] 0.77 -1.14 [-34.96;32.68] 0.94 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 70.47 [-31.71;172.65] 0.17 190.36 [83.50;297.21] <0.001 
          randomized for glycemic control postoperatively -43.18 [-117.96;31.60] 0.25 72.16 [-14.82;159.13] 0.10 
     Complicated/high risk surgery or trauma -30.86 [-142.75;81.04] 0.58 -127.78 [-260.93;5.38] 0.05 
     Neurological medical disorders 162.20 [-45.38;369.78] 0.12 49.03 [-191.68;289.74] 0.68 
     Infectious medical diseases -127.34 [-269.84;15.15] 0.07 -69.97 [-285.58;145.63] 0.52 
     Other medical disorders -108.09 [-256.93;40.74] 0.15 -27.83 [-194.24;138.57] 0.74 
     Solid organ transplants 76.80 [-152.47;306.06] 0.50 -85.96 [-306.47;134.55] 0.44 
PeLOD score first 24 hrs (per point added) -16.38 [-97.49;64.73] 0.69 21.45 [-66.42;109.33] 0.63 
PICU stay (per day added) 18.12 [-77.56;113.81] 0.70 187.47 [23.22;351.73] 0.02 
Exceeding potentially harmful threshold for phthalate exposure 57.19 [21.24;93.15] 0.002 41.30 [4.88;77.71] 0.02 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-19. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP exposure and reaction time overall (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -19.49 [-52.36;13.38] 0.24 -6.52 [-41.18;28.14] 0.71 
Age at sampling (per year added) -418.92 [-496.61;-341.24] <0.001 -411.49 [-501.52;-321.47] <0.001 
Caucasian vs. other race -18.44 [-136.07;99.18] 0.75 48.41 [-64.97;161.79] 0.40 
Exclusively European vs. other origin -4.40 [-101.90;93.10] 0.92 -100.83 [-216.78;15.12] 0.08 
Exclusively Dutch language vs. non-exclusively Dutch language 52.11 [-0.56;104.78] 0.05 62.94 [1.75;124.13] 0.04 
Socioeconomic status (per category of 1 to 66) -87.81 [-165.18;-10.44] 0.02 -100.45 [-183.37;-17.52] 0.01 
Pre-existing syndrome vs. no pre-existing syndrome 26.50 [-16.53;69.52] 0.22 54.88 [10.34;99.42] 0.01 
History vs. no history of malignancy -35.24 [-154.58;84.10] 0.56 15.98 [-86.92;118.88] 0.75 
History vs. no history of diabetes -39.11 [-201.02;122.79] 0.63   
Randomization to strict glycemic control vs. conventional therapy 5.57 [-26.87;38.02] 0.73 9.36 [-25.91;44.62] 0.60 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 265.20 [63.37;467.02] 0.01 129.94 [-30.05;289.92] 0.11 
          randomized for glycemic control postoperatively 144.30 [-42.31;330.91] 0.12 39.81 [-94.05;173.68] 0.55 
     Complicated/high risk surgery or trauma 52.68 [-145.65;251.01] 0.60 -116.34 [-267.33;34.66] 0.13 
     Neurological medical disorders 47.90 [-274.59;370.39] 0.76 1.02 [-271.60;273.64] 0.99 
     Infectious medical diseases -299.90 [-547.53;-52.27] 0.01 6.36 [-231.28;244.01] 0.95 
     Other medical disorders -244.66 [-442.53;-46.79] 0.01 30.71 [-204.70;266.13] 0.79 
     Solid organ transplants 34.49 [-305.81;374.79] 0.84 -91.51 [-348.96;165.94] 0.48 
PeLOD score first 24 hrs (per point added) -6.47 [-101.98;89.05] 0.89 -3.44 [-96.71;89.83] 0.94 
PICU stay (per day added) -281.54 [-715.61;152.54] 0.20 -420.94 [-1246.95;405.06] 0.31 
Extracorporeal circulation versus no extracorporeal circulation a -47.67 [-120.50;25.15] 0.19 -39.29 [-101.84;23.26] 0.21 
Aortic clamp time (per min added)  -17.07 [-113.93;79.79] 0.72 120.83 [-19.91;261.58] 0.09 
Duration of mechanical ventilation (per day added) 285.02 [-66.00;636.05] 0.11 711.04 [-50.86;1472.94] 0.06 
Peak creatinine (per mg/dl added) 5.27 [-203.64;214.18] 0.96 -31.66 [-252.89;189.57] 0.77 
Peak bilirubine (per mg/dl added) -105.33 [-259.47;48.82] 0.17 268.40 [-51.11;587.90] 0.09 
Infection vs. no infection 16.20 [-39.32;71.73] 0.56 31.18 [-21.00;83.36] 0.23 
Antibiotics (per day added) -5.12 [-227.77;217.53] 0.96 -366.30 [-964.88;232.28] 0.22 
Duration of hemodynamic support (per day added) 47.66 [-145.87;241.19] 0.62 277.14 [-330.75;885.04] 0.36 
Duration of corticosteroid treatment (per day added) 249.39 [-90.45;589.23] 0.14 178.55 [-240.26;597.35] 0.40 
Cumulative dose of opioids (per mg morphine-equivalent added) 43.87 [-201.19;288.94] 0.72 -155.62 [-398.02;86.77] 0.20 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 96.57 [-150.29;343.43] 0.44 -112.00 [-287.79;63.79] 0.21 
Received hypnotics versus no hypnotics -123.32 [-294.76;48.13] 0.15 47.40 [-93.73;188.54] 0.50 
Exceeding potentially harmful threshold for phthalate exposure 58.33 [19.98;96.69] 0.003 37.30 [-0.48;75.07] 0.05 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
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eTable 5-20. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP exposure and no. of valid synchronous taps 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 0.48 [-0.55;1.51] 0.36 0.08 [-1.08;1.24] 0.89 
Age at sampling (per year added) 15.85 [13.79;17.91] <0.001 16.84 [14.08;19.60] <0.001 
Caucasian vs. other race -0.13 [-3.97;3.71] 0.94 -1.59 [-5.36;2.18] 0.40 
Exclusively European vs. other origin -1.52 [-4.64;1.59] 0.33 1.89 [-2.06;5.84] 0.34 
Exclusively Dutch language vs. non-exclusively Dutch language 0.59 [-1.06;2.24] 0.48 0.05 [-2.14;2.23] 0.96 
Socioeconomic status (per category of 1 to 66) 1.21 [-1.22;3.64] 0.32 0.65 [-2.09;3.40] 0.63 
Pre-existing syndrome vs. no pre-existing syndrome -0.32 [-1.65;1.00] 0.63 -2.16 [-3.68;-0.64] 0.005 
History vs. no history of malignancy -1.01 [-4.72;2.70] 0.59 1.99 [-1.44;5.42] 0.25 
History vs. no history of diabetes 3.42 [-1.80;8.63] 0.19   
Randomization to strict glycemic control vs. conventional therapy 0.33 [-0.69;1.34] 0.52 0.48 [-0.67;1.64] 0.41 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 4.17 [0.79;7.54] 0.01 2.08 [-1.53;5.69] 0.25 
          randomized for glycemic control postoperatively 1.43 [-1.03;3.90] 0.25 2.12 [-0.82;5.06] 0.15 
     Complicated/high risk surgery or trauma 1.96 [-1.63;5.55] 0.28 3.37 [-0.95;7.69] 0.12 
     Neurological medical disorders -3.85 [-10.65;2.94] 0.26 -5.96 [-14.02;2.09] 0.14 
     Infectious medical diseases -0.94 [-5.61;3.72] 0.69 0.02 [-7.19;7.23] >0.99 
     Other medical disorders 0.97 [-3.91;5.86] 0.69 5.89 [0.33;11.45] 0.03 
     Solid organ transplants -3.74 [-11.25;3.78] 0.32 -7.52 [-14.87;-0.17] 0.04 
PeLOD score first 24 hrs (per point added) 1.54 [-1.15;4.22] 0.26 1.86 [-1.09;4.81] 0.21 
PICU stay (per day added) -0.98 [-4.12;2.15] 0.53 -1.15 [-6.60;4.30] 0.67 
Exceeding potentially harmful threshold for phthalate exposure -2.53 [-3.72;-1.34] 0.00004 -1.77 [-3.00;-0.53] 0.005 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-20. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
MEHP exposure and no. of valid synchronous taps (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 0.59 [-0.50;1.67] 0.28 -0.02 [-1.21;1.17] 0.97 
Age at sampling (per year added) 15.86 [13.30;18.43] <0.001 15.80 [12.73;18.88] <0.001 
Caucasian vs. other race 0.41 [-3.61;4.43] 0.84 -1.87 [-5.72;1.98] 0.33 
Exclusively European vs. other origin -1.22 [-4.44;2.00] 0.45 2.61 [-1.38;6.60] 0.19 
Exclusively Dutch language vs. non-exclusively Dutch language -0.09 [-1.85;1.67] 0.91 -0.38 [-2.61;1.86] 0.74 
Socioeconomic status (per category of 1 to 66) 1.48 [-1.07;4.02] 0.25 0.88 [-1.94;3.70] 0.53 
Pre-existing syndrome vs. no pre-existing syndrome -0.68 [-2.10;0.75] 0.35 -2.12 [-3.68;-0.56] 0.007 
History vs. no history of malignancy -0.90 [-4.79;3.00] 0.65 2.39 [-1.10;5.88] 0.17 
History vs. no history of diabetes 3.29 [-2.03;8.61] 0.22   
Randomization to strict glycemic control vs. conventional therapy 0.56 [-0.52;1.64] 0.30 -0.03 [-1.22;1.17] 0.96 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 2.85 [-3.83;9.53] 0.40 1.60 [-3.88;7.09] 0.56 
          randomized for glycemic control postoperatively 0.60 [-5.55;6.75] 0.84 1.98 [-2.56;6.53] 0.38 
     Complicated/high risk surgery or trauma 1.01 [-5.45;7.47] 0.75 4.91 [-0.23;10.04] 0.06 
     Neurological medical disorders -4.49 [-15.11;6.12] 0.40 -6.86 [-16.14;2.41] 0.14 
     Infectious medical diseases -2.65 [-10.80;5.49] 0.52 1.32 [-6.50;9.13] 0.74 
     Other medical disorders 2.61 [-3.89;9.12] 0.42 3.27 [-4.70;11.25] 0.41 
     Solid organ transplants 0.08 [-11.11;11.26] 0.98 -6.22 [-14.88;2.45] 0.15 
PeLOD score first 24 hrs (per point added) 0.97 [-2.21;4.15] 0.54 1.24 [-1.97;4.46] 0.44 
PICU stay (per day added) 4.27 [-10.10;18.63] 0.55 -13.08 [-42.27;16.11] 0.37 
Extracorporeal circulation versus no extracorporeal circulation a 0.63 [-1.79;3.05] 0.60 2.56 [0.39;4.73] 0.02 
Aortic clamp time (per min added)  0.95 [-2.27;4.16] 0.56 -3.68 [-8.51;1.14] 0.13 
Duration of mechanical ventilation (per day added) 2.06 [-9.53;13.64] 0.72 22.11 [-4.07;48.30] 0.09 
Peak creatinine (per mg/dl added) -0.20 [-7.14;6.75] 0.95 6.81 [-0.66;14.28] 0.07 
Peak bilirubine (per mg/dl added) -1.17 [-6.31;3.97] 0.65 -4.77 [-16.25;6.71] 0.41 
Infection vs. no infection 0.97 [-0.87;2.81] 0.30 -0.60 [-2.37;1.18] 0.50 
Antibiotics (per day added) -4.72 [-12.06;2.63] 0.20 -3.37 [-24.63;17.89] 0.75 
Duration of hemodynamic support (per day added) -5.77 [-12.11;0.56] 0.07 -6.35 [-24.58;11.88] 0.49 
Duration of corticosteroid treatment (per day added) -3.98 [-15.15;7.19] 0.48 -1.00 [-14.72;12.72] 0.88 
Cumulative dose of opioids (per mg morphine-equivalent added) -4.38 [-12.43;3.68] 0.28 5.94 [-2.10;13.97] 0.14 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) -2.40 [-10.53;5.74] 0.56 -0.05 [-6.02;5.92] 0.98 
Received hypnotics versus no hypnotics 0.13 [-5.52;5.78] 0.96 -1.81 [-6.60;2.98] 0.46 
Exceeding potentially harmful threshold for phthalate exposure -2.73 [-4.00;-1.45] 0.00004 -1.60 [-2.90;-0.31] 0.01 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
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eTable 5-21. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5cx-MEPP exposure and working memory (repeating numbers, backward) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -0.49 [-1.05;0.07] 0.08 -0.03 [-0.72;0.66] 0.93 
Age at sampling (per year added) -0.98 [-2.12;0.17] 0.09 -1.52 [-2.96;-0.08] 0.03 
Caucasian vs. other race -0.02 [-2.29;2.26] 0.98 -1.35 [-3.53;0.82] 0.21 
Exclusively European vs. other origin -0.69 [-2.35;0.97] 0.41 -0.02 [-2.06;2.03] 0.98 
Exclusively Dutch language vs. non-exclusively Dutch language 0.03 [-0.86;0.91] 0.94 1.25 [-0.02;2.51] 0.05 
Socioeconomic status (per category of 1 to 66) 1.28 [-0.04;2.59] 0.05 0.72 [-0.67;2.12] 0.30 
Pre-existing syndrome vs. no pre-existing syndrome -0.75 [-1.41;-0.09] 0.02 -1.05 [-1.86;-0.24] 0.01 
History vs. no history of malignancy 0.33 [-1.25;1.91] 0.67 0.24 [-1.60;2.09] 0.79 
History vs. no history of diabetes -1.50 [-4.44;1.44] 0.31   
Randomization to strict glycemic control vs. conventional therapy 0.28 [-0.28;0.85] 0.32 -0.51 [-1.25;0.24] 0.18 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 3.48 [1.21;5.76] 0.003 0.65 [-1.90;3.19] 0.61 
          randomized for glycemic control postoperatively 0.52 [-0.73;1.77] 0.41 0.77 [-0.90;2.44] 0.36 
     Complicated/high risk surgery or trauma 0.66 [-1.08;2.40] 0.45 0.61 [-1.61;2.83] 0.58 
     Neurological medical disorders -0.74 [-4.27;2.79] 0.67 0.79 [-3.41;4.99] 0.70 
     Infectious medical diseases -1.46 [-3.87;0.95] 0.23 -0.48 [-3.61;2.65] 0.76 
     Other medical disorders -2.46 [-4.90;-0.02] 0.04 0.50 [-2.27;3.27] 0.71 
     Solid organ transplants   -2.84 [-7.53;1.85] 0.23 
PeLOD score first 24 hrs (per point added) -0.54 [-2.16;1.08] 0.50 0.74 [-1.18;2.66] 0.44 
PICU stay (per day added) 0.46 [-1.33;2.25] 0.60 0.02 [-3.51;3.55] 0.99 
Exceeding potentially harmful threshold for phthalate exposure -0.95 [-1.67;-0.22] 0.01 0.26 [-0.50;1.03] 0.49 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-21. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5cx-MEPP exposure and working memory (repeating numbers, backward) (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -0.40 [-1.03;0.23] 0.20 0.05 [-0.67;0.78] 0.88 
Age at sampling (per year added) -1.01 [-2.47;0.46] 0.17 -0.99 [-2.64;0.65] 0.23 
Caucasian vs. other race -0.01 [-2.89;2.87] 0.99 -0.29 [-2.51;1.94] 0.79 
Exclusively European vs. other origin -0.74 [-2.74;1.27] 0.46 0.38 [-1.69;2.45] 0.71 
Exclusively Dutch language vs. non-exclusively Dutch language -0.38 [-1.42;0.67] 0.47 0.39 [-1.02;1.81] 0.58 
Socioeconomic status (per category of 1 to 66) 1.11 [-0.37;2.59] 0.13 0.97 [-0.43;2.36] 0.17 
Pre-existing syndrome vs. no pre-existing syndrome -0.56 [-1.34;0.22] 0.15 -0.86 [-1.73; 0.00] 0.05 
History vs. no history of malignancy -0.16 [-1.95;1.64] 0.85 -0.43 [-2.45;1.59] 0.67 
History vs. no history of diabetes -1.21 [-4.30;1.87] 0.43   
Randomization to strict glycemic control vs. conventional therapy 0.22 [-0.44;0.87] 0.51 -0.53 [-1.36;0.31] 0.21 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 2.85 [-4.71;10.40] 0.45 -1.63 [-5.38;2.11] 0.38 
          randomized for glycemic control postoperatively 0.60 [-6.58;7.78] 0.86 1.93 [-4.81;0.96] 0.18 
     Complicated/high risk surgery or trauma 2.75 [-3.73;9.22] 0.39 0.45 [-2.49;3.40] 0.75 
     Neurological medical disorders -2.09 [-10.17;5.98] 0.60 -0.92 [-6.30;4.46] 0.73 
     Infectious medical diseases -3.24 [-10.08;3.60] 0.34 2.50 [-1.87;6.86] 0.25 
     Other medical disorders -0.86 [-7.70;5.98] 0.80 1.48 [-2.63;5.59] 0.47 
     Solid organ transplants   0.05 [-5.70;5.79] 0.98 
PeLOD score first 24 hrs (per point added) -0.85 [-2.93;1.24]  0.41 0.30 [-1.69;2.28] 0.76 
PICU stay (per day added) 2.54 [-7.33;12.42] 0.60 6.83 [-9.72;23.39] 0.41 
Extracorporeal circulation versus no extracorporeal circulation a 0.88 [-1.22;2.98] 0.40 2.09 [0.29;3.90] 0.02 
Aortic clamp time (per min added)  0.76 [-0.92;2.45] 0.36 -2.45 [-4.93;0.04] 0.05 
Duration of mechanical ventilation (per day added) 1.65 [-5.64;8.95] 0.65 5.80 [-10.36;21.96] 0.47 
Peak creatinine (per mg/dl added) 0.53 [-3.19;4.26] 0.77 0.20 [-3.73;4.14] 0.91 
Peak bilirubine (per mg/dl added) -1.43 [-4.21;1.36] 0.30 -2.63 [-5.29;0.04] 0.05 
Infection vs. no infection 0.31 [-1.09;1.71] 0.65 2.70 [1.11;4.28] 0.001 
Antibiotics (per day added) -4.47 [-10.69;1.74] 0.15 -21.54 [-38.57;-4.51] 0.01 
Duration of hemodynamic support (per day added) 0.95 [-2.40;4.30] 0.57 2.71 [-4.83;10.26] 0.47 
Duration of corticosteroid treatment (per day added) 1.11 [-2.73;4.94] 0.56 -0.35 [-10.69;9.99] 0.94 
Cumulative dose of opioids (per mg morphine-equivalent added) -3.71 [-6.98;-0.44] 0.02 3.43 [-0.93;7.79] 0.12 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) -1.08 [-4.29;2.14] 0.50 -0.98 [-3.65;1.68] 0.46 
Received hypnotics versus no hypnotics -1.08 [-7.11;4.94 0.72 1.21 [-1.15;3.57] 0.30 
Exceeding potentially harmful threshold for phthalate exposure -0.75 [-1.64;0.13] 0.09 0.63 [-0.19;1.46] 0.12 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
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eTable 5-22. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and reaction time dominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -11.92 [-46.89;23.05] 0.50 -2.42 [-37.56;32.73] 0.89 
Age at sampling (per year added) -420.17 [-493.50;-346.84] <0.001 -384.54 [-474.95;-294.13] <0.001 
Caucasian vs. other race 28.86 [-98.08;155.81] 0.65 83.39 [-33.64;200.43] 0.16 
Exclusively European vs. other origin -10.27 [-115.75;95.21] 0.84 -124.94 [-245.38;-4.50] 0.04 
Exclusively Dutch language vs. non-exclusively Dutch language 56.55 [1.22;111.88] 0.04 51.06 [-12.54;114.67] 0.11 
Socioeconomic status (per category of 1 to 66) -104.72 [-187.18;-22.26] 0.01 -61.41 [-146.58;23.76] 0.15 
Pre-existing syndrome vs. no pre-existing syndrome 36.49 [-8.65;81.63] 0.11 51.15 [4.94;97.36] 0.03 
History vs. no history of malignancy -23.61 [-151.02;103.80] 0.71 9.21 [-98.04;116.46] 0.86 
History vs. no history of diabetes -11.53 [-189.80;166.73] 0.89   
Randomization to strict glycemic control vs. conventional therapy 2.80 [-31.63:37.24] 0.87 -12.71 [-48.11;22.70] 0.47 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 64.84 [-49.53;179.20] 0.26 217.54 [107.00;328.08] <0.001 
          randomized for glycemic control postoperatively -55.30 [-138.87;28.27] 0.19 82.87 [-7.65;173.40] 0.07 
     Complicated/high risk surgery or trauma -44.31 [-169.38;80.77] 0.48 -94.16 [-232.80;44.47] 0.18 
     Neurological medical disorders 228.79 [-3.25;460.84]  0.05 12.28 [-238.20;262.75] 0.92 
     Infectious medical diseases -191.14 [-349.37;-32.90] 0.01 -62.19 [-286.61;162.23] 0.58 
     Other medical disorders -86.69 [-252.32;78.93] 0.30 -76.95 [-251.30;97.39] 0.38 
     Solid organ transplants 83.81 [-171.34;338.96] 0.51 -79.39 [-309.02;150.25] 0.49 
PeLOD score first 24 hrs (per point added) -62.69 [-155.68;30.30] 0.18 9.37 [-83.00;101.74] 0.84 
PICU stay (per day added) -0.62 [-113.73;112.49] 0.99 84.62 [-90.58;259.82] 0.34 
Exceeding potentially harmful threshold for phthalate exposure 82.72 [34.77;130.66] 0.0008 100.67 [59.92;141.41] 0.000002 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-22. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and reaction time dominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -15.69 [-52.85;21.46] 0.40 -16.08 [-51.09;18.93] 0.36 
Age at sampling (per year added) -419.89 [-510.28;-329.49] <0.001 -348.42 [-445.18;-251.65] <0.001 
Caucasian vs. other race 6.45 [-126.56;139.47] 0.92 80.88 [-34.83;196.59] 0.16 
Exclusively European vs. other origin -0.74 [-111.00;109.52] 0.98 -118.95 [-237.20;-0.70] 0.04 
Exclusively Dutch language vs. non-exclusively Dutch language 51.15 [-8.46;110.76] 0.09 62.88 [0.21;125.54] 0.04 
Socioeconomic status (per category of 1 to 66) -113.21 [-200.77;-25.65] 0.01 -79.04 [-163.90;5.82] 0.06 
Pre-existing syndrome vs. no pre-existing syndrome 41.52 [-7.18;90.21] 0.09 60.08 [14.53;105.63] 0.01 
History vs. no history of malignancy -31.32 [-166.66;104.02] 0.64 -11.78 [-117.12;93.57] 0.82 
History vs. no history of diabetes -28.38 [-211.94;155.18] 0.76   
Randomization to strict glycemic control vs. conventional therapy 0.03 [-36.92;36.98] 0.99 -4.11 [-40.47;32.25] 0.82 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 263.20 [35.21;491.20] 0.02 155.24 [-8.80;319.29] 0.06 
          randomized for glycemic control postoperatively 143.91 [-67.43;355.24] 0.18 52.82 [-83.43;189.07] 0.44 
     Complicated/high risk surgery or trauma 67.90 [-156.56;292.36] 0.55 -70.19 [-224.76;84.37] 0.37 
     Neurological medical disorders 83.43 [-281.09;447.95] 0.65 -68.05 [-347.06;210.95] 0.63 
     Infectious medical diseases -393.22 [-673.38;-113.06] 0.006 24.65 [-218.31;267.60] 0.84 
     Other medical disorders -219.38 [-443.54;4.77] 0.05 -26.24 [-267.37;214.89] 0.83 
     Solid organ transplants 54.16 [-329.26;437.59] 0.78 -68.23 [-331.39;194.94] 0.60 
PeLOD score first 24 hrs (per point added) -61.39 [-171.09;48.30] 0.27 -9.56 [-105.12;86.00] 0.84 
PICU stay (per day added) -402.95 [-895.14;89.24] 0.10 -527.75 [-1377.75;322.25] 0.22 
Extracorporeal circulation versus no extracorporeal circulation a -39.55 [-121.89;42.78] 0.34 -35.39 [-99.36;28.58] 0.27 
Aortic clamp time (per min added)  8.67 [-100.21;117.54] 0.87 118.75 [-25.08;262.58] 0.10 
Duration of mechanical ventilation (per day added) 404.64 [7.21;802.07] 0.04 819.49 [40.14;1598.85] 0.03 
Peak creatinine (per mg/dl added) 15.03 [-220.08;250.15] 0.89 -102.72 [-328.55;123.11] 0.37 
Peak bilirubine (per mg/dl added) -65.20 [-240.02;109.61] 0.46 401.90 [75.84;727.97] 0.01 
Infection vs. no infection 9.87 [-53.49;73.23] 0.75 14.11 [-39.89;68.11] 0.60 
Antibiotics (per day added) 17.77 [-233.96;269.50] 0.88 -396.44 [-1013.76;220.88] 0.20 
Duration of hemodynamic support (per day added) 5.18 [-214.62;224.98] 0.96 193.06 [-428.44;814.56] 0.54 
Duration of corticosteroid treatment (per day added) 282.70 [-101.57;666.96] 0.14 179.92 [-248.66;608.49] 0.40 
Cumulative dose of opioids (per mg morphine-equivalent added) 53.97 [-222.35;330.28] 0.70 -185.97 [-432.53;60.58] 0.13 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 38.49 [-240.68;317.67] 0.78 -136.16 [-313.39;41.07] 0.13 
Received hypnotics versus no hypnotics -148.17 [-342.37;46.04] 0.13 27.97 [-116.37;172.30] 0.70 
Exceeding potentially harmful threshold for phthalate exposure 88.28 [35.89;140.66] 0.001 108.20 [66.91;149.49] 0.0000006 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
a with exposure to large bore tubings  
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eTable 5-23. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and reaction time nondominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -21.37 [-52.99;10.25] 0.18 10.75 [-22.33;43.82] 0.52 
Age at sampling (per year added) -364.69 [-431.05;-298.34] <0.001 -377.60 [-462.68;-292.51] <0.001 
Caucasian vs. other race -14.13 [-129.69;101.44] 0.80 25.31 [-84.83;135.45] 0.65 
Exclusively European vs. other origin -16.42 [-112.38;79.54] 0.73 -100.63 [-213.98;12.71] 0.08 
Exclusively Dutch language vs. non-exclusively Dutch language 50.92 [0.67;101.16] 0.04 64.27 [4.42;124.13] 0.03 
Socioeconomic status (per category of 1 to 66) -52.92 [-127.48;21.65] 0.16 -100.33 [-180.48;-20.18] 0.01 
Pre-existing syndrome vs. no pre-existing syndrome 21.85 [-18.62;62.32] 0.28 46.94 [3.45;90.42] 0.03 
History vs. no history of malignancy -9.79 [-125.78;106.21] 0.86 28.73 [-72.21;129.66] 0.57 
History vs. no history of diabetes 24.27 [-138.01;186.55] 0.76    
Randomization to strict glycemic control vs. conventional therapy 1.00 [-30.08;32.07] 0.94 -5.26 [-38.57;28.06] 0.75 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 33.51 [-70.56;137.58] 0.52 198.68 [94.65;302.70] <0.001 
          randomized for glycemic control postoperatively -16.91 [-92.54;58.73] 0.65 68.70 [-16.49;153.89] 0.11 
     Complicated/high risk surgery or trauma -3.54 [-117.41;110.33] 0.95 -193.82 [-324.29;-63.35] 0.003 
     Neurological medical disorders 112.50 [-98.53;323.54] 0.29 99.79 [-135.92;335.51] 0.40 
     Infectious medical diseases -118.96 [-262.99;25.07] 0.10 -55.44 [-266.64;155.76] 0.60 
     Other medical disorders -114.24 [-264.99;36.51] 0.13 -66.78 [-230.86;97.29] 0.42 
     Solid organ transplants 107.63 [-124.61;339.87] 0.36 -51.12 [-267.23;164.98] 0.64 
PeLOD score first 24 hrs (per point added) -31.16 [-115.31;52.99] 0.46 -9.06 [-95.99;77.87] 0.83 
PICU stay (per day added) -54.62 [-155.58;46.35] 0.28 140.44 [-24.43;305.32] 0.09 
Exceeding potentially harmful threshold for phthalate exposure 92.93 [50.07;135.79] 0.00003 73.85 [35.51;112.20] 0.0002 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-23. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and reaction time nondominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -21.84 [-54.24;10.56] 0.18 2.18 [-31.23;35.58] 0.89 
Age at sampling (per year added) -370.46 [-449.43;-291.49] <0.001 -351.27 [-443.60;-258.94] <0.001 
Caucasian vs. other race -41.17 [-157.86;75.53] 0.48 30.85 [-79.56;141.25] 0.58 
Exclusively European vs. other origin -6.97 [-103.62;89.68] 0.88 -98.39 [-211.21;14.44] 0.08 
Exclusively Dutch language vs. non-exclusively Dutch language 50.61 [-1.52;102.74] 0.05 74.49 [14.70;134.28] 0.01 
Socioeconomic status (per category of 1 to 66) -60.27 [-136.51;15.96] 0.12 -119.78 [-200.75;-38.81] 0.004 
Pre-existing syndrome vs. no pre-existing syndrome 23.46 [-18.52;65.44] 0.27 50.95 [7.49;94.42] 0.02 
History vs. no history of malignancy -7.32 [-126.01;111.37] 0.90 8.38 [-92.14;108.89] 0.86 
History vs. no history of diabetes 2.95 [-158.02;163.92] 0.97   
Randomization to strict glycemic control vs. conventional therapy -0.23 [-32.29;31.83] 0.98 5.26 [-29.43;39.96] 0.76 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 238.74 40.04;437.44] 0.01 150.92 [-5.60;307.45] 0.05 
          randomized for glycemic control postoperatively 176.94 [-7.34;361.23] 0.05 40.60 [-89.41;170.60] 0.53 
     Complicated/high risk surgery or trauma 61.75 [-134.43;257.92] 0.53 -203.40 [-350.88;-55.92] 0.007 
     Neurological medical disorders 9.03 [-310.35;328.41] 0.95 101.58 [-164.64;367.79] 0.45 
     Infectious medical diseases -300.65 [-546.19;-55.10] 0.01 -19.22 [-251.03;212.60] 0.87 
     Other medical disorders -297.61 [-494.03;-101.18] 0.003 32.13 [-197.94;262.20] 0.78 
     Solid organ transplants 111.79 [-224.63;448.21] 0.51 -102.61 [-353.71;148.49] 0.42 
PeLOD score first 24 hrs (per point added) -27.81 [-123.32;67.69] 0.56 -16.41 [-107.59;74.77] 0.72 
PICU stay (per day added) -280.76 [-704.43;142.92] 0.19 -699.85 [-1510.88;111.18] 0.09 
Extracorporeal circulation versus no extracorporeal circulation a -48.75 [-118.67;21.18] 0.17 -58.05 [-119.09;2.98] 0.06 
Aortic clamp time (per min added)  -37.26 [-132.21;57.68] 0.43 94.49 [-42.74;231.72] 0.17 
Duration of mechanical ventilation (per day added) 279.52 [-62.86;621.91] 0.10 526.41 [-217.21;1270.03] 0.16 
Peak creatinine (per mg/dl added) 53.18 [-152.46;258.82] 0.61 -54.93 [-270.41;160.55] 0.61 
Peak bilirubine (per mg/dl added) -185.50 [-338.46;-32.54] 0.01 296.36 [-14.75;607.47] 0.06 
Infection vs. no infection -1.60 [-56.97;53.77] 0.95 10.64 [-40.88;62.17] 0.68 
Antibiotics (per day added) -51.91 [-272.58;168.76] 0.64 -1.99 [-591.01;587.03] 0.99 
Duration of hemodynamic support (per day added) 24.70 [-167.70;217.10] 0.80 341.20 [-251.80;934.21] 0.25 
Duration of corticosteroid treatment (per day added) 226.17 [-109.48;561.82] 0.18 236.16 [-172.76;645.08] 0.25 
Cumulative dose of opioids (per mg morphine-equivalent added) 174.71 [-67.72;417.14] 0.15 -151.85 [-387.10;83.40] 0.20 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 139.09 [-105.57;383.75] 0.26 -116.59 [-285.70;52.51] 0.17 
Received hypnotics versus no hypnotics -129.10 [-299.48;41.27] 0.13 80.41 [-57.31;218.13] 0.25 
Exceeding potentially harmful threshold for phthalate exposure 107.79 [62.64;152.93] 0.000005 83.31 [43.91;122.71] 0.00004 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
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eTable 5-24. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and reaction time overall 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -18.09 [-48.89;12.72]  0.24 5.43 [-26.93;37.78] 0.74 
Age at sampling (per year added) -388.84 [-453.44;-324.24] <0.001 -380.48 [-463.71;-297.26] <0.001 
Caucasian vs. other race 7.50 [-104.34;119.34] 0.89 54.06 [-53.67;161.79] 0.32 
Exclusively European vs. other origin -13.28 [-106.21;79.65] 0.77 -112.01 [-222.88;-1.14] 0.04 
Exclusively Dutch language vs. non-exclusively Dutch language 51.90 [3.15;100.64] 0.03 56.91 [-1.64;115.46] 0.05 
Socioeconomic status (per category of 1 to 66) -74.94 [-147.59;-2.29] 0.04 -83.00 [-161.39;-4.60] 0.03 
Pre-existing syndrome vs. no pre-existing syndrome 27.09 [-12.68;66.85] 0.18 46.44 [3.90;88.97] 0.03 
History vs. no history of malignancy -17.06 [-129.31;95.18] 0.76 19.78 [-78.94;118.51] 0.69 
History vs. no history of diabetes 8.37 [-148.67;165.42] 0.91   
Randomization to strict glycemic control vs. conventional therapy 1.40 [-28.94;31.74] 0.92 -9.80 [-42.39;22.79] 0.55 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects       
          randomized for glycemic control preoperatively 48.55 [-52.21;149.30] 0.34 205.69 [103.93;307.44] <0.001 
          randomized for glycemic control postoperatively -39.59 [-113.21;34.03] 0.29 72.36 [-10.97;115.69] 0.08 
     Complicated/high risk surgery or trauma -23.88 [-134.07;86.32] 0.66 -143.67 [-271.29;-16.05] 0.02 
     Neurological medical disorders 173.79 [-30.64;378.22] 0.09 59.87 [-170.69;290.44] 0.60 
     Infectious medical diseases -154.48 [-293.88;-15.07] 0.03 -59.80 [-266.38;146.78] 0.56 
     Other medical disorders -102.42 [-248.33;43.50] 0.16 -70.35 [-230.83;90.14] 0.38 
     Solid organ transplants 98.02 [-126.77;322.80] 0.39 -64.11 [-275.49;147.27] 0.55 
PeLOD score first 24 hrs (per point added) -45.17 [-127.10;36.75] 0.27 -2.13 [-87.16;82.90] 0.96 
PICU stay (per day added) -24.78 [-124.43;74.87] 0.62 113.35 [-47.93;274.62] 0.16 
Exceeding potentially harmful threshold for phthalate exposure 87.12 [44.88;129.37] 0.00007 88.60 [51.10;126.11] 0.000006 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-24. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and reaction time overall (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender -20.19 [-52.29;11.90] 0.21 -5.46 [-37.77;26.85] 0.73 
Age at sampling (per year added) -391.65 [-469.74;-313.57] <0.001 -348.19 [-437.51;-258.88] <0.001 
Caucasian vs. other race -17.10 [-132.00;97.80] 0.76 55.50 [-51.30;162.30] 0.30 
Exclusively European vs. other origin -3.80 [-99.04;91.45] 0.93 -108.18 [-217.32;0.96] 0.05 
Exclusively Dutch language vs. non-exclusively Dutch language 49.01 [-2.48;100.50] 0.06 68.00 [10.15;125.83] 0.02 
Socioeconomic status (per category of 1 to 66) -83.05 [-158.69;-7.42] 0.03 -101.47 [-179.79;-23.14] 0.01 
Pre-existing syndrome vs. no pre-existing syndrome 30.79 [-11.28;72.85] 0.15 52.52 [10.48;94.56] 0.01 
History vs. no history of malignancy -19.79 [-136.70;97.11] 0.73 -0.63 [-97.86;96.60] 0.98 
History vs. no history of diabetes -11.75 [-170.31;146.82] 0.88   
Randomization to strict glycemic control vs. conventional therapy -0.16 [-32.08;31.76] 0.99 -0.44 [-34.01;33.12] 0.97 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 254.45 [57.51;451.40] 0.01 151.70 [0.28;303.12] 0.04 
          randomized for glycemic control postoperatively 161.53 [-21.03;344.09] 0.08 44.10 [-81.66;169.86] 0.48 
     Complicated/high risk surgery or trauma 64.50 [-129.39;258.38] 0.51 -137.33 [-280.00;5.33] 0.05 
     Neurological medical disorders 44.12 [-270.76;359.00] 0.78 19.67 [-237.85;277.20] 0.88 
     Infectious medical diseases -349.36 [-591.37;-107.36] 0.004 0.49 [-223.76;224.74] 0.99 
     Other medical disorders -261.64 [-455.27;-68.01] 0.008 3.76 [-218.80;226.33] 0.97 
     Solid organ transplants 86.40 [-244.80;417.61] 0.60 -82.40 [-325.30;160.51] 0.50 
PeLOD score first 24 hrs (per point added) -44.07 [-138.83;50.69] 0.35 -15.74 [-103.95;72.46] 0.72 
PICU stay (per day added) -344.83 [-769.99;80.32] 0.11 -611.27 [-1395.83;173.29] 0.12 
Extracorporeal circulation versus no extracorporeal circulation a -46.80 [-117.92;24.32] 0.19 -47.12 [-106.17;11.92] 0.11 
Aortic clamp time (per min added)  -12.01 [-106.06;82.03] 0.80 105.97 [-26.78;238.72] 0.11 
Duration of mechanical ventilation (per day added) 346.37 [3.06;689.67] 0.04 687.27 [-32.09;1406.62] 0.06 
Peak creatinine (per mg/dl added) 37.15 [-165.95;240.24] 0.71 -77.36 [-285.80;131.08] 0.46 
Peak bilirubine (per mg/dl added) -122.21 [-273.22;28.80] 0.11 337.48 [36.52;638.43] 0.02 
Infection vs. no infection 5.25 [-49.48;59.98] 0.85 13.30 [-36.54;63.14] 0.59 
Antibiotics (per day added) -15.08 [-232.52;202.37] 0.89 -203.10 [-772.90;366.69] 0.48 
Duration of hemodynamic support (per day added) 15.01 [-174.86;204.88] 0.87 263.64 [-310.01;837.29] 0.36 
Duration of corticosteroid treatment (per day added) 252.33 [-79.61;584.26] 0.13 199.43 [-196.14;595.01] 0.32 
Cumulative dose of opioids (per mg morphine-equivalent added) 112.93 [-125.76;351.61] 0.35 -169.44 [-397.01;58.13] 0.14 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 88.08 [-153.07;329.24] 0.47 -126.54 [-290.13;37.04] 0.12 
Received hypnotics versus no hypnotics -139.96 [-307.72;27.80] 0.10 54.62 [-78.61;187.84] 0.41 
Exceeding potentially harmful threshold for phthalate exposure 96.98 [51.73;142.23] 0.00003 96.82 [58.71;134.93] 0.000001 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
  
72 
 
eTable 5-25. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and inconsistency of reaction time dominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 15.85 [-13.86;45.56] 0.29 0.75 [-32.13;33.62] 0.96 
Age at sampling (per year added) -311.35 [-373.66;-249.04] <0.001 -296.33 [-380.91;-211.75] <0.001 
Caucasian vs. other race 41.07 [-66.80;148.94] 0.45 68.89 [-40.59;178.37] 0.21 
Exclusively European vs. other origin -34.76 [-124.39;54.87] 0.44 -91.82 [-204.49;20.84] 0.10 
Exclusively Dutch language vs. non-exclusively Dutch language 25.41 [-21.61;72.42] 0.28 28.18 [-31.32;87.68] 0.35 
Socioeconomic status (per category of 1 to 66) -82.69 [-152.76;-12.63] 0.02 -109.44 [-189.11;-29.77] 0.007 
Pre-existing syndrome vs. no pre-existing syndrome 32.18 [-6.17;70.53] 0.09 64.00 [20.78;107.23] 0.003 
History vs. no history of malignancy -12.05 [-120.31;96.20] 0.82 48.66 [-51.67;148.99] 0.33 
History vs. no history of diabetes 4.92 [-146.54;156.39] 0.94   
Randomization to strict glycemic control vs. conventional therapy 10.95 [-40.21;18.31] 0.46 -0.60 [-33.72;32.52] 0.97 
Diagnostic category (as compared with all other categories)     
Cardiac surgery for congenital heart defects       
     randomized for glycemic control preoperatively 75.58 [-21.60;172.76] 0.12 157.35 [53.95;260.76] 0.003 
     randomized for glycemic control postoperatively -13.34 [-84.34;57.67] 0.71 63.16 [-21.52;147.84] 0.14 
     Complicated/high risk surgery or trauma -12.97 [-119.25;93.31] 0.81 -94.76 [-224.44;34.93] 0.15 
     Neurological medical disorders 146.62 [-50.55;343.79] 0.14 7.39 [-226.91;241.70] 0.95 
     Infectious medical diseases -139.97 [-274.42;-5.51] 0.04 -30.13 [-240.06;179.81] 0.77 
     Other medical disorders -30.25 [-170.98;110.49] 0.67 -110.09 [-273.18;53.00] 0.18 
     Solid organ transplants -25.68 [-242.48;191.12] 0.81 7.06 [-207.75;221.88] 0.94 
PeLOD score first 24 hrs (per point added) -29.90 [-108.92;49.11] 0.45 7.94 [-78.47;94.35] 0.85 
PICU stay (per day added) -10.04 [-106.14;86.07] 0.83 9.76 [-154.14;173.65] 0.90 
Exceeding potentially harmful threshold for phthalate exposure 64.82 [24.07;105.56] 0.002 91.91 [53.80;130.03] 0.000004 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-25. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and inconsistency of reaction time dominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 10.56 [-21.37;42.49] 0.51 -13.58 [-46.49;19.32] 0.41 
Age at sampling (per year added) -317.99 [-395.68;-240.30] <0.001 -267.55 [-358.51;-176.59] <0.001 
Caucasian vs. other race 33.82 [-80.49;148.14] 0.56 81.03 [-27.74;189.79] 0.14 
Exclusively European vs. other origin -36.35 [-131.11;58.41] 0.45 -105.00 [-216.16;6.15] 0.06 
Exclusively Dutch language vs. non-exclusively Dutch language 23.80 [-27.43;75.02] 0.36 34.55 [-24.36;93.45] 0.24 
Socioeconomic status (per category of 1 to 66) -81.10 [-156.35;-5.85] 0.03 -123.42 [-203.19;-43.65] 0.002 
Pre-existing syndrome vs. no pre-existing syndrome 38.55 [-3.30;80.39] 0.07 71.45 [28.64;114.27] 0.001 
History vs. no history of malignancy -14.58 [-130.89;101.74] 0.80 36.86 [-62.16;135.89] 0.46 
History vs. no history of diabetes -9.02 [-166.77;148.74] 0.91   
Randomization to strict glycemic control vs. conventional therapy -10.21 [-41.97;21.54] 0.52 6.83 [-27.35;41.01] 0.69 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 209.12 [13.18;405.06] 0.03 67.55 [-86.66;221.76] 0.38 
          randomized for glycemic control postoperatively 119.38 [-62.25;301.01] 0.19 5.42 [-122.66;133.50] 0.93 
     Complicated/high risk surgery or trauma 48.10 [-144.80;241.00] 0.62 -121.09 [-266.38;24.20] 0.10 
     Neurological medical disorders 15.08 [-298.20;328.35] 0.92 -7.30 [-269.58;254.97] 0.95 
     Infectious medical diseases -234.98 [-475.76;5.80] 0.05 45.25 [-183.13;273.64] 0.69 
     Other medical disorders -101.07 [-293.71;91.57] 0.30 -45.04 [-271.71;181.62] 0.69 
     Solid organ transplants -55.63 [-385.15;273.89] 0.73 55.21 [-192.18;302.59] 0.66 
PeLOD score first 24 hrs (per point added) -43.62 [-137.89;50.66] 0.36 -32.37 [-122.20;57.46] 0.47 
PICU stay (per day added) -244.42 [-667.41;178.58] 0.25 477.94 [-321.09;1276.96] 0.23 
Extracorporeal circulation versus no extracorporeal circulation a -18.85 [-89.61;51.91] 0.59 -4.77 [-64.91;55.36] 0.87 
Aortic clamp time (per min added)  -12.23 [-105.80;81.33] 0.79 152.51 [17.31;287.71] 0.02 
Duration of mechanical ventilation (per day added) 204.71 [-136.85;546.27] 0.23 441.02 [-291.59;1173.64] 0.23 
Peak creatinine (per mg/dl added) 47.46 [-154.60;249.52] 0.64 18.00 [-194.28;230.29] 0.86 
Peak bilirubine (per mg/dl added) 0.23 [-150.01;150.47] 0.99 323.15 [16.64;629.66] 0.03 
Infection vs. no infection 23.54 [-30.92;77.99] 0.39 33.30 [-17.46;84.05] 0.19 
Antibiotics (per day added) 15.43 [-200.92;231.77] 0.88 -787.96 [-1368.26;-207.66] 0.008 
Duration of hemodynamic support (per day added) -7.89 [-196.79;181.02] 0.93 -251.50 [-835.72;332.73] 0.39 
Duration of corticosteroid treatment (per day added) 168.31 [-161.94;498.55] 0.31 50.58 [-352.29;453.45] 0.80 
Cumulative dose of opioids (per mg morphine-equivalent added) 69.67 [-167.80;307.15] 0.56 -258.90 [-490.66;-27.13] 0.02 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 48.97 [-190.96;288.90] 0.68 -82.52 [-249.12;84.09] 0.32 
Received hypnotics versus no hypnotics -77.74 [-244.64;89.17] 0.35 73.62 [-62.06;209.29] 0.28 
Exceeding potentially harmful threshold for phthalate exposure 63.76 [18.74;108.78] 0.005 87.75 [48.93;126.56] 0.00001 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
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eTable 5-26. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and inconsistency of reaction time nondominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender -2.40 [-30.94;26.13] 0.86 5.11 [-27.37;37.59] 0.75 
Age at sampling (per year added) -255.86 [-315.75;-195.98] <0.001 -289.76 [-373.30;-206.21] <0.001 
Caucasian vs. other race 14.26 [-90.02;118.54] 0.78 20.49 [-87.65;128.64] 0.70 
Exclusively European vs. other origin -46.44 [-133.03;40.15] 0.29 -84.45 [-195.75;26.84] 0.13 
Exclusively Dutch language vs. non-exclusively Dutch language 44.55 [-0.79;89.89] 0.05 49.66 [-9.12;108.43] 0.09 
Socioeconomic status (per category of 1 to 66) -34.13 [-101.42;33.15] 0.31 -87.83 [-166.53;-9.13] 0.02 
Pre-existing syndrome vs. no pre-existing syndrome 22.93 [-13.60;59.45] 0.21 44.23 [1.53;86.92] 0.04 
History vs. no history of malignancy -46.05 [-150.72;58.63] 0.38 16.44 [-82.67;115.54] 0.74 
History vs. no history of diabetes 20.50 [-125.94;166.94] 0.78   
Randomization to strict glycemic control vs. conventional therapy -9.59 [-37.63;18.45] 0.50 3.36 [-29.36;36.08] 0.83 
Diagnostic category (as compared with all other categories)     
Cardiac surgery for congenital heart defects        
     randomized for glycemic control preoperatively 29.46 [-64.45;123.38] 0.53 168.26 [66.12;270.41] 0.001 
     randomized for glycemic control postoperatively 27.95 [-40.30;96.20] 0.42 48.93 [-34.72;132.58] 0.25 
     Complicated/high risk surgery or trauma 55.70 [-47.06;158.45] 0.28 -217.05 [-345.16;-88.94] 0.001 
     Neurological medical disorders 44.90 [-145.53;235.34] 0.64 156.42 [-75.03;387.87] 0.18 
     Infectious medical diseases -133.75 [-263.72;-3.78] 0.04 -109.72 [-317.10;97.66] 0.29 
     Other medical disorders -76.52 [-212.55;59.51] 0.26 -66.30 [-227.41;98.80] 0.41 
     Solid organ transplants 52.26 [-157.31;261.83] 0.62 19.45 [-192.74;231.65] 0.85 
PeLOD score first 24 hrs (per point added) -13.45 [-89.38;62.49] 0.72 21.15 [-64.21;106.50] 0.62 
PICU stay (per day added) -12.77 [-103.88;78.34] 0.78 52.71 [-109.19;214.61] 0.52 
Exceeding potentially harmful threshold for phthalate exposure 56.30 [17.62;94.97] 0.004 48.76 [11.11;86.41] 0.01 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-26. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of circulating 
5oxo-MEHP exposure and inconsistency of reaction time nondominant hand (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 1.21 [-28.37;30.79] 0.93 -0.42 [-34.20;33.35] 0.98 
Age at sampling (per year added) -276.98 [-349.08;-204.89] <0.001 -282.75 [-376.10;-189.40] <0.001 
Caucasian vs. other race -4.73 [-111.27;101.81] 0.93 23.45 [-88.17;135.08] 0.67 
Exclusively European vs. other origin -43.70 [-131.93;44.54] 0.32 -81.51 [-195.59;32.56] 0.16 
Exclusively Dutch language vs. non-exclusively Dutch language 48.82 [1.23;96.41] 0.04 58.02 [-2.44;118.47] 0.05 
Socioeconomic status (per category of 1 to 66) -42.77 [-112.36;26.83] 0.22 -110.70 [-192.56;-28.83] 0.008 
Pre-existing syndrome vs. no pre-existing syndrome 26.25 [-12.08;64.58] 0.17 46.33 [2.39;90.27] 0.03 
History vs. no history of malignancy -62.65 [-171.01;45.71] 0.25 1.97 [-99.65;103.60] 0.96 
History vs. no history of diabetes 11.98 [-134.98;158.94] 0.87   
Randomization to strict glycemic control vs. conventional therapy -13.58 [-42.85;15.68] 0.36 11.86 [-23.22;46.93] 0.50 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 138.72 [-42.69;320.13] 0.13 195.52 [37.27;353.78] 0.01 
          randomized for glycemic control postoperatively 134.68 [-33.56;302.93] 0.11 81.84 [-49.60;213.29] 0.22 
     Complicated/high risk surgery or trauma 116.85 [-62.25;295.95] 0.19 -234.56 [-383.67;-85.45] 0.002 
     Neurological medical disorders 15.40 [-276.18;306.98] 0.91 164.43 [-104.73;433.59] 0.22 
     Infectious medical diseases -201.17 [-425.34;23.00] 0.07 -102.22 [-336.60;132.17] 0.39 
     Other medical disorders -172.88 [-352.21;6.45] 0.05 -10.22 [-242.84;222.40] 0.93 
     Solid organ transplants -31.60 [-338.74;275.53] 0.83 -94.80 [-348.68;159.08] 0.46 
PeLOD score first 24 hrs (per point added) -18.75 [-105.94;68.44] 0.67 9.75 [-82.44;101.93] 0.83 
PICU stay (per day added) -251.37 [-638.17;135.43] 0.20 -557.89 [-1377.90;262.12] 0.18 
Extracorporeal circulation versus no extracorporeal circulation a -24.01 [-87.85;39.83] 0.45 -65.00 [-126.71;-3.29] 0.03 
Aortic clamp time (per min added)  -13.02 [-99.70;73.66] 0.76 114.42 [-24.33;253.17] 0.10 
Duration of mechanical ventilation (per day added) 267.49 [-45.09;580.07] 0.09 429.37 [-322.49;1181.22] 0.26 
Peak creatinine (per mg/dl added) 115.74 [-71.99;303.48] 0.22 28.85 [-189.02;246.71] 0.79 
Peak bilirubine (per mg/dl added) -175.77 [-315.42;-36.13] 0.01 148.07 [-166.48;462.63] 0.35 
Infection vs. no infection -19.69 [-70.24;30.87] 0.44 17.82 [-34.27;69.91] 0.50 
Antibiotics (per day added) -53.19 [-254.65;148.28] 0.60 -80.61 [-676.15;514.93] 0.78 
Duration of hemodynamic support (per day added) 52.27 [-123.38;227.92] 0.55 111.91 [-487.66;711.48] 0.71 
Duration of corticosteroid treatment (per day added) 319.64 [13.20;626.07] 0.04 366.24 [-47.21;779.69] 0.08 
Cumulative dose of opioids (per mg morphine-equivalent added) 159.91 [-61.42;381.24] 0.15 -55.57 [-293.43;182.28] 0.64 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 122.10 [-101.27;345.46] 0.28 -64.26 [-235.24;106.72] 0.45 
Received hypnotics versus no hypnotics -63.71 [-219.25;91.84] 0.42 58.59 [-80.66;197.83] 0.40 
Exceeding potentially harmful threshold for phthalate exposure 69.11 [27.89;110.32] 0.001 51.40 [11.57;91.24] 0.01 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
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eTable 5-27. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of 
circulating 5oxo-MEHP exposure and inconsistency of reaction time overall 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 6.16 [-19.48;31.79] 0.63 0.86 [-27.93;29.64] 0.95 
Age at sampling (per year added) -291.71 [-345.47;-237.95] <0.001 -296.68 [-370.45;-222.91] <0.001 
Caucasian vs. other race 29.78 [-63.29;122.85] 0.52 44.42 [-51.08;139.91] 0.36 
Exclusively European vs. other origin -40.63 [-117.96;36.70] 0.30 -88.86 [-187.13;9.42] 0.07 
Exclusively Dutch language vs. non-exclusively Dutch language 37.75 [-2.81;78.32] 0.06 42.39 [-9.52;94.30] 0.10 
Socioeconomic status (per category of 1 to 66) -52.54 [-112.99;7.92] 0.08 -99.16 [-168.76;-29.56] 0.005 
Pre-existing syndrome vs. no pre-existing syndrome 27.46 [-5.63;60.55] 0.10 53.01 [14.98;91.05] 0.006 
History vs. no history of malignancy -30.68 [-124.08;62.73] 0.51 33.04 [-54.49;120.57] 0.45 
History vs. no history of diabetes 5.61 [-125.08;136.29] 0.93   
Randomization to strict glycemic control vs. conventional therapy -9.20 [-34.45;16.05] 0.47 -1.48 [-30.44;27.47] 0.91 
Diagnostic category (as compared with all other categories)     
Cardiac surgery for congenital heart defects        
     randomized for glycemic control preoperatively 54.02 [-29.83;137.86] 0.20 157.88 [67.53;248.22] <0.001 
     randomized for glycemic control postoperatively 1.14 [-60.13;62.40] 0.97 57.46 [-16.69;131.61] 0.12 
     Complicated/high risk surgery or trauma 20.26 [-71.44;111.96] 0.66 -143.41 [-256.53;-30.29] 0.01 
     Neurological medical disorders 108.37 [-61.75;278.49] 0.21 82.70 [-121.76;287.17] 0.42 
     Infectious medical diseases -130.34 [-246.34;-14.33] 0.02 -74.68 [-257.79;108.44] 0.42 
     Other medical disorders -48.20 [-169.62;73.23] 0.43 -90.32 [-232.60;51.97] 0.21 
     Solid organ transplants -5.25 [-192.31;181.81] 0.95 10.37 [-177.02;197.75] 0.91 
PeLOD score first 24 hrs (per point added) -16.72 [-84.90;51.45] 0.62 13.81 [-61.64;89.26] 0.71 
PICU stay (per day added) -9.20 [-92.12;73.72] 0.82 27.89 [-115.06;170.84] 0.70 
Exceeding potentially harmful threshold for phthalate exposure 62.34 [27.19;97.50] 0.0006  74.64 [41.32;107.96] 0.00001 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-27. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of 
circulating 5oxo-MEHP exposure and inconsistency of reaction time overall 
(continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 4.86 [-22.27;31.99] 0.72 -9.19 [-38.67;20.29] 0.53 
Age at sampling (per year added) -311.43 [-377.44;-245.43] <0.001 -277.95 [-359.11;-196.80] <0.001 
Caucasian vs. other race 15.74 [-81.38;112.87] 0.74 51.39 [-45.63;148.41] 0.29 
Exclusively European vs. other origin -40.88 [-121.39;39.63] 0.31 -93.69 [-192.84;5.47] 0.06 
Exclusively Dutch language vs. non-exclusively Dutch language 38.68 [-4.84;82.20] 0.08 50.18 [-2.37;102.73] 0.06 
Socioeconomic status (per category of 1 to 66) -54.67 [-118.61;9.27] 0.09 -118.64 [-189.91;-47.37] 0.001 
Pre-existing syndrome vs. no pre-existing syndrome 32.88 [-2.67;68.44] 0.06 57.89 [19.28;96.49] 0.003 
History vs. no history of malignancy -42.04 [-140.86;56.78] 0.40 19.56 [-68.80;107.93] 0.66 
History vs. no history of diabetes -6.39 [-140.43;127.64] 0.92   
Randomization to strict glycemic control vs. conventional therapy -10.73 [-37.71;16.26] 0.43 6.47 [-24.11;37.04] 0.67 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 178.84 [12.36;345.32] 0.03 133.61 [-3.94;271.17] 0.05 
          randomized for glycemic control postoperatively 125.31 [-29.01;279.63] 0.11 51.35 [-62.94;165.64] 0.37 
     Complicated/high risk surgery or trauma 87.77 [-76.13;251.67] 0.29 -163.27 [-292.88;-33.66] 0.01 
     Neurological medical disorders 3.55 [-262.62;269.72] 0.97 70.87 [-163.13;304.86] 0.55 
     Infectious medical diseases -220.02 [-424.59;-15.45] 0.03 -39.56 [-243.35;164.24] 0.70 
     Other medical disorders -131.48 [-295.15;32.20] 0.11 -39.84 [-242.02;162.34] 0.69 
     Solid organ transplants -43.98 [-323.95;235.99] 0.75 -13.16 [-233.90;207.58] 0.90 
PeLOD score first 24 hrs (per point added) -33.92 [-114.02;46.18] 0.40 -12.49 [-92.76;67.77] 0.75 
PICU stay (per day added) -268.87 [-628.26;90.52] 0.14 -42.10 [-754.83;670.62] 0.90 
Extracorporeal circulation versus no extracorporeal circulation a -16.95 [-77.07;43.17] 0.57 -35.38 [-89.04;18.28] 0.19 
Aortic clamp time (per min added)  -15.88 [-95.37;63.62] 0.69 131.84 [11.25;252.44] 0.03 
Duration of mechanical ventilation (per day added) 254.83 [-35.37;545.03] 0.08 417.01 [-236.97;1070.99] 0.20 
Peak creatinine (per mg/dl added) 113.17 [-58.51;284.85] 0.19 13.83 [-175.58;203.23] 0.88 
Peak bilirubine (per mg/dl added) -81.96 [-209.61;45.69] 0.20 260.25 [-13.42;533.91] 0.06 
Infection vs. no infection 3.63 [-42.64;49.89] 0.87 26.43 [-18.87;71.74] 0.25 
Antibiotics (per day added) -9.93 [-193.74;173.89] 0.91 -406.59 [-924.23;111.05] 0.12 
Duration of hemodynamic support (per day added) 11.33 [-149.17;171.83] 0.88 -79.38 [-600.78;442.01] 0.76 
Duration of corticosteroid treatment (per day added) 236.68 [-43.90;517.27] 0.09 194.21 [-165.32;553.74] 0.28 
Cumulative dose of opioids (per mg morphine-equivalent added) 107.59 [-94.17;309.36] 0.29 -152.64 [-359.37;54.10] 0.14 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 81.45 [-122.40;285.31] 0.43 -87.64 [-236.25;60.97] 0.24 
Received hypnotics versus no hypnotics -78.82 [-220.63;62.99] 0.27 56.12 [-64.91;177.14] 0.36 
Exceeding potentially harmful threshold for phthalate exposure 67.80 [29.55;106.05] 0.0006 74.42 [39.74;109.10] 0.00003 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
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eTable 5-28. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of 
circulating 5oxo-MEHP exposure and tapping dominant hand 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 0.28 [-0.65;1.20] 0.55 -0.01 [-1.21;1.18] 0.98 
Age at sampling (per year added) 18.86 [16.92;20.80] <0.001 19.65 [16.59;22.71] <0.001 
Caucasian vs. other race 2.04 [-1.34;5.42] 0.23 -1.53 [-5.48;2.43] 0.44 
Exclusively European vs. other origin -2.11 [-4.92;0.70] 0.14 2.73 [-1.41;6.87] 0.19 
Exclusively Dutch language vs. non-exclusively Dutch language -0.68 [-2.15;0.79] 0.36 -0.79 [-3.09;1.50] 0.49 
Socioeconomic status (per category of 1 to 66) 1.31 [-0.90;3.51] 0.24 -1.93 [-4.79;0.93] 0.18 
Pre-existing syndrome vs. no pre-existing syndrome 0.48 [-0.71;1.68] 0.42 -1.11 [-2.69;0.47] 0.16 
History vs. no history of malignancy -0.31 [-3.68;3.06] 0.85 0.22 [-3.38;3.82] 0.90 
History vs. no history of diabetes 1.34 [-3.41;6.09] 0.57   
Randomization to strict glycemic control vs. conventional therapy 0.24 [-0.68;1.15] 0.60 0.45 [-0.75;1.64] 0.46 
Diagnostic category (as compared with all other categories)     
Cardiac surgery for congenital heart defects        
     randomized for glycemic control preoperatively 1.32 [-1.73;4.36] 0.39 -2.30 [-6.02;1.41] 0.22 
     randomized for glycemic control postoperatively 2.77 [0.54;4.99] 0.01 -0.82 [-3.89;2.26] 0.60 
     Complicated/high risk surgery or trauma -081 [-4.07;2.45] 0.62 -1.73 [-6.27;2.82] 0.45 
     Neurological medical disorders -3.53 [-9.70;2.64] 0.26 -0.31 [-8.78;8.15] 0.94 
     Infectious medical diseases -2.11 [-6.32;2.10] 0.32 -0.44 [-8.02;7.14] 0.90 
     Other medical disorders 2.15 [-2.26;6.56] 0.33 2.75 [-3.14;8.64] 0.35 
     Solid organ transplants 0.23 [-6.57;7.02] 0.94 2.85 [-4.88;10.58] 0.46 
PeLOD score first 24 hrs (per point added) 0.89 [-1.59;3.36] 0.48 0.50 [-2.59;3.60] 0.74 
PICU stay (per day added) 0.58 [-2.44;3.59] 0.70 -1.03 [-6.87;4.80] 0.72 
Exceeding potentially harmful threshold for phthalate exposure -1.89 [-3.17;-0.61] 0.004 -0.93 [-2.30;0.45] 0.18 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-28. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of 
circulating 5oxo-MEHP exposure and tapping dominant hand (continued) 
 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 0.40 [-0.58;1.37] 0.42 0.02 [-1.22;1.26] 0.97 
Age at sampling (per year added) 17.47 [15.10;19.85] <0.001 18.39 [14.97;21.81] <0.001 
Caucasian vs. other race 2.16 [-1.33;5.65] 0.22 -1.82 [-5.91;2.27] 0.38 
Exclusively European vs. other origin -2.27 [-5.16;0.63] 0.12 3.28 [-0.96;7.52] 0.12 
Exclusively Dutch language vs. non-exclusively Dutch language -0.74 [-2.30;0.81] 0.34 -0.81 [-3.19;1.58] 0.50 
Socioeconomic status (per category of 1 to 66) 1.39 [-0.91;3.69] 0.23 -1.73 [-4.70;1.24] 0.25 
Pre-existing syndrome vs. no pre-existing syndrome 0.64 [-0.63;1.91] 0.32 -1.10 [-2.73;0.54] 0.18 
History vs. no history of malignancy -0.89 [-4.41;2.63] 0.61 0.58 [-3.14;4.31] 0.75 
History vs. no history of diabetes 1.95 [-2.87;6.76] 0.42   
Randomization to strict glycemic control vs. conventional therapy 0.12 [-0.85;1.09] 0.80 0.26 [-1.00;1.51] 0.68 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively -3.46 [-9.41;2.49] 0.25 -0.86 [-6.64;4.92] 0.76 
          randomized for glycemic control postoperatively -1.39 [-6.91;4.12] 0.61 0.19 [-4.59;4.96] 0.93 
     Complicated/high risk surgery or trauma -0.33 [-6.16;5.50] 0.91 0.04 [-5.38;5.46] 0.98 
     Neurological medical disorders -3.18 [-12.74;6.38] 0.51 0.19 [-9.67;10.06] 0.96 
     Infectious medical diseases 0.11 [-7.25;7.46] 0.97 -0.18 [-8.51;8.16] 0.96 
     Other medical disorders 4.93 [-0.95;10.82] 0.09 0.98 [-7.52;9.48] 0.82 
     Solid organ transplants 3.33 [-6.72;13.37] 0.51 -0.37 [-9.58;8.85] 0.93 
PeLOD score first 24 hrs (per point added) 0.06 [-2.80;2.93] 0.96 0.77 [-2.62;4.16] 0.65 
PICU stay (per day added) -2.47 [-15.38;10.44] 0.70 -17.77 [-44.70;9.17] 0.19 
Extracorporeal circulation versus no extracorporeal circulation a 2.49 [0.37;4.60] 0.02 0.66 [-1.58;2.90] 0.55 
Aortic clamp time (per min added)  0.93 [-1.94;3.81] 0.52 -2.28 [-7.41;2.84] 0.38 
Duration of mechanical ventilation (per day added) 5.06 [-5.38;15.49] 0.34 2.67 [-23.69;29.02] 0.84 
Peak creatinine (per mg/dl added) 3.86 [-2.30;10.01] 0.21 4.33 [-3.58;12.24] 0.28 
Peak bilirubine (per mg/dl added) 1.30 [-3.28;5.88] 0.57 -0.10 [-12.20;11.99] 0.98 
Infection vs. no infection 0.24 [-1.42;1.90] 0.77 -0.73 [-2.59;1.13] 0.43 
Antibiotics (per day added) -1.83 [-8.44;4.77] 0.58 6.07 [-15.08;27.23] 0.57 
Duration of hemodynamic support (per day added) -3.67 [-9.41;2.07] 0.20 -0.01 [-19.27;19.25] 0.99 
Duration of corticosteroid treatment (per day added) -1.67 [-11.75;8.42] 0.74 11.28 [-2.87;25.42] 0.11 
Cumulative dose of opioids (per mg morphine-equivalent added) -3.30 [-10.55;3.95] 0.37 3.44 [-5.08;11.95] 0.42 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) 1.90 [-5.42;9.22] 0.60 4.39 [-1.86;10.63] 0.16 
Received hypnotics versus no hypnotics 1.06 [-4.04;6.15] 0.68 -1.49 [-6.60;3.62] 0.56 
Exceeding potentially harmful threshold for phthalate exposure -2.16 [-3.53;-0.78] 0.002 -0.77 [-2.23;0.69] 0.29 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
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eTable 5-29. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of 
circulating 5oxo-MEHP exposure and no. of valid synchronous taps 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
A. Corrected for baseline risk factors and PICU stay 
Male vs. female gender 0.44 [-0.62;1.50] 0.41 -0.16 [-1.33;1.01] 0.78 
Age at sampling (per year added) 15.82 [13.63;18.02] <0.001 17.11 [14.05;20.17] <0.001 
Caucasian vs. other race 0.19 [-3.75;4.13] 0.92 -1.09 [-4.93;2.74] 0.57 
Exclusively European vs. other origin -1.61 [-4.81;1.59] 0.32 1.28 [-2.73;5.29] 0.52 
Exclusively Dutch language vs. non-exclusively Dutch language 0.47 [-1.23;2.16] 0.58 0.00 [-2.23;2.23] >0.99 
Socioeconomic status (per category of 1 to 66) 1.14 [-1.37;3.66] 0.37 0.61 [-2.19;3.42] 0.66 
Pre-existing syndrome vs. no pre-existing syndrome -0.04 [-1.41;1.32] 0.95 -2.17 [-3.74;-0.61] 0.006 
History vs. no history of malignancy -0.97 [-4.78;2.85] 0.61 1.40 [-2.09;4.89] 0.43 
History vs. no history of diabetes 2.41 [-2.98;7.81] 0.37   
Randomization to strict glycemic control vs. conventional therapy 0.17 [-0.87;1.21] 0.75 0.51 [-0.67;1.69] 0.39 
Diagnostic category (as compared with all other categories)     
Cardiac surgery for congenital heart defects        
     randomized for glycemic control preoperatively 4.91 [1.43;8.38] 0.005 1.49 [-2.17;5.15] 0.42 
     randomized for glycemic control postoperatively 1.58 [-0.95;4.11] 0.21 2.29 [-0.71;5.29] 0.13 
     Complicated/high risk surgery or trauma 2.22 [-1.46;5.91] 0.23 3.67 [-0.74;8.08] 0.10 
     Neurological medical disorders -3.53 [-10.51;3.45] 0.31 -5.30 [-13.54;2.93] 0.20 
     Infectious medical diseases 0.20 [-4.57;4.97] 0.93 -0.36 [-7.72;7.00] 0.92 
     Other medical disorders 0.04 [-4.95;5.02] 0.98 6.03 [0.33;11.74] 0.03 
     Solid organ transplants -5.41 [-13.11;2.29] 0.16 -7.82 [-15.32;-0.32] 0.04 
PeLOD score first 24 hrs (per point added) 1.61 [-1.19;4.41] 0.25 1.59 [-1.44;4.62] 0.30 
PICU stay (per day added) -1.52 [-4.81;1.77] 0.36 -2.41 [-8.03;3.22] 0.39 
Exceeding potentially harmful threshold for phthalate exposure -1.76 [-3.12;-0.41] 0.01 -0.35 [-1.73;1.04] 0.62 
CI: confidence interval; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit. 
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eTable 5-29. Multivariable linear regression analyses determining significant and 
independent associations between exceeding a potentially harmful threshold of 
circulating 5oxo-MEHP exposure and no. of valid synchronous taps (continued) 
 
VARIABLE DEVELOPMENT COHORT VALIDATION COHORT 
Estimate (95% CI) P value Estimate (95% CI) P value 
B. Corrected for baseline risk factors, PICU stay, extracorporeal circulation, aortic clamp time and complications/treatments during PICU stay 
Male vs. female gender 0.56 [-0.56;1.68] 0.32 -0.25 [-1.44;0.94] 0.67 
Age at sampling (per year added) 15.95 [13.24;18.66] <0.001 16.17 [12.84;19.50] <0.001 
Caucasian vs. other race 0.86 [-3.30;5.01] 0.68 -1.43 [-5.32;2.47] 0.47 
Exclusively European vs. other origin -1.23 [-4.54;2.09] 0.46 2.11 [-1.92;6.15] 0.30 
Exclusively Dutch language vs. non-exclusively Dutch language -0.21 [-2.03;1.60] 0.81 -0.41 [-2.69;1.86] 0.71 
Socioeconomic status (per category of 1 to 66) 1.28 [-1.36;3.92] 0.33 0.86 [-2.01;3.73] 0.55 
Pre-existing syndrome vs. no pre-existing syndrome -0.42 [-1.91;1.06] 0.57 -2.20 [-3.79;-0.60] 0.007 
History vs. no history of malignancy -0.80 [-4.81;3.22] 0.69 2.01 [-1.54;5.55] 0.26 
History vs. no history of diabetes 2.44 [-3.08;7.96] 0.38   
Randomization to strict glycemic control vs. conventional therapy 0.40 [-0.71;1.50] 0.47 -0.03 [-1.25;1.19] 0.95 
Diagnostic category (as compared with all other categories)     
     Cardiac surgery for congenital heart defects      
          randomized for glycemic control preoperatively 3.10 [-3.78;9.99] 0.37 1.66 [-3.92;7.24] 0.55 
          randomized for glycemic control postoperatively 0.17 [-6.18;6.52] 0.95 2.55 [-2.05;7.15] 0.27 
     Complicated/high risk surgery or trauma 1.65 [-5.00;8.30] 0.62 5.17 [-0.05;10.39] 0.05 
     Neurological medical disorders -3.13 [-14.08;7.82] 0.57 -6.44 [-15.89;3.01] 0.18 
     Infectious medical diseases -0.78 [-9.21;7.65] 0.85 0.99 [-6.96;8.94] 0.80 
     Other medical disorders 2.41 [-4.30;9.13] 0.47 2.83 [-5.28;10.94] 0.49 
     Solid organ transplants -3.43 [-15.01;8.15] 0.55 -6.76 [-15.57;2.05] 0.13 
PeLOD score first 24 hrs (per point added) 1.50 [-1.82;4.82] 0.37 1.06 [-2.21;4.33] 0.52 
PICU stay (per day added) 6.33 [-8.60;21.26] 0.40 -14.84 [-44.88;15.21] 0.33 
Extracorporeal circulation versus no extracorporeal circulation a 1.11 [-1.37;3.60] 0.37 2.32 [0.12;4.52] 0.03 
Aortic clamp time (per min added)  0.48 [-2.82;3.79] 0.77 -4.22 [-9.13;0.68] 0.09 
Duration of mechanical ventilation (per day added) -0.39 [-12.43;11.64] 0.94 22.88 [-3.77;49.53] 0.09 
Peak creatinine (per mg/dl added) -2.01 [-9.15;5.13] 0.57 7.58 [-0.01;15.16] 0.05 
Peak bilirubine (per mg/dl added) -1.45 [-6.75;3.85] 0.59 -6.19 [-17.84;5.46] 0.29 
Infection vs. no infection 0.93 [-1.01;2.87] 0.34 -0.78 [-2.61;1.05] 0.40 
Antibiotics (per day added) -5.17 [-12.76;2.42] 0.18 -3.04 [-24.92;18.84] 0.78 
Duration of hemodynamic support (per day added) -5.34 [-11.89;1.21] 0.10 -6.39 [-24.94;12.15] 0.49 
Duration of corticosteroid treatment (per day added) -2.48 [-14.00;9.04] 0.67 -0.14 [-14.10;13.83] 0.98 
Cumulative dose of opioids (per mg morphine-equivalent added) -6.27 [-14.53;1.99] 0.13 4.81 [-3.31;12.93] 0.24 
Cumulative dose of benzodiazepines (per mg midazolam-eqv added) -2.36 [-10.74;6.03] 0.58 1.19 [-4.83;7.22] 0.69 
Received hypnotics versus no hypnotics 0.38 [-5.47;6.22] 0.89 -2.01 [-6.89;2.86] 0.41 
Exceeding potentially harmful threshold for phthalate exposure -1.95 [-3.46;-0.45] 0.01 -0.30 [-1.76;1.16] 0.68 
CI: confidence interval; eqv: equivalent; PeLOD score: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit.  
a with exposure to large bore tubings 
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eTable 6. Multivariable linear regression analyses determining significant and independent 
associations between exceeding a potentially harmful threshold of circulating DEHP 
metabolite exposure and deficits in alertness and motor coordination, further adjusted for 
number of indwelling medical devices 
 
Phthalate 
exposurea 
Neurocognitive functions from the development 
cohort, significantly affected in validation cohortb 
Best threshold 
(µmol/l ×days)c 
of development 
cohort 
R² of 
the 
model Estimate [95% CI] P value 
Total DEHPd Attention and motor coordination     
0.72 Alertness (msec)f     
(0.34-2.19)  Reaction time dominant hand >0.551 0.60 58.90 [13.78;104.02] 0.01 
(µmol/l×days)  Reaction time nondominant hand >0.551 0.61 42.58 [0.24;84.91] 0.04 
e  Reaction time overall >0.551 0.63 52.03 [10.49;93.58] 0.01 
 Inconsistency of alertness (msec)g     
  SD reaction time dominant hand  >0.551 0.54 56.43 [15.24;97.62] 0.007 
  SD reaction time overall >0.551 0.57 41.03 [4.08;77.97] 0.02 
 Motor coordination (No. of taps in 10s)h     
  No. of unimanual taps     
  
 Nondominant hand 
>0.551 0.65 -1.53 [-3.01;-0.05] 0.04 
5oxo-MEHP Attention and motor co rdination     
0.03 Alertness (msec)f     
(0.02-0.10)  Reaction time dominant hand >0.031 0.64 107.92 [63.87;151.96] 0.000003 
(µmol/l×days)  Reaction time nondominant hand >0.031 0.64 81.04 [39.00;123.08] 0.0002 
e  Reaction time overall >0.031 0.66 95.34 [54.62;136.06] 0.000007 
 Inconsistency of alertness (msec)g      
  SD reaction time dominant hand  >0.031 0.56 84.04 [42.91;125.16] 0.00008 
  SD reaction time nondominant 
hand 
>0.031 0.52 44.17 [2.03;86.31] 0.04 
  SD reaction time overall >0.031 0.60 70.18 [33.40;106.96] 0.0002 
 
a “Exposure” was defined as the product of the last day concentrations in µmol/l and the number of days exposed in PICU. 
b Neurocognitive functions, that were significantly associated with the phthalate exposure in the development cohort, were tested in the validation 
cohort. Only the remaining functions that were also significantly associated with the phthalate exposure in the validation cohort are listed.  
c Threshold values are rounded to three decimals.  
d Exposure to the sum of MEHP and its metabolites 5cx-MEPP, 5oxo-MEHP and 5-OH-MEHP.  
e Distribution of metabolite exposures within the patient cohort (µmol/l ×days). Data are median (interquartile range). 
f For reaction times, higher scores reflect worse performance. Mean scores for healthy children are 558 (95% CI 521-595) for the dominant hand 
reaction time, 562 (95% CI 524-600) for the nondominant hand reaction time and 560 (95% CI 524-600) for the overall reaction time.1  
g For inconsistency of alertness, higher scores reflect worse performance. Mean scores for healthy children are 259 (95% CI 229-290) for the 
dominant hand, 262 (95% CI 232-292) for the nondominant hand and 275 (95% CI 246-304) for the overall SD, standard deviation.1  
h For motor coordination, higher scores reflect better performance. Mean scores for healthy children are 36 (95% CI 34-38) for dominant hand 
unimanual taps, 32 (95% CI 30-33) for nondominant hand unimanual taps and 22 (95% CI 20-24) for valid synchronous taps.1  
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eTable 7. Multivariable linear regression analyses determining significant and independent associations between exposure to a potentially harmful threshold of circulating phthalate 
metabolites and neurocognitive functions in the subgroup of cardiac surgery patients and further corrected for the “Risk Adjusted classification for Congenital Heart Surgery” (RACHS) 
score  
   Development cohort Validation cohort 
Phthalate 
exposurea 
Neurocognitive functions affected, as determined by 
a multivariable bootstrap approachb 
Potentially 
harmful 
threshold 
(µmol/l 
×days)c,d 
R² of 
the 
model Estimate [95% CI] P value 
 
R² of 
the 
model Estimate [95% CI] P value 
Total DEHPe Attention and motor coordination        
0.78  Alertness (msec)h        
(0.34-2.66)   Reaction time dominant hand >0.551 0.57 86.99 [33.89;140.10] 0.001 0.59 73.07 [24.61;121.53] 0.003 
(µmol/l×days)   Reaction time nondominant hand >0.551 0.56 74.64 [25.09;124.19] 0.003 0.61 58.58 [13.11;104.04] 0.01 
g   Reaction time overall  >0.551 0.60 79.57 [32.07;127.08] 0.001 0.62 67.35 [22.85;111.86] 0.003 
 Inconsistency of alertness (msec)i        
   SD reaction time dominant hand  >0.551 0.51 58.00 [11.97;104.02] 0.01 0.56 68.66 [25.57;111.75] 0.002 
   SD reaction time nondominant 
hand 
>0.551 0.46 59.09 [15.60;102.58] 0.008 0.50 40.99 [-3.48;85.46] 0.07 
   SD reaction time overall >0.551 0.55 60.34 [20.50;100.17] 0.003 0.58 56.14 [17.14;95.14] 0.005 
 Motor coordination (No. of taps in 10s)j        
   No. of valid synchronous taps >0.551 0.70 -2.24 [-3.75;-0.74] 0.003 0.55 -1.15 [-2.72;0.42] 0.14 
MEHP Attention and motor coordination        
Metabolitesf Alertness (msec)h        
0.47   Reaction time dominant hand >0.365 0.57 100.26 [42.61;157.92] 0.0008 0.58 57.81 [7.84;107.78] 0.02 
(0.22-1.80)   Reaction time nondominant hand >0.365 0.56 78.45 [24.46;132.44] 0.004 0.60 54.97 [8.51;101.44] 0.02 
(µmol/l×days)   Reaction time overall >0.365 0.61 89.56 [37.89;141.22] 0.0008 0.62 58.18 [12.44;103.92] 0.01 
g Inconsistency of alertness (msec)i        
   SD reaction time dominant hand  >0.365 0.52 72.10 [22.26;121.95] 0.004 0.55 56.81 [12.39;101.22] 0.01 
   SD reaction time nondominant 
hand 
>0.365 0.46 65.31 [18.06;112.57] 0.007 0.49 36.82 [-8.59;82.24] 0.11 
   SD reaction time overall >0.365 0.56 71.24 [28.04;114.43] 0.001 0.57 49.29 [9.23;89.35] 0.01 
 Motor coordination (No. of taps in 10s)j        
   No. of valid synchronous taps >0.365 0.70 -1.98 [-3.65;-0.31] 0.02 0.54 -0.33 [-1.94;1.28] 0.68 
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eTable 7. Multivariable linear regression analyses determining significant and independent associations between exposure to a potentially harmful threshold of circulating 
phthalate metabolites and neurocognitive functions in the subgroup of cardiac surgery patients and further corrected for the “Risk Adjusted classification for Congenital Heart 
Surgery” (RACHS) score (continued) 
 
MEHP Attention and motor coordination        
0.23 Alertness (msec)h        
(0.10-0.68)  Reaction time dominant hand >0.157 0.56 66.73 [14.07;119.38] 0.01 0.58 51.91 [3.17;100.65] 0.03 
(µmol/l×days)  Reaction time nondominant hand >0.157 0.55 60.93 [11.94;109.93] 0.01 0.60 38.57 [-7.05;84.19] 0.09 
g  Reaction time overall >0.157 0.59 62.39 [15.31;109.47] 0.009 0.61 46.55 [1.74;91.36] 0.04 
 Motor coordination (No. of taps in 10s)j        
  No. of valid synchronous taps >0.157 
0.71 
-2.52 [-4.01;-1.04] 0.001 0.56 -1.51 [-3.06;0.03] 0.05 
5oxo-MEHP Attention and motor coordination        
0.03 Alertness (msec)h        
(0.01-0.12)   Reaction time dominant hand >0.031 0.59 123.93 [64.42;183.44] 0.00006 0.62 111.69 [62.31;161.07] 0.00001 
(µmol/l×days)   Reaction time nondominant hand >0.031 0.60 136.19 [82.78;189.60] 0.000001
1 
0.62 88.83 [41.99;135.66] 0.0003 
g   Reaction time overall >0.031 0.64 129.26 [77.11;181.41] 0.000002 0.65 101.46 [56.02;146.90] 0.00002 
 Inconsistency of alertness (msec)i        
   SD reaction time dominant hand  >0.031 0.53 87.61 [35.81;139.41] 0.001 0.57 87.72 [42.94;132.49] 0.0002 
   SD reaction time nondominant 
hand 
>0.031 0.48 88.50 [40.07;136.93] 0.0004 0.51 58.02 [11.49;104.56] 0.01 
   SD reaction time overall >0.031 0.57 88.45 [43.81;133.09] 0.0001 0.59 76.11 [35.75;116.46] 0.0003 
 Motor coordination (No. of taps in 10s)j        
   No. of unimanual taps        
  Dominant hand >0.031 0.78 -1.81 [-3.39;-0.23] 0.02 0.58 -1.02 [-2.77;0.73] 0.25 
 
a“Exposure” was defined as the product of the last day concentrations in µmol/l and the number of days exposed in PICU. 
bOnly the neurocognitive functions that were significantly associated with the phthalate exposures as identified by bootstrapping are listed.   
cidentified via bootstrap resampling.  
dthreshold values are rounded to three decimals.  
eExposure to the sum of MEHP and its metabolites 5cx-MEPP, 5oxo-MEHP and 5OH-MEHP.  
fExposure to the sum of 5cx-MEPP, 5oxo-MEHP and 5OH-MEHP. 
gDistribution of metabolite exposures within the patient cohort (µmol/l ×days). Data are median (interquartile range). 
hFor reaction times, higher scores reflect worse performance. Mean scores for healthy children are 558 (95% CI 521-595) for the dominant hand reaction time, 562 (95% CI 524-600) for the nondominant hand 
reaction time and 560 (95% CI 524-600) for the overall reaction time (ref 1).  
iFor inconsistency of alertness, higher scores reflect worse performance. Mean scores for healthy children are 259 (95% CI 229-290) for the dominant hand, 262 (95% CI 232-292) for the nondominant hand 
and 275 (95% CI 246-304) for the overall SD, standard deviation (ref 1).  
jFor motor coordination, higher scores reflect better performance. Mean scores for healthy children are 36 (95% CI 34-38) for dominant hand unimanual taps, 32 (95% CI 30-33) for nondominant hand 
unimanual taps and 22 (95% CI 20-24) for valid synchronous taps (ref 1). 
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eTable 8. Multivariable linear regression analyses determining significant and independent associations between exposure to a potentially harmful threshold of circulating phthalate 
metabolites and neurocognitive functions in the subgroup of patients in whom DEHP metabolite concentrations were higher on the last day in PICU than upon PICU admission 
   Development cohort Validation cohort 
Phthalate 
exposurea 
Neurocognitive functions affected, as determined by 
a multivariable bootstrap approachb 
Potentially 
harmful 
threshold 
(µmol/l 
×days)c,d 
R² of 
the 
model Estimate [95% CI] P value 
 
R² of 
the 
model Estimate [95% CI] P value 
Total DEHPe Attention and motor coordination        
0.78  Alertness (msec)g        
(0.34-2.66)  Reaction time dominant hand >0.551 0.62 93.68 [43.92;143.43] 0.0003 0.63 75.98 [31.29;120.67] 0.001 
(µmol/l×days)  Reaction time nondominant hand >0.551 0.62 78.93 [35.14;122.73] 0.0005 0.64 64.02 [22.65;105.39] 0.002 
f  Reaction time overall  >0.551 0.66 85.54 [43.07;128.01] 0.0001 0.66 71.74 [30.75;112.73] 0.0007 
 Inconsistency of alertness (msec)h        
  SD reaction time dominant hand  >0.551 0.53 60.13 [16.60;103.66] 0.007 0.56 66.02 [22.06;109.97] 0.003 
  SD reaction time nondominant hand >0.551 0.53 56.13 [16.06;96.20] 0.006 0.52 51.34 [8.84;93.83] 0.01 
  SD reaction time overall >0.551 0.60 62.12 [25.46;98.78] 0.001 0.58 57.65 [18.56;96.73] 0.004 
 Motor coordination (No. of taps in 10s)i        
  No. of unimanual taps        
   Dominant hand >0.551 0.73 -1.10 [-2.54;0.35] 0.13 0.63 -0.81 [-2.54;0.92] 0.35 
   Nondominant hand >0.551 0.76 -0.83 [-2.06;0.40] 0.18 0.66 -1.88 [-3.56;-0.19] 0.02 
  No. of valid synchronous taps >0.551 0.65 -2.04 [-3.57;-0.51] 0.009 0.57 -1.75 [-3.37;-0.12] 0.03 
5oxo-MEHP Attention and motor coordination        
0.03 Alertness (msec)g        
(0.01-0.12)  Reaction time dominant hand >0.031 0.65 90.59 [36.89;144.30] 0.001 0.71 114.57 [70.46;158.68] 0.000001 
(µmol/l×days)  Reaction time nondominant hand >0.031 0.66 124.74 [74.97;174.51] 0.000002 0.69 86.38 [44.72;128.04] 0.00007 
f  Reaction time overall >0.031 0.70 106.96 [59.96;153.97] 0.00001 0.72 101.85 [61.46;142.23] 0.000002 
 Inconsistency of alertness (msec)h        
  SD reaction time dominant hand  >0.031 0.52 58.76 [5.69;111.84] 0.03 0.62 88.06 [42.77;133.34] 0.0002 
  SD reaction time nondominant hand >0.031 0.56 84.12 [38.37;129.87] 0.0004 0.57 67.71 [22.61;112.81] 0.003 
  SD reaction time overall >0.031 0.62 72.24 [29.16;115.32] 0.001 0.65 82.15 [42.28;122.02] 0.00008 
 Motor coordination (No. of taps in 10s)i        
  No. of unimanual taps        
       Dominant hand >0.031 0.76 -2.50 [-4.19;-0.81] 0.004 0.66 -0.84 [-2.75;1.08] 0.38 
                                No. of valid synchronous taps >0.024  0.65 -2.03 [-3.83;-0.23] 0.02 0.58 -0.69 [-2.62;1.24] 0.48 
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a“Exposure” was defined as the product of the last day concentrations in µmol/l and the number of days exposed in PICU. 
bOnly the neurocognitive functions that were significantly associated with the phthalate exposures as identified by bootstrapping are listed.   
cidentified via bootstrap resampling.  
dthreshold values are rounded to three decimals.  
eExposure to the sum of MEHP and its metabolites 5cx-MEPP, 5oxo-MEHP and 5OH-MEHP.  
fDistribution of metabolite exposures within the patient cohort (µmol/l ×days). Data are median (interquartile range). 
gFor reaction times, higher scores reflect worse performance. Mean scores for healthy children are 558 (95% CI 521-595) for the dominant hand reaction time, 562 (95% CI 524-600) for the nondominant hand reaction 
time and 560 (95% CI 524-600) for the overall reaction time (ref 1).  
hFor inconsistency of alertness, higher scores reflect worse performance. Mean scores for healthy children are 259 (95% CI 229-290) for the dominant hand, 262 (95% CI 232-292) for the nondominant hand and 275 
(95% CI 246-304) for the overall SD, standard deviation (ref 1).  
iFor motor coordination, higher scores reflect better performance. Mean scores for healthy children are 36 (95% CI 34-38) for dominant hand unimanual taps, 32 (95% CI 30-33) for nondominant hand unimanual taps 
and 22 (95% CI 20-24) for valid synchronous taps (ref 1). 
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eTable 9. Multivariable linear regression analyses determining significant and independent associations between exposure to a potentially harmful threshold of circulating phthalate 
metabolites and neurocognitive functions with exposure calculated with the admission concentration when last day concentration is higher than admission concentration 
   Development cohort Validation cohort 
Phthalate 
exposurea 
Neurocognitive functions affected, as determined by 
a multivariable bootstrap approachb 
Potentially 
harmful 
threshold 
(µmol/l 
×days)c,d 
R² of 
the 
model Estimate [95% CI] P value 
 
R² of 
the 
model Estimate [95% CI] P value 
Total DEHPe Attention and motor coordination        
0.78  Alertness (msec)g        
(0.34-2.66)  Reaction time dominant hand >0.551 0.57 58.50 [12.94;104.05] 0.01 0.60 62.44 [19.90;104.98] 0.004 
(µmol/l×days)  Reaction time nondominant hand >0.551 0.58 56.11 [15.49;96.73] 0.007 0.61 56.18 [16.48;95.88] 0.005 
f  Reaction time overall  >0.551 0.61 56.26 [16.34;96.18] 0.006 0.63 60.65 [21.65;99.65] 0.002 
 Inconsistency of alertness (msec)h        
  SD reaction time dominant hand  >0.551 0.50 36.81 [-2.32;75.94] 0.06 0.53 51.54 [12.05;91.04] 0.01 
  SD reaction time nondominant hand >0.551 0.47 44.70 [8.52;80.88] 0.01 0.49 38.59 [-0.83;78.00] 0.05 
  SD reaction time overall >0.551 0.56 43.54 [10.19;76.89] 0.01 0.56 45.79 [10.65;80.93] 0.01 
 Motor coordination (No. of taps in 10s)i        
  No. of unimanual taps        
   Dominant hand >0.551 0.76 -0.98 [-2.18;0.22] 0.10 0.65 -0.77 [-2.20;0.66] 0.28 
   Nondominant hand >0.551 0.78 -0.74 [-1.84;0.35] 0.18 0.66 -1.97 [-3.33;-0.61] 0.004 
  No. of valid synchronous taps >0.551 0.66 -2.07 [-3.42;-0.71] 0.003 0.62 -1.47 [-2.83;-0.11] 0.03 
5oxo-MEHP Attention and motor coordination        
0.03 Alertness (msec)g        
(0.01-0.12)  Reaction time dominant hand >0.031 0.57 55.31 [3.94;106.67] 0.03 0.63 105.97 [62.34;149.60] 0.000003 
(µmol/l×days)  Reaction time nondominant hand >0.031 0.59 83.38 [39.01;127.74] 0.0003 0.62 77.95 [36.30;119.60] 0.0003 
f  Reaction time overall >0.031 0.61 67.64 [23.01;112.27] 0.003 0.65 93.02 [52.68;133.36] 0.00001 
 Inconsistency of alertness (msec)h        
  SD reaction time dominant hand  >0.031 0.50 27.96 [-16.17;72.08] 0.21 0.54 74.74 [33.33;116.15] 0.0005 
  SD reaction time nondominant hand >0.031 0.48 59.59 [19.71;99.48] 0.003 0.50 51.41 [9.65;93.17] 0.01 
  SD reaction time overall >0.031 0.55 42.61 [5.04;80.18] 0.02 0.58 65.75 [28.91;102.58] 0.0005 
 Motor coordination (No. of taps in 10s)i        
  No. of unimanual taps        
       Dominant hand >0.031 0.77 -1.56 [-2.90;-0.21] 0.02 0.65 -0.78 [-2.31;0.75] 0.31 
                                No. of valid synchronous taps >0.024  0.65 -1.61 [-3.08;-0.14] 0.03 0.61 -0.67 [-2.15;0.82] 0.37 
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a“Exposure” was defined as the product of the last day concentrations in µmol/l and the number of days exposed in PICU. 
bOnly the neurocognitive functions that were significantly associated with the phthalate exposures as identified by bootstrapping are listed.   
cidentified via bootstrap resampling.  
dthreshold values are rounded to three decimals.  
eExposure to the sum of MEHP and its metabolites 5cx-MEPP, 5oxo-MEHP and 5OH-MEHP.  
fDistribution of metabolite exposures within the patient cohort (µmol/l ×days). Data are median (interquartile range). 
gFor reaction times, higher scores reflect worse performance. Mean scores for healthy children are 558 (95% CI 521-595) for the dominant hand reaction time, 562 (95% CI 524-600) for the nondominant hand reaction 
time and 560 (95% CI 524-600) for the overall reaction time (ref 1).  
hFor inconsistency of alertness, higher scores reflect worse performance. Mean scores for healthy children are 259 (95% CI 229-290) for the dominant hand, 262 (95% CI 232-292) for the nondominant hand and 275 
(95% CI 246-304) for the overall SD, standard deviation (ref 1).  
iFor motor coordination, higher scores reflect better performance. Mean scores for healthy children are 36 (95% CI 34-38) for dominant hand unimanual taps, 32 (95% CI 30-33) for nondominant hand unimanual taps 
and 22 (95% CI 20-24) for valid synchronous taps (ref 1). 
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eTable 10. Percentage of neurocognitive deficit in critically ill children that can be explained by exposure above a potentially 
harmful threshold of circulating DEHP metabolites 
 
 Total DEHP metabolites > 0.551 
(µmol/l)xPICUdays 
Total MEHP metabolites > 0.365 
(µmol/l)xPICUdays 
MEHP > 0.157 
(µmol/l)xPICUdays 
5-oxo-MEHP > 0.031 
(µmol/l)xPICUdays* 
 
Develop. 
cohort 
(N=228) 
% 
Validation 
cohort 
(N=221) 
% 
Average 
 
 % 
Develop. 
cohort 
(N=228) 
% 
Validation 
cohort 
(N=221) 
% 
Average  
 
% 
Develop. 
cohort 
(N=228) 
% 
Validation 
cohort 
(N=221) 
% 
Average  
 
% 
Develop. 
cohort 
(N=228) 
% 
Validation 
cohort 
(N=221) 
% 
Average 
 
 % 
Alertness (msec) 
            
     Reaction time dominant hand 57 36 46 64 26 45 42 23 32 64 63 63 
     Reaction time nondominant hand 65 35 50 69 32 50 56 22 39 100 57 78 
     Reaction time overall 62 36 49 68 30 49 49 24 36 81 61 71 
Inconsistency of alertness (msec)             
     SD reaction time dominant hand 38 35 36 45 27 36 - - - 47 56 51 
     SD reaction time nondominant hand 56 - - 62 - - - - - 81 37 59 
     SD reaction time overall 49 30 39 56 24 40 - - - 62 50 56 
Motor coordination (number of taps in 10s)             
     Number of unimanual taps             
          Dominant hand 34 - - - - - - - - 54 - - 
          Nondominant hand 25 27 26 - - - - - - - - - 
     Number of valid alternating taps - - - - - - - - - - - - 
     Number of valid synchronous taps 59 - - 54 - - 68 32 50 49 - - 
The percentage of the deficit in the different neurocognitive functions explained by exceeding a potentially harmful threshold of phthalate exposure was calculated by dividing the scaled estimate for 
exceeding the potentially harmful threshold obtained in the respective multiple regression analyses (when independently associated with the respective test result, see Table 2 and Table 3) by the 
difference of the mean scores for critically ill and healthy children (see eTable 2A) and then multiplying by 100. * a lower potentially harmful threshold of 0.024 µmol/l was identified for number of valid 
synchronous taps. 
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eTable 11-1. Identification of a potentially harmful threshold for circulating [total 
DEHP metabolite] at last PICU day 
 
A. Descriptive statistics 
Concentration of Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
Total DEHP metabolites 228 227 0.265013879 0.13675816 0.523832112 0.387073952 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median  
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Memory span, numbers 0.075160868 0.066834676 0.102730937 9.27 0.450761084 0.0000568 
Delayed memory, word pairs 0.079695249 0.075160868 0.097155165 5.68 0.481291106 0.000425228 
Immediate memory, word pairs 0.102730937 0.075034689 0.165727907 23.43 0.423819688 0.030210072 
Memory, learning word pairs 0.102730937 0.04457308 0.175194092 33.75 0.439595043 0.045707626 
Memory, learning index 0.103106871 0.077428059 0.143670286 17.11 0.509902372 0.016584652 
Memory, learning dots 0.110435775 0.103106871 0.341668494 61.63 0.384664643 0.005914816 
Flexibility, no. of errors 0.111135028 0.058349635 0.527632752 121.24 0.203611521 0.095852657 
Tapping dominant hand 0.141483083 0.088220903 0.346865883 66.82 0.762964783 0.14653212 
Valid alternating taps 0.161007146 0.104960707 1.956240604 478.28 0.379919207 0.192656788 
Visual-motor integration 0.199586618 0.165727907 0.305008801 35.98 0.372080754 0.031237881 
Valid synchronous taps 0.220184303 0.07490851 0.443735314 95.29 0.65484027 0.034208916 
Reaction time dominant hand 0.25320974 0.109406291 0.292874702 47.40 0.57720718 0.004416003 
Overall reaction time 0.25320974 0.117833404 0.292874702 45.22 0.597024973 0.010376002 
Reaction time nondominant hand 0.266870782 0.088547073 0.40673982 82.20 0.551250074 0.041935607 
Delayed memory, dots 0.274719898 0.103106871 0.521530322 108.10 0.368531342 0.148491884 
Verbal IQ 0.301949141 0.120570777 0.705184663 151.03 0.378483739 0.076227949 
Memory span, pictures 0.319934118 0.116705456 0.473735273 92.24 0.497835324 0.057330213 
Tapping nondominant hand 0.361228402 0.100183733 0.526133901 110.04 0.771116921 0.062010316 
Flexibility, ∆ reaction time 0.375782474 0.025943037 2.462670777 629.53 0.324073422 0.012810833 
Externalizing problems 0.378009023 0.038386796 0.708691208 173.17 0.1940692 0.060360165 
Working memory 0.391355678 0.115456693 0.40673982 75.25 0.418149206 0.00231869 
Inhibition, no. of errors 0.504813466 0.093700709 0.67637121 150.53 0.134967283 0.049261525 
Memory, recognition word pairs 0.557224262 0.169595807 0.627847002 118.39 0.383055108 0.028117649 
Immediate memory, dots 0.677267751 0.391355678 1.195336789 207.71 0.377686778 0.068773091 
Full-scale IQ 0.708691208 0.423471295 0.722133205 77.16 0.372434115 0.011748062 
Total behavioral problems 0.708691208 0.386948102 0.715934537 84.99 0.221374219 0.11693596 
Performance IQ 0.715934537 0.462316933 0.722133205 67.12 0.318763365 0.007582272 
Internalizing problems 0.715934537 0.375782474 1.399357122 264.44 0.224939657 0.154304698 
Inhibition, ∆ reaction time 0.789868549 0.589287844 0.871546911 72.92 0.300226098 0.022151555 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together 
around a similar cut-off are shown in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off 
that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.079695249 Delayed memory, word pairs 0.489567533 0.000189504 0.000128218 0.001087138 
Memory span, numbers 0.430052754 0.001415544 0.001118141 0.005809536 
Memory, learning index 0.488686124 0.023024307 0.016611423 0.057880771 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. The threshold 
dichotomizes the development cohort with at least 10 patients per group and is retained for further analyses. Neurocognitive tests 
are ordered from the lowest to the highest median exposure covariate P value found for comparison of patients according to the 
identified potentially harmful threshold.  
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eTable 11-2. Identification of a potentially harmful threshold for circulating [total 
MEHP metabolite] at last PICU day 
 
A. Descriptive statistics 
Concentration of Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
Total MEHP metabolites 228 227 0.17510705 0.078694899 0.369338857 0.290643958 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Flexibility, ∆ reaction time 0.02893957 0.024928618 0.564941319 185.80 0.32416967 0.029610968 
Memory, learning index 0.029161952 0.020337293 0.071991914 17.77 0.489847708 0.094335423 
Flexibility, no. of errors 0.031380998 0.0280355 0.282606213 87.59 0.202893746 0.122037318 
Memory span, numbers 0.042563161 0.040273422 0.060708004 7.03 0.440298349 0.001161451 
Memory, learning word pairs 0.042982854 0.0280355 0.116532846 30.45 0.427097094 0.176194587 
Delayed memory, word pairs 0.058495772 0.044976832 0.05945961 4.98 0.445046614 0.004311239 
Immediate memory, word pairs 0.058931959 0.042563161 0.081988321 13.56 0.421893796 0.052998697 
Tapping dominant hand 0.068419367 0.022125146 0.191810036 58.38 0.763088188 0.24288781 
Memory, learning dots 0.069642098 0.02223316 0.263655708 83.06 0.361597338 0.023495877 
Tapping nondominant hand 0.081163992 0.047586096 0.3074486 89.41 0.768850415 0.104441224 
Memory, recognition word pairs 0.101344386 0.048253821 0.438859879 134.39 0.383563937 0.027554948 
Verbal IQ 0.108737178 0.082777238 0.483086495 137.73 0.38158156 0.027676425 
Valid alternating taps 0.116532846 0.045932321 1.672173757 559.53 0.379511023 0.262718959 
Visual-motor integration 0.124297778 0.033807673 0.236870876 69.87 0.368206515 0.092033649 
Inhibition, no. of errors 0.124697649 0.027644982 0.363240017 115.47 0.135921713 0.096572873 
Delayed memory, dots 0.159442314 0.033807673 0.302940772 92.60 0.366071027 0.234862055 
Externalizing problems 0.166199901 0.037983683 0.56340115 180.78 0.194776645 0.070079194 
Memory span, pictures 0.170983284 0.039584339 0.355686508 108.76 0.488378142 0.129014522 
Working memory 0.208462249 0.112686201 0.282606213 58.46 0.407750993 0.002324747 
Reaction time nondominant hand 0.2365302 0.041283597 0.317812249 95.14 0.551561551 0.024974509 
Reaction time dominant hand 0.2517791 0.098452556 0.276108909 61.13 0.579010189 0.001976719 
Overall reaction time 0.2517791 0.216293336 0.282606213 22.82 0.598366094 0.004702477 
Valid synchronous taps 0.304799859 0.181001275 0.375326361 66.86 0.65349177 0.041479816 
Performance IQ 0.317812249 0.02223316 0.585532451 193.81 0.315510553 0.011574361 
Full-scale IQ 0.317812249 0.058495772 0.477211363 144.06 0.373195705 0.024623509 
Internalizing problems 0.342723614 0.170983284 0.56340115 135.02 0.22644358 0.065079829 
Total behavioral problems 0.447654943 0.170983284 0.56340115 135.02 0.221476971 0.077647172 
Inhibition, ∆ reaction time 0.483086495 0.040128633 0.651840249 210.47 0.30137977 0.014898837 
Immediate memory, dots 0.585532451 0.137477722 0.916323626 267.97 0.381380924 0.058385939 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together 
around a similar cut-off are shown in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off 
that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.042563161 Memory span, numbers 0.443131639 0.000696449 0.000630885 0.002066042 
Delayed memory, word pairs 0.434233046 0.014728026 0.010666136 0.031093607 
0.245287147 Overall reaction time 0.599666995 0.002668944 0.001833563 0.010018913 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. Both thresholds 
dichotomize the development cohort with at least 10 patients per group and are retained for further analyses. Neurocognitive tests 
are ordered from the lowest to the highest median exposure covariate P value found for comparison of patients according to the 
identified potentially harmful threshold.  
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eTable 11-3. Identification of a potentially harmful threshold for circulating MEHP 
concentration at last PICU day 
 
A. Descriptive statistics 
Concentration of Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
MEHP 228 222 0.079267992 0.039457565 0.134696383 0.095238818 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Memory span, numbers 0.009224844 0.009224844 0.0154489 6.54 0.45033264 0.000503795 
Memory, learning word pairs 0.028006302 0.020574938 0.068348771 50.16 0.44300905 0.045806893 
Delayed memory, word pairs 0.032597707 0.007582544 0.274618049 280.39 0.443515178 0.005081461 
Memory, learning index 0.033088839 0.027732961 0.257874614 241.65 0.511457172 0.006795703 
Delayed memory, dots 0.038625297 0.031114957 0.161831278 137.25 0.389620411 0.034334606 
Inhibition, no. of errors 0.041765526 0.023066662 0.327946181 320.12 0.127926018 0.302917722 
Memory, learning dots 0.046420641 0.030448416 0.161831278 137.95 0.364764653 0.017595044 
Verbal IQ 0.047937981 0.0232829 0.085203792 65.02 0.374629589 0.10243251 
Full-scale IQ 0.049122499 0.0232829 0.185071104 169.88 0.357902193 0.198259988 
Valid synchronous taps 0.05614508 0.051790198 0.059689498 8.29 0.664224976 0.000854805 
Reaction time dominant hand 0.059126802 0.057896817 0.079952437 23.16 0.57959824 0.001887146 
Overall reaction time 0.059126802 0.057896817 0.080125372 23.34 0.603085508 0.002910632 
Visual-motor integration 0.065037288 0.035389154 0.123244148 92.25 0.369195446 0.056497063 
Flexibility, no. of errors 0.095459093 0.031114957 0.103670159 76.18 0.204273671 0.058878578 
Reaction time nondominant hand 0.097641947 0.057896817 0.101353746 45.63 0.557608588 0.005553527 
Valid alternating taps 0.097641947 0.068348771 0.888650877 861.31 0.379705345 0.186781514 
Inhibition, ∆ reaction time 0.121437126 0.069440539 1.374668534 1370.48 0.281619207 0.170678232 
Tapping nondominant hand 0.121466112 0.05473274 0.136286714 85.63 0.769262915 0.035463395 
Memory span, pictures 0.126157873 0.04011091 0.211739871 180.21 0.484358957 0.136359659 
Tapping dominant hand 0.135533629 0.051790198 0.136286714 88.72 0.764680658 0.046053251 
Working memory 0.14137508 0.040669369 0.224331974 192.84 0.352652399 0.17543165 
Performance IQ 0.193225922 0.065037288 0.888650877 864.79 0.302070424 0.174463647 
Immediate memory, word pairs 0.224331974 0.023659609 0.274618049 263.50 0.42757841 0.025551499 
Externalizing problems 0.22682206 0.109813264 0.28345916 182.33 0.208696336 0.007739372 
Memory, recognition word pairs 0.274618049 0.116084275 0.327946181 222.45 0.386151274 0.026327984 
Immediate memory, dots 0.279013163 0.202010192 0.327946181 132.23 0.410278731 0.001369197 
Total behavioral problems 0.28006758 0.20219232 0.325959344 129.95 0.248175641 0.001936213 
Internalizing problems 0.28006758 0.215310507 0.325959344 116.18 0.246042838 0.004289826 
Flexibility, ∆ reaction time 0.497150804 0.080125372 1.374668534 1359.26 0.316377025 0.089963309 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together 
around a similar cut-off are shown in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off 
that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.009224844 Memory span, numbers 0.454031281 0.000226603 0.000173324 0.000957854 
0.05614508 Valid synchronous taps 0.665824412 0.000502058 0.000322517 0.003032893 
Reaction time dominant hand 0.57580753 0.002193173 0.001558686 0.005270529 
Overall reaction time 0.600173168 0.001856856 0.001369492 0.005073703 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. Only the green threshold 
dichotomizes the development cohort with at least 10 patients per group and is retained for further analyses. Neurocognitive tests 
are ordered from the lowest to the highest median exposure covariate P value found for comparison of patients according to the 
identified potentially harmful threshold.  
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eTable 11-4. Identification of a potentially harmful threshold for circulating 5cx-
MEHP concentration at last PICU day 
 
A. Descriptive statistics 
Concentration of Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
5cx-MEPP 228 227 0.136783366 0.054936002 0.32299271 0.268056709 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median  
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Memory, learning index 0.015080876 0.00777936 0.047292114 14.74 0.489966961 0.0743 
Flexibility, no. of errors 0.015080876 0.015080876 0.192565928 66.21 0.203162346 0.118664482 
Flexibility, ∆ reaction time 0.02064542 0.006162229 0.545848605 201.33 0.32172857 0.030350446 
Memory span, numbers 0.029608537 0.021184412 0.046504986 9.45 0.435036714 0.002192874 
Delayed memory, word pairs 0.032022208 0.030507951 0.042267165 4.39 0.456782583 0.003163658 
Immediate memory, word pairs 0.032022208 0.030507951 0.052317063 8.14 0.428379643 0.030900855 
Memory, learning dots 0.032022208 0.00777936 0.20758189 74.54 0.352783157 0.046336231 
Memory, learning word pairs 0.034631472 0.015080876 0.134605035 44.59 0.425589923 0.171184516 
Tapping dominant hand 0.04728603 0.009170522 0.178667379 63.23 0.762542945 0.310736001 
Tapping nondominant hand 0.061221368 0.026210264 0.18612576 59.66 0.768199633 0.159858275 
Inhibition, no. of errors 0.075100413 0.030356181 0.490483919 171.65 0.134204279 0.086268461 
Memory, recognition word pairs 0.085535044 0.035299197 0.387490568 131.39 0.381890504 0.025899055 
Valid alternating taps 0.090331004 0.032022208 1.45066713 529.23 0.379483362 0.174015775 
Memory span, pictures 0.09124143 0.021591974 0.321805798 112.00 0.483541591 0.278991999 
Visual-motor integration 0.117732529 0.030302621 0.199027753 62.94 0.369587648 0.059733403 
Delayed memory, dots 0.140287245 0.021591974 0.321805798 112.00 0.365384248 0.230972245 
Externalizing problems 0.143569783 0.017966963 0.498047678 179.10 0.194469532 0.073125193 
Reaction time nondominant hand 0.157136201 0.022352712 0.294287148 101.45 0.549468279 0.079158081 
Overall reaction time 0.163487193 0.156590985 0.20758189 19.02 0.597171599 0.008182309 
Reaction time dominant hand 0.168539415 0.156590985 0.20758189 19.02 0.577944576 0.002232262 
Internalizing problems 0.175923736 0.143345839 0.503406597 134.32 0.231618184 0.031001504 
Working memory 0.189265176 0.11359402 0.244350808 48.78 0.405893384 0.002840406 
Valid synchronous taps 0.201566383 0.156590985 0.354330162 73.77 0.654200025 0.024632028 
Verbal IQ 0.263014222 0.066383338 0.461579972 147.43 0.384618972 0.0140168 
Inhibition, ∆ reaction time 0.297707674 0.156590985 0.594775102 163.47 0.303057073 0.013866932 
Performance IQ 0.398814639 0.032022208 0.461579972 160.25 0.318846126 0.018102306 
Full-scale IQ 0.404670082 0.179233313 0.461579972 105.33 0.375971553 0.005297722 
Total behavioral problems 0.43615222 0.143457811 0.503406597 134.28 0.22491035 0.045156505 
Immediate memory, dots 0.531538336 0.134605035 0.681307825 203.95 0.382409545 0.045002561 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together 
around a similar cut-off are shown in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off 
that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.029608537 Memory span, numbers 0.439555957 0.000787319 0.000635054 0.00225929 
Delayed memory, word pairs 0.429435292 0.016284382 0.010508319 0.038975036 
Immediate memory, word pairs 0.408694892 0.081896219 0.053358674 0.162774828 
Memory, learning index 0.458098955 0.352534194 0.277911801 0.467286324 
0.168539415 Reaction time dominant hand 0.58233023 0.000913681 0.000595235 0.003305614 
Overall reaction time 0.600174211 0.00513789 0.003167005 0.014935434 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. Both thresholds 
dichotomize the development cohort with at least 10 patients per group and are retained for further analyses. Neurocognitive tests 
are ordered from the lowest to the highest median exposure covariate P value found for comparison of patients according to the 
identified potentially harmful threshold.  
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eTable 11-5. Identification of a potentially harmful threshold for circulating 5OH-
MEHP concentration at last PICU day 
 
A. Descriptive statistics 
Concentration of Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
5OH-MEHP 228 185 0.019350548 0.008709822 0.044730445 0.036020623 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Tapping nondominant hand 0.004181393 0.004181393 0.012008082 21.73 0.77341636 0.00222 
Memory span, numbers 0.010574613 0.00645512 0.035723481 81.25 0.375915825 0.145251716 
Delayed memory, word pairs 0.012138002 0.008666983 0.019286538 29.48 0.412084018 0.074835123 
Working memory 0.012495992 0.011677718 0.023228562 32.07 0.363307797 0.049486269 
Valid alternating taps 0.015032343 0.008922871 0.271526335 729.04 0.379955421 0.148328021 
Visual-motor integration 0.015426152 0.008666983 0.041274579 90.52 0.364056312 0.182216911 
Memory, recognition word pairs 0.019350548 0.00645512 0.027083477 57.27 0.351384922 0.127928569 
Memory, learning index 0.019414558 0.015102948 0.024412998 25.85 0.470495586 0.171984632 
Memory, learning word pairs 0.019414558 0.01016529 0.058673535 134.67 0.415644394 0.341917231 
Immediate memory, word pairs 0.01984075 0.008333629 0.035723481 76.04 0.400186582 0.296254057 
Full-scale IQ 0.019940679 0.011536245 0.046929775 98.26 0.360586557 0.096663205 
Verbal IQ 0.020049169 0.011536245 0.042870787 86.99 0.375187033 0.075837998 
Memory, learning dots 0.022179911 0.019085561 0.024412998 14.79 0.356668158 0.024921518 
Valid synchronous taps 0.023133233 0.022311957 0.024659232 6.52 0.654354547 0.018329301 
Memory span, pictures 0.024412998 0.016377026 0.065699422 136.93 0.491063139 0.059575704 
Tapping dominant hand 0.024412998 0.009072959 0.072942568 177.31 0.762654989 0.199296002 
Reaction time dominant hand 0.025301007 0.024659232 0.025301007 1.78 0.596560755 0.0000231109 
Overall reaction time 0.025301007 0.024659232 0.029897295 14.54 0.613677269 0.000148708 
Delayed memory, dots 0.025301007 0.0202115 0.058673535 106.78 0.376411734 0.116149528 
Reaction time nondominant hand 0.029897295 0.025947162 0.035723481 27.14 0.566425068 0.000830736 
Performance IQ 0.03984983 0.013585416 0.239220817 626.41 0.304034604 0.068252089 
Flexibility, no. of errors 0.065405492 0.028896812 0.1520641 341.94 0.201265497 0.125674022 
Immediate memory, dots 0.065699422 0.029562165 0.125143638 265.35 0.382971223 0.017308081 
Total behavioral problems 0.067929356 0.027083477 0.129849327 285.30 0.220808439 0.14005548 
Internalizing problems 0.067929356 0.020867529 0.127496483 296.02 0.22450072 0.161440234 
Externalizing problems 0.069675778 0.014850677 0.129849327 319.26 0.191371801 0.130431136 
Inhibition, ∆ reaction time 0.071460518 0.011167301 0.096095688 235.78 0.280817867 0.190989586 
Inhibition, no. of errors 0.075604207 0.019105242 0.079907143 168.80 0.142409427 0.047817931 
Flexibility, ∆ reaction time 0.134026363 0.025177155 0.20312378 494.01 0.31711806 0.063976901 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together 
around a similar cut-off are shown in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off 
that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.004181393 Tapping nondominant hand 0.774123614 0.001633652 0.00143229 0.002367302 
0.025301007 Reaction time dominant hand 0.600940147 0.00000832 0.00000532 0.0000427 
Overall reaction time 0.618866671 0.0000323 0.0000238 0.000188346 
Valid synchronous taps 0.656171705 0.011159618 0.007735086 0.031461639 
Memory, learning dots 0.332517756 0.087818866 0.066284414 0.163898896 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. Only the green threshold 
dichotomizes the development cohort with at least 10 patients per group and is retained for further analyses. Neurocognitive tests 
are ordered from the lowest to the highest median exposure covariate P value found for comparison of patients according to the 
identified potentially harmful threshold.   
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eTable 11-6. Identification of a potentially harmful threshold for circulating 5oxo-
MEHP concentration at last PICU day 
 
A. Descriptive statistics 
Concentration of Number of 
patients 
Number of 
unique values 
Median 25th 
percentile 
75th 
percentile 
Interquartile 
range 
5oxo-MEHP 228 148 0.009540407 0.006499504 0.020394375 0.013894871 
 
B. Selection of significant and stable cut-offs 
Neurocognitive test Median 
cut-off 
25th 
percentile 
cut-off 
75th 
percentile 
cut-off 
IQR cut-off / 
IQR 
exposure (%) 
Median 
R2 
Median exposure 
covariate 
P value 
Verbal IQ 0.006499504 0.006334561 0.013011503 48.05 0.375642332 0.0634 
Delayed memory, word pairs 0.006895201 0.006196198 0.013766183 54.48 0.399104565 0.299855094 
Memory span, numbers 0.007325794 0.006196198 0.020801823 105.12 0.365043253 0.37956931 
Visual-motor integration 0.008529539 0.00489703 0.01338206 61.07 0.370206697 0.064878069 
Working memory 0.008529539 0.006499504 0.012737636 44.90 0.350363039 0.13944208 
Tapping dominant hand 0.008868966 0.006334561 0.024422765 130.18 0.762922308 0.111711179 
Memory, learning dots 0.009910871 0.009856868 0.01120982 9.74 0.376143622 0.009768178 
Inhibition, ∆ reaction time 0.009910871 0.00489703 0.041620094 264.29 0.286258472 0.093858778 
Memory, learning index 0.009942002 0.007325794 0.010205969 20.73 0.484096414 0.050195227 
Memory, learning word pairs 0.009942002 0.007325794 0.024679015 124.89 0.417101882 0.187212616 
Performance IQ 0.010205969 0.006334561 0.034663576 203.88 0.303445721 0.098281491 
Memory, recognition word pairs 0.010205969 0.006895201 0.017671239 77.55 0.34242153 0.292475606 
Valid synchronous taps 0.010402614 0.006499504 0.014558539 58.00 0.651919724 0.078277263 
Full-scale IQ 0.010402614 0.006334561 0.024422765 130.18 0.364415745 0.09112564 
Tapping nondominant hand 0.012233924 0.002383856 0.021319536 136.28 0.770314088 0.039666841 
Memory span, pictures 0.012233924 0.009467712 0.028653806 138.08 0.485399068 0.094109172 
Delayed memory, dots 0.012233924 0.00985449 0.036304458 190.36 0.370595206 0.109403706 
Immediate memory, word pairs 0.013752617 0.006196198 0.024422765 131.17 0.402373362 0.221331663 
Overall reaction time 0.013766183 0.010402614 0.017661309 52.24 0.609457019 0.000446171 
Reaction time nondominant hand 0.013766183 0.010253254 0.015767544 39.69 0.564173665 0.002127026 
Reaction time dominant hand 0.014230521 0.010402614 0.017661309 52.24 0.58890791 0.000306435 
Flexibility, no. of errors 0.014420029 0.014300052 0.069485544 397.16 0.203774165 0.101576339 
Inhibition, no. of errors 0.026604113 0.021319536 0.032494871 80.43 0.142534334 0.024824398 
Valid alternating taps 0.032494871 0.009958553 0.125707462 833.03 0.376602738 0.318769842 
Immediate memory, dots 0.036304458 0.024422765 0.098948686 536.36 0.394426932 0.004705647 
Externalizing problems 0.0368674 0.00489703 0.037866754 237.28 0.199606469 0.03791726 
Total behavioral problems 0.037464027 0.034184727 0.043641043 68.06 0.224822899 0.060294382 
Internalizing problems 0.037665391 0.033222808 0.057563398 175.18 0.23112608 0.033670697 
Flexibility, ∆ reaction time 0.069485544 0.013049462 0.086354987 527.57 0.313218415 0.098418515 
Criteria met for selection (stability and significance of the determined cut-off) are shown in bold. Responses grouped together 
around a similar cut-off are shown in the same color. Neurocognitive tests are ordered from the lowest to the highest median cut-off 
that was identified.  
 
C. Determination of a potentially harmful threshold per grouped responses 
Potentially 
harmful 
threshold 
Neurocognitive test Median 
R2 
Median 
exposure 
covariate P value 
25th percentile 
exposure 
covariate P value 
75th percentile 
exposure 
covariate P value 
0.009910871 Memory, learning dots 0.383660057 0.00352465 0.002443359 0.010025297 
Criteria met for selection (median, 25th and 75th percentile lower than or equal to 0.05) are shown in bold. The threshold 
dichotomizes the development cohort with at least 10 patients per group and is retained for further analyses.  
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eTable 12. Multivariable linear regression analyses determining significant and independent 
associations between a potentially harmful threshold of circulating phthalate metabolite 
concentrations on the last PICU day and neurocognitive functions in the development cohort 
(N=228) 
 
Phthalate 
concentrationc 
Neurocognitive functions affected,  
as determined by a multivariable bootstrap 
approachd 
Potentially 
harmful 
threshold 
(µmol/l)a,b 
R² of 
the 
model Estimate [95% CI] P value 
Total DEHPe Memory     
0.27 Verbal-auditoryh     
(0.14-0.52) Memory span, repeating numbers  
repeating numbers   
 
 backward (up to 19 numbers) 
§§§ 
    
(µmol/l)g forw rd (up to 19 numbers)  >0.080 0.42 -1.60 [-2.46;-0.75] 0.0003 
 Delayed memory, word pairs (proportion of     
 (proportion of correct responses) >0.080 0.45 -0.09 [-0.14;-0.04] 0.0002 
 Immediate memory, word pairs     
 (proportion of correct responses) >0.080 0.39 -0.06 [-0.12;-0.01] 0.03 
MEHP Attention and motor coordination     
Metabolitesf Alertness (msec)i     
0.18 Reaction time overall >0.245 0.58 49.61 [13.84;85.38] 0.007 
(0.08-0.37) Memory     
(µmol/l)g Verbal-auditoryh     
 Memory span, repeating numbers  
repeating numbers   
 
 backward (up to 19 numbers) 
§§§ 
    
 forw rd (up to 19 numbers)  >0.043 0.41 -1.36 [-2.16;-0.57] 0.001 
 Delayed memory, word pairs (proportion of     
 (proportion of correct responses) >0.043 0.39 -0.06 [-0.10;-0.01] 0.02 
MEHP Attention and motor coordination     
0.08 Alertness (msec)i     
(0.04-0.14) Reaction time dominant hand >0.056 0.59 52.33 [19.32;85.35] 0.002 
(µmol/l)g Reaction time overall >0.056 0.59 57.19 [21.24;93.15] 0.002 
 Motor coordination (No. of taps in 10s)j     
 No. of valid synchronous taps >0.056 0.66 -1.98 [-3.09;-0.88] 0.0005 
5-cx-MEPP Attention and motor coordination     
0.14 Alertness (msec)i     
(0.05-0.32) Reaction time dominant hand >0.169 0.57 65.76 [27.08;104.44] 0.001 
(µmol/l)g Reaction time overall >0.169 0.59 52.82 [18.14;87.49] 0.003 
 Memory     
 Verbal-auditoryh     
 Memory span, repeating numbers  
repeating numbers   
 
 backward (up to 19 numbers) 
§§§ 
    
 forw rd (up to 19 numbers)  >0.030 0.41 -1.36 [-2.16;-0.57] 0.001 
 Delayed memory, word pairs (proportion of     
 (proportion of correct responses) >0.030 0.39 -0.06 [-0.10;-0.01] 0.02 
5-OH-MEHP Attention and motor coordination     
0.02 Alertness (msec)i     
(0.01-0.4) Reaction time dominant hand >0.025 0.59 93.17 [53.07;133.27] 0.000008 
(µmol/l)g Reaction time overall >0.025 0.60 77.12 [41.10;113.15] 0.00003 
 Motor coordination (No. of taps in 10s)j     
 No. of valid synchronous taps >0.025 0.64 -1.62 [-2.88;-0.37] 0.01 
5-oxo-MEHP Memory     
0.01 Nonverbal, visual-spatialk     
(0.01-0.02) Dots: learning (proportion of correct      
(µmol/l)g responses) >0.010 0.30 -0.05 [-0.09;-0.003] 0.04 
aidentified via bootstrap resampling. bcut-off values are rounded to three decimals. c“Concentration” was defined as the last day concentrations in 
µmol/l. dOnly these neurocognitive functions that were significantly associated with the phthalate exposures as identified by mining multivariable 
bootstrap approach are listed. eThe sum of MEHP and its metabolites 5-cx-MEPP, 5-oxo-MEHP and 5-OH-MEHP. fThe sum of 5-cx-MEPP, 5-oxo-
MEHP and 5-OH-MEHP. gDistribution of metabolites within the patient cohort (µmol/l). Data are median (interquartile range). hFor verbal-auditory 
memory, higher scores reflect better performance. Mean scores for healthy children are children are 9 (95% CI 9-10) for memory span (repeating 
numbers forward), 0.42 (95% CI 0.38-0.45) for delayed memory and 0.50 (95% CI 0.46-0.53) for immediate memory.1 iFor reaction times, higher 
scores reflect worse performance. Mean scores for healthy children are 558 (95% CI 521-595) for the dominant hand reaction time and 560 (95% 
CI 524-596) for the overall reaction time.1 jFor motor coordination, higher scores reflect better performance. Mean scores for healthy children are 22 
(95% CI 20-24) for valid synchronous taps.1 kVisual-spatial nonverbal memory, higher scores reflect better performance. Mean scores for healthy 
children are children are 0.86 (95% CI 0.84-0.89) for learning dots.S1 
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eTable 13. Multivariable linear regression analyses determining significant and independent 
associations between a potentially harmful threshold of circulating phthalate metabolite 
concentrations on the last PICU day and neurocognitive functions in the validation cohort (N=221) 
 
Phthalate 
exposureb 
Neurocognitive functions from the 
development cohort, significantly affected in 
validation cohortc 
Best threshold 
(µmol/l)a of 
development cohort 
R² of 
the 
model Estimate [95% CI] P value 
MEHP Attention and motor coordination     
metabolitesd Alertness (msec)f     
0.21 Reaction time overall >0.245 0.57 35.41 [0.34;70.47] 0.05 
(0.08-0.47) 
 
     
(µmol/l)e      
MEHP Attention and motor coordination     
0.07 Alertness (msec)f     
(0.04-0.12) Reaction time dominant hand >0.056 0.53 40.81 [3.62;78.00] 0.03 
(µmol/l)e      
5-OH-MEHP Attention and motor coordination     
0.02 Alertness (msec)f     
(0.01-0.05) Reaction time dominant hand >0.025 0.55 67.80 [27.5;108.1] 
[27.50;108.10] 
0.001 
(µmol/l)e Reaction time overall >0.025 0.59 69.61[32.98;106.2
3] 
0.0002 
acut-off values are rounded to three decimal places. b“Exposure” was defined as the product of the last day concentrations in µmol/l and the 
number of days exposed in PICU. cNeurocognitive functions, that were significantly associated with the phthalate exposure in the development 
cohort, were tested in the validation cohort. Only the remaining functions that were also significantly associated with the phthalate exposure in the 
validation cohort are listed. dExposure to the sum of 5-cx-MEPP, 5-oxo-MEHP and 5-OH-MEHP. eDistribution of metabolites within the patient 
cohort (µmol/l). Data are median (interquartile range). fFor reaction times, higher scores reflect worse performance. Mean scores for healthy 
children are 558 (95% CI 521-595) for the dominant hand reaction time and 560 (95% CI 524-596) for the overall reaction time.S1  
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